日本臨牀　71/増刊2　最新の骨粗鬆症学

出版社： 日本臨牀社
発行日： 2013-04-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新の骨粗鬆症学―骨粗鬆症の最新知見
電子書籍版： 2013-04-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

17,050 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,050 円(税込)

購入する

目次

  • 日本臨牀　71/増刊2　最新の骨粗鬆症学

    ―目次―

    特集　最新の骨粗鬆症学―骨粗鬆症の最新知見

    I． 概　論 　 　
    　1 骨粗鬆症の定義とその変遷
    　2 骨粗鬆症の疫学
    　3 骨粗鬆症の発症メカニズム
    　4 骨粗鬆症の予防と治療ガイドラインの概要

    II． 骨の基礎研究 　 　
    　1 骨の構造と機能 　 　
    　2 骨の微細構造の展開 　 　
    　3 骨の制御因子 　 　
    　4 骨の基質 　 　

    III． 骨研究フロンティア―基礎から臨床まで― 　 　
    　1 RANKLによる新たな破骨細胞分化機序　
    　2 活性化T細胞による破骨細胞分化機序
    　3 骨形成における転写因子の役割
    　4 骨細胞による骨吸収調節機構
    　5 骨細胞のリン代謝調節機序
    　6 骨形成・骨吸収における関連因子の働き 　 　
    　7 骨粗鬆症のゲノム解析
    　8 生活習慣病と骨粗鬆症
    　9 皮膚細胞からの軟骨細胞誘導法

    IV． 骨粗鬆症の診断 　 　
    　1 骨粗鬆症の臨床像
    　2 医療面接・身体診察
    　3 骨密度・骨量測定法 　 　
    　4 画像診断 　 　
    　5 骨代謝マーカー 　 　

    V． 骨粗鬆症の治療 　 　
    　1 薬物治療の開始基準　
    　2 薬物治療 　 　
    　3 骨粗鬆症治療薬の継続と投薬管理　
    　4 骨粗鬆症治療薬の副作用対策 　 　
    　5 骨粗鬆症治療薬の今後の展望　

    VI． 骨粗鬆症の発症予防 　 　
    　1 骨粗鬆症検診の現状と問題点
    　2 運動療法・日常生活　 　 　
    　3 食事・栄養療法

    VII． 骨粗鬆症の疼痛管理 　 　
    　1 疼痛発症メカニズム
    　2 薬物治療
    　3 理学療法(運動療法・物理療法)

    VIII． 骨粗鬆症による骨折の予防・治療 　 　
    　1 骨粗鬆症による骨折の疫学
    　2 骨粗鬆症による骨折の危険因子とその評価 　 　
    　3 骨粗鬆症による骨折の予防 　 　
    　4 骨粗鬆症による骨折の病態・診断・評価・治療 　 　

    IX． 続発性骨粗鬆症 　 　
    　1 内分泌性骨粗鬆症
    　2 慢性腎臓病(CKD)患者と血液透析患者の骨粗鬆症
    　3 糖尿病性骨粗鬆症
    　4 関節リウマチと骨粗鬆症
    　5 移植後骨粗鬆症
    　6 不動性骨粗鬆症
    　7 ステロイド性骨粗鬆症
    　8 遺伝性骨粗鬆症　

    X． 骨粗鬆症の類縁疾患の診断と治療 　 　
    　1 骨軟化症
    　2 骨パジェット病
    　3 がんの骨転移とがん治療に伴う骨粗鬆症
    　4 多発性骨髄腫
    　5 骨粗鬆症・偽神経膠腫症候群

    XI． 大規模臨床試験の概要・住民コホート研究の概要 　 　
    　1 JOINT-02試験と成果
    　2 JOINT-03試験
    　3 JOINT-04試験
    　4 ROAD スタディ
    　5 LOCOMO スタディ

    XII． 特　論 　 　
    　1 生活習慣病合併骨粗鬆症に対する骨吸収抑制薬の有用性
    　2 骨粗鬆症治療の医療経済

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 概論

P.10 掲載の参考文献
1) Albright F, et al : Postmenopausal osteoporosis : its clinical features. J Am Med Assoc 116:2465-2474, 1941.
 
2) Consensus Development Conference : Prophylaxis and treatment of osteoporosis. Am J Med 90:107-110, 1991.
PubMed
3) World Health Organization Study Group : Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, WHO, Geneva, 1994.
 
4) Riggs BL, Melton LJ III : Involutional osteoporosis. N Engl J Med 314:1676-1686, 1986.
 
5) 折茂肇ほか ; 日本骨粗鬆症学会, 日本骨代謝学会, 骨粗鬆症財団 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン, 2011年版, ライフサイエンス出版, 2011.
 
6) 折茂肇ほか : 原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18:76-82, 2001.
Medical*Online
7) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1-45, 2000.
PubMed
8) Fujiwara S, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547-1553, 2003.
PubMed
9) 西澤良記ほか ; 日本骨粗鬆症学会 骨代謝マーカー検討委員会 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン, 2012年版. Osteoporosis Japan 20:33-55, 2012.
 
10) Siris ES, et al : Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1112, 2004.
PubMed
11) Kanis JA, et al : Assessment of fracture risk. Osteoporos Int 16:581-589, 2005.
PubMed
12) Dawson-Hughes B, et al : Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449-458, 2008.
 
13) Kanis JA et al : Case findings for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 19:1395-1408, 2008.
 
P.15 掲載の参考文献
1) Yoshimura N, et al : Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women : the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27(5):620-628, 2009.
PubMed
2) Iki M, et al : Bone mineral density of the spine, hip and distal forearm in representative samples of the Japanese female population : Japanese Population-Based Osteoporosis (JPOS) Study. Osteoporos Int 12(7):529-537, 2001.
PubMed
3) 国立社会保障・人口問題研究所 : 日本の将来推計人口(平成24年1月推計) [http://www.ipss.go.jp/syoushika/tohkei/newest04/sh2401smm.html], 2012年9月30日.
 
4) 厚生労働省大臣官房統計情報部(編) : 平成20年患者調査下巻, 厚生統計協会, 2010.
 
5) Fitzgerald G, et al ; for the GLOW Investigators : Differing risk profiles for individual fracture sites : Evidence from the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res 27(9):1907-1915, 2012.
 
6) Orimo H, et al : Hip fracture incidence in Japan : estimates of new patients in 2007 and 20-year trends. Arch Osteoporos 4(1-2):71-77, 2009.
 
7) Cooper C, et al ; IOF CSA Working Group on Fracture Epidemiology : Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22(5):1277-1288, 2011.
 
8) Hagino H, et al : Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int 20(4):543-548, 2009.
PubMed
9) Ross PD, et al : Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24(6):1171-1177, 1995.
PubMed
10) Kadowaki E, et al : Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women : the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 21(9):1513-1522, 2010.
PubMed
11) Fujiwara S, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18(8):1547-1553, 2003.
PubMed
12) Iki M : Epidemiology : Osteoporosis in Japan. Osteoporosis Jpn 9(Suppl 4):120-131, 2011.
 
13) Yoshimura N, et al : Cumulative incidence and changes in the prevalence of vertebral fractures in a rural Japanese community : a 10-year follow-up of the Miyama cohort. Arch Osteoporos 1:43-49, 2006.
 
14) Fujiwara S, et al : The incidence of thoracic vertebral fractures in a Japanese population, Hiroshima and Nagasaki, 1958-86. J Clin Epidemiol 44(10):1007-1014, 1991.
 
15) Hagino H : Features of limb fractures : a review of epidemiology from a Japanese perspective. J Bone Miner Metab 25(5):261-265, 2007.
PubMed
16) Hagino H, et al : Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 24(3):265-270, 1999.
PubMed
17) Cheng SY, et al : Geographic trends in incidence of hip fractures : a comprehensive literature review. Osteoporos Int 22(10):2575-2586, 2011.
PubMed
P.20 掲載の参考文献
1) Lieben L, et al : Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest 122(5):1803-1815, 2012.
PubMed
2) Schinke T, et al : Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 15(6):674-681, 2009.
PubMed
3) Zebaze RM, et al : Intracortical remodelling and porosity in the distal radius and postmortem femurs of women : a cross-sectional study. Lancet 375(9727):1729-1736, 2010.
PubMed
4) Manolagas SC : From estrogen-centric to aging and oxidative stress : a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31(3):266-300, 2010.
PubMed
5) Manolagas SC, Parfitt AM : What old means to bone. Trends Endocrinol Metab 21(6):369-374, 2010.
PubMed
6) Kuilman T, Peeper DS : Senescence-messaging secretome : SMS-ing cellular stress. Nat Rev Cancer 9(2):81-94, 2009.
PubMed
7) Negishi-Koga T, Takayanagi H : Bone cell communication factors and Semaphorins [http://www.nature.com/bonekeyreports/2012/120919/bonekey2012183/full/bonekey2012183.html].
 
8) Austad SN : Ageing : Mixed results for dieting monkeys. Nature 489(7415):210-211, 2012.
PubMed
9) Tatsumi S, et al : Life-long caloric restriction reveals biphasic and dimorphic effects on bone metabolism in rodents. Endocrinology 149(2):634-641, 2008.
 
10) Devlin MJ, et al : Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 25(9):2078-2088, 2010.
PubMed
11) Wu J, et al : Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150(2):366-376, 2012.
PubMed
12) Kaneko K, et al : Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res 26(12):2959-2966, 2011.
PubMed
13) Asaba Y, et al : Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24(2):241-250, 2009.
PubMed
14) Richards JB, et al : Genetics of osteoporosis from genome-wide association studies : advances and challenges. Nat Rev Genet 13(8):576-588, 2012.
PubMed
15) Ecker JR, et al : Genomics : ENCODE explained. Nature 489(7414):52-55, 2012.
PubMed
P.27 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 2006.
 
2) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
3) 日本骨粗鬆症学会 生活習慣病における骨折リスク評価委員会(編) : 生活習慣病骨折リスクに関する診療ガイド, ライフサイエンス出版, 2011.
 

II 骨の基礎研究

P.37 掲載の参考文献
1) Anderson HC : Vesicles associated with calcification in the matrix of epiphyseal cartilage. J Cell Biol 41:59-72, 1969.
PubMed
2) Amizuka N, et al : Histology of epiphyseal cartilage calcification and endochondral ossification. Front Biosci 4:2085-2100, 2012.
PubMed
3) Bonucci E : Fine structure of early cartilage calcification. J Ultrastruct Res 20:33-50, 1967.
PubMed
4) Belanger LF : Osteocytic osteolysis. Calcif Tissue Res 4:1-12, 1969.
PubMed
5) Lane NE, et al : Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466-476, 2006.
PubMed
6) Urakawa I, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774, 2006.
PubMed
7) Feng JQ, et al : Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315, 2006.
PubMed
8) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234, 2011.
PubMed
9) Takahashi N, et al : Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front Biosci 16:21-30, 2011.
PubMed
10) Yagi M, et al : DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351, 2005.
PubMed
11) Kornak U, et al : Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104(2):205-215, 2001.
PubMed
12) Salo J, et al : Removal of osteoclast bone resorption products by transcytosis. Science 276:270-273, 1997.
PubMed
13) 網塚憲生ほか : コラーゲン線維の石灰化とその異常-微細構造学的見地から. 腎と骨代謝 22:185-194, 2009.
 
14) 網塚憲生ほか : 骨基質の石灰化. 日本臨牀 65(増刊号9):194-201, 2007.
Medical*Online
15) 網塚憲生, 小澤英浩 : 骨とカルシウム-骨の細胞とカルシウム調節機構-, カルシウム その基礎と臨床(西沢良記ほか編), p20-34, 社団法人全国牛乳普及協会, 1999.
 
P.42 掲載の参考文献
1) 須田立雄ほか : 新骨の科学, p20-24, 医歯薬出版, 2007.
 
2) Hauge EM, et al : Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16:1575-1582, 2001.
PubMed
3) Eriksen EF : Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11:219-227, 2010.
PubMed
4) Nakamura H, et al : Localization of Thy-1-positive cells in the perichondrium during endochondral ossification. J Histochem Cytochem 58:455-462, 2010.
PubMed
5) Nakamura H, et al : Role of heparan sulfate proteoglycans surrounding osteoblast lineage cells. J Oral Biosci 54:43-47, 2012.
 
6) Mach DB, et al : Origins of skeletal pain : sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166, 2002.
PubMed
7) Ducy P, et al : Leptin inhibits bone formation through a hypothalamic relay : a central control of bone mass. Cell 100:197-207, 2000.
PubMed
8) Takeda S, et al : Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317, 2002.
PubMed
9) Uemura T, et al : Epinephrine accelerates osteoblastic differentiation by enhancing bone morphogenetic protein signaling through a cAMP/protein kinase A signaling pathway. Bone 47:756-765, 2010.
PubMed
10) Williams GA, et al : Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res 26:1698-1709, 2011.
PubMed
11) Baldock PA, et al : Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 4:e8415, 2009.
PubMed
12) Lee NJ, et al : Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 48:461-467, 2011.
PubMed
13) Igwe JC, et al : Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 108:621-630, 2009.
PubMed
14) Negishi-Koga T, et al : Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17:1473-1480, 2011.
PubMed
15) Hayashi M, et al : Osteoprotection by semaphorin 3A. Nature 485:69-74, 2012.
PubMed
P.46 掲載の参考文献
1) Long F : Building strong bones : molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 13:27-38, 2012.
 
2) Karsenty G : Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 9:183-196, 2008.
PubMed
3) Dalle Carbonare L et al : Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev 8:891-897, 2012.
PubMed
4) Marie PJ : Signaling pathways affecting skeletal health. Curr Osteoporos Rep 10:190-198, 2012.
PubMed
5) Yang X, et al : ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology ; implication for Coffin-Lowry Syndrome. Cell 117:387-398, 2004.
 
6) Kenner L, et al : Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 164:613-623, 2004.
PubMed
7) Kawamata A, et al : JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. J Cell Biochem 103:1037-1045, 2008.
PubMed
8) Bozec A, et al : Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 190:1093-1106, 2010.
PubMed
9) Hassan MQ, et al : Dlx3 transcriptional regulation of osteoblast differentiation : temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol 24:9248-9261, 2004.
PubMed
10) Matsuguchi T : Roles of kinases in osteoblast functions. In : Advances in Protein Kinases (ed by Da Silva Xavier G), p313-332, InTech, Rijeka, 2012.
 
11) Matsuguchi T, et al : Jnk activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res 24(3):398-410, 2009.
PubMed
12) Kasai T, et al : Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol 221:740-749, 2009.
PubMed
13) Takatani T, et al : AMP-activated protein kinase attenuates Wnt/β-catenin signaling in human osteoblastic Saos-2 cells. Mol Cell Endocrinol 339:114-119, 2011.
 
P.51 掲載の参考文献
1) Matsuo K, Irie N : Osteoclast-osteoblast communication. Arch Biochem Biophys 473:201-209, 2008.
PubMed
2) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234, 2011.
PubMed
3) Xiong J, et al : Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241, 2011.
PubMed
4) Barrow AD, et al : OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 121:3505-3516, 2011.
PubMed
5) Kuroda Y, et al : Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis. Proc Natl Acad Sci USA 105:8643-8648, 2008.
 
6) Kuroda Y, et al : Cot kinase promotes Ca2+ oscillation/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein. Mol Cell Biol 32:2954-2963, 2012.
PubMed
7) Maeda K et al : Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18:405-412, 2012.
PubMed
8) Irie N, et al : Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 284:14637-14644, 2009.
PubMed
9) Hayashi M, et al : Osteoprotection by semaphorin 3A. Nature 485:69-74, 2012.
PubMed
10) Tang Y, et al : TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757-765, 2009.
 
11) Xian L, et al : Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18:1095-1101, 2012.
PubMed
12) Zhao C, et al : Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121, 2006.
PubMed
13) Cheng S, et al : Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice. PLoS One 7:e32887, 2012.
PubMed
14) Negishi-Koga T, et al : Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17:1473-1480, 2011.
PubMed
15) Okamoto M, et al : Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26:2511-2522, 2011.
PubMed
P.56 掲載の参考文献
1) Fukumoto S, Shimizu Y : Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 29:507-514, 2011.
PubMed
2) Lee NK et al : Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469, 2007.
PubMed
3) Hwang YC, et al : Circulating osteocalcin level is not associated with incident type 2 diabetes in middle aged subjects. Mean 8.4-year retrospective follow-up study. Diabetes Care 35:1919-1924, 2012.
 
4) Motyl KJ, et al : Bone and glucose metabolism : a two-way street. Arch Biochem Biophys 503:2-10, 2010.
PubMed
5) Ferron M, et al : Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296-308, 2010.
PubMed
6) Oury F, et al : Endocrine regulation of male fertility by the skeleton. Cell 144:796-809, 2011.
PubMed
7) Pi M, et al : GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res 26:1680-1683, 2011.
 
8) Takeda S, et al : Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317, 2002.
PubMed
9) Richards JB, et al : Effects of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194, 2007.
PubMed
10) Schlienger RG, et al : Use of beta-blockers and risk of fractures. JAMA 292:1326-1332, 2004.
PubMed
11) Shimizu T, et al : Notch signaling pathway enhances bone morphogenetic protein 2(BMP2)responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells. J Biol Chem 286:19138-19148, 2011.
 
12) Suga T, et al : Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb 18:670-683, 2011.
 
13) Schulz E, et al : Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246-4253, 2004.
PubMed
14) Osako MK, et al : Estrogen inhibits vascular calcification via vascular RANKL system : common mechanism of osteoporosis and vascular calcification. Circ Res 107:466-475, 2010.
PubMed
15) Tanko LB, et al : Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912-1920, 2005.
PubMed
P.62 掲載の参考文献
1) Bouxsein ML, et al : Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468-1486, 2010.
PubMed
2) Parfitt AM, et al : Bone histomorphometry : standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610, 1987.
 
3) Odgaard A, Gundersen HJ : Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 14:173-182, 1993.
PubMed
4) Hildebrand T, Ruegsegger P : Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1:15-23, 1997.
PubMed
5) Szulc P, et al : Structural determinants of hip fracture in elderly women : re-analysis of the data from the EPIDOS study. Osteoporos Int 17:231-236, 2006.
PubMed
6) Voide R, et al : Time-lapsed assessment of microcrack initiation and propagation in murine cortical bone at submicrometer resolution. Bone 45:164-173, 2009.
PubMed
7) Seeman E : Bone quality : the material and structural basis of bone strength. J Bone Miner Metab 26:1-8, 2008.
PubMed
8) Mori H, et al : Minodronic acid(ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:840-848, 2008.
PubMed
9) Burr DB, et al : Intemlittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165, 2001.
PubMed
10) Jerome CP, et al : Treatment with human parathyroid hormone(1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys(Macaca fascicularis). Bone 28:150-159, 2001.
PubMed
11) Sato M, et al : Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629, 2004.
 
12) Jiang Y, et al : Recombinant human parathyroid hormone(1-34)[teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941, 2003.
PubMed
13) Chen P, et al : Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. J Bone Miner Res 22:841-848, 2007.
PubMed
P.66 掲載の参考文献
1) Langer M, et al : X-Ray Phase Nanotomography Resolves the 3D Human Bone Ultrastructure. PLoS One 7:e35691, 2012.
PubMed
2) Matsumoto T, et al : Three-dimensional cortical bone microstructure in a rat model of hypoxia-induced growth retardation. Calcif Tissue Int 88:54-62, 2011.
 
3) Matsumoto T, et al : Monochromatic synchrotron radiation muCT reveals disuse-mediated canal network rarefaction in cortical bone of growing rat tibiae. J Appl Physiol 100:274-280, 2006.
PubMed
4) Fujino H, et al : Regression of capillary network in atrophied soleus muscle induced by hindlimb unweighting. J Appl Physiol 98:1407-1413, 2005.
PubMed
5) Noble BS, et al : Mechanical loading : biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J physiol Cell Physiol 284:C934-C943, 2003.
PubMed
6) Wagatsuma A : Effect of hindlimb unweighting on expression of hypoxia-inducible factor-1alpha vascular endothelial growth factor, angiopoietin, and their receptors in mouse skeletal muscle. Physiol Res 57:613-620, 2008.
PubMed
7) Perrien DS, et al : Aging alters the skeletal response to disuse in the rat. Am J Physiol 292:R988-R996, 2007.
 
8) Britz HM, et al : The effects of immobilization on vascular canal orientation in rat cortical bone. J Anat 220:67-76, 2012.
PubMed
9) Cooper DM, et al : Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft. Bone 40:957-965, 2007.
PubMed
10) Hirose S, et al : A histological assessment on the distribution of the osteocytic lacunar canalicular system using silver staining. J Bone Miner Metab 25:374-382, 2007.
PubMed
11) Zebaze RM, et al : Intracortical remodelling and porosity in the distal radius and postmortem femurs of women : a cross-sectional study. Lancet 375:1729-1736, 2010.
PubMed
12) Tommasini SM, et al : Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT. Bone 50:596-604, 2012.
PubMed
13) Sharma D, et al : Alterations in the osteocyte lacunar-canalicular microenvironment due to estrogen deficiency. Bone 51:488-497, 2012.
PubMed
14) Taylor D, et al : Living with cracks : Damage and repair in human bone. Nat Mater 6:263-268, 2007.
PubMed
15) Voide R, et al : The importance of murine cortical bone microstructure for microcrack initiation and propagation. Bone 49:1186-1193, 2011.
PubMed
P.72 掲載の参考文献
1) Moses HL, Roberts AB : The discovery of TGF-β. In : The TGF-β Family, p1-28, Cold Spring Harbor Laboratory Press, New York, 2008.
 
2) Massague J : TGFβ in Cancer. Cell 134:215-230, 2008.
 
3) Beyer TA, et al : The TGFβ superfamily in stem cell biology and early mammalian embryonic development. Biochim Biophys Acta 1830:2268-2279, 2013.
 
4) Bierie B, Moses HL : Tumour microenvironment : TGFβ : the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-520, 2006.
 
5) Miyazono K, et al : Bone morphogenetic protein receptors and signal transduction. J Biochem 147:35-51, 2010.
PubMed
6) Cai J, et al : BMP signaling in vascular diseases. FEBS Lett 586:1993-2002, 2012.
PubMed
7) Miyazawa K, et al : Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 7:1191-1204, 2002.
 
8) Massague J, et al : Smad transcription factors. Genes Dev 19:2783-2810, 2005.
 
9) Chen G, et al : TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8:272-288, 2012.
 
10) Shore EM, et al : A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525-527, 2006.
PubMed
11) Fukuda T, et al : A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun 377:905-909, 2008.
 
12) Yu PB, et al : BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14:1363-1369, 2008.
PubMed
P.76 掲載の参考文献
1) Chusho H, et al : Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 98:4016-4021, 2001.
PubMed
2) Tamura N, et al : Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA 101:17300-17305, 2004.
PubMed
3) Moffatt P, et al : Osteocrin is a specific ligand of the natriuretic Peptide clearance receptor that modulates bone growth. J Biol Chem 282:36454-36462, 2007.
PubMed
4) Pfeifer A, et al : Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinaseII. Science 274:2082-2086, 1996.
 
5) Yamashita Y, et al : Concentration of mRNA for the natriuretic peptide receptor-C in hypertrophic chondrocytes of the fetal mouse tibia. J Biochem 127:177-179, 2000.
PubMed
6) Miyazawa T, et al : Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 143:3604-3610, 2002.
 
7) Yasoda A, et al: Targeted overexpression of CNP in chondrocytes rescues achondroplasia through MAPK-dependent pathway. Nat Med 10:80-86, 2004.
PubMed
8) Kake T, et al : Chronically elevated plasma C-type natriuretic peptide (CNP) level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 297:E1339-1348, 2009.
PubMed
9) Yasoda A, et al : Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150:3138-3144, 2009.
PubMed
10) Matsukawa N, et al : The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96:7403-7408, 1999.
PubMed
11) Bartels CF : Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75:27-34, 2004.
PubMed
12) Olney RC : Heterozygous mutations in natriuretic peptide receptor-B(NPR2) are associated with short stature. J Clin Endocrinol Metab 91:1229-1232, 2006.
PubMed
13) Miura K, et al : An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene. PLoS One 7:e42180, 2012.
PubMed
14) Hagiwara H : cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 270:C1311-1318, 1996.
PubMed
15) Holliday LS : C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures. J Biol Chem 270:18983-18989, 1995.
PubMed
P.82 掲載の参考文献
1) Migliaccio S, et al : The differential effects of bisphosphonates, SERMS(selective estrogen receptor modulator), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2(1):55-64, 2007.
 
2) 神崎晋ほか : ホルモンによる成長の制御. 小児科診療 70(10):1615-1619, 2007.
 
3) Sirns NA, et al : Skeletal phenotypes of estrogen receptors α, β and double knockouts suggest α dual role for ERβ in bone remodeling. Bone 30:18-25, 2002.
 
4) Nakamura T, et al : Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130:811-823, 2007.
 
5) Pacifici R : Estrogen deficiency, T cells and bone loss. Cell Immunol 252:68-80, 2008.
PubMed
6) Simonet WS, et al : Osteoprotegerin : a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997.
PubMed
7) Bucay N, et al : Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998.
PubMed
8) Hofbauer LC, et al : Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370, 1999.
PubMed
9) Devleta B, et al : Hypergonadotropic amenorrhea and bone density : new approach to an old problem. J Bone Miner Metab 22:360-364, 2004.
 
10) Sun L, et al : FSH directly regulates bone mass. Cell 125:247-260, 2006.
PubMed
11) Iqbal J, et al : Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103:14925-14930, 2006.
PubMed
P.86 掲載の参考文献
1) Archbold HC, et al : How do they do Wnt they do? : regulation of transcription by the Wnt/β-catenin pathway. Acta Physiol(Oxf) 204:74-109, 2012.
 
2) Clevers H, Nusse R : Wnt/beta-catenin signaling and disease. Cell 149:1192-1205, 2012.
PubMed
3) Li VS, et al : Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149:1245-1256, 2012.
 
4) Gong Y, et al : LDL receptor-related protein 5(LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001.
PubMed
5) Boyden LM, et al : High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521, 2002.
PubMed
6) Glass DA 2nd, et al : Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764, 2005.
PubMed
7) Grigoryan T, et al : Deciphering the function of canonical Wnt signals in development and disease : conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 22:2308-2341, 2008.
PubMed
8) Cui Y, et al : Lrp5 functions in bone to regulate bone mass. Nat Med 17:684-691, 2011.
PubMed
9) Kramer I, et al : Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30:3071-3085, 2010.
PubMed
10) Wei W, et al : Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 31:4706-4719, 2011.
PubMed
11) Yadav VK, et al : Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837, 2008.
PubMed
12) Yadav VK, et al : Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16:308-312, 2010.
PubMed
13) Anastasilakis AD, et al : Role of wingless tail signaling pathway in osteoporosis : an update of current knowledge. Curr Opin Endocrinol Diabetes Obes 18:383-388, 2011.
PubMed
14) Ke HZ, et al : Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747-783, 2012.
PubMed
P.93 掲載の参考文献
1) Haynes BF, et al : Introduction to the immune system. In : Harrison's Principles of Internal Medicine, 18th ed(ed by Fauci AS, et al), p2650-2685, McGraw-Hill, Columbus, 2011.
 
2) Nakayamada S, et al : Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 35:919-931, 2011.
PubMed
3) Scott DL et al : Rheumatoid arthritis. Lancet 376:1094-1108, 2010.
PubMed
4) Redlich K, Smolen JS : Inflammatory bone loss : pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234-250, 2012.
PubMed
5) Rachner TD, et al : Osteoporosis : now and the future. Lancet 377:1276-1287, 2011.
PubMed
6) Schett G, et al : From bone biology to clinical outcome : state of the art and future perspectives. Ann Rheum Dis 69:1415-1419, 2010.
PubMed
7) Catrina AI, et al : Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54:76-81, 2006.
PubMed
P.98 掲載の参考文献
1) Oxlund H, et al : Reduced concentrations of colagen cross-links are associated with reduced strength of bone. Bone 17:365S-371S, 1995.
 
2) Saito M, Marumo K : Collagen cross-links as a determinant of bone quality : a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195-214, 2010.
PubMed
3) Yamauchi M : Collagen biochemistry : An overview. In : Bone Morphogenetic Protein and Collagen (ed by Phillips GO), p93-148, World Scientific, Toh Tuck Link, 2003.
 
4) Yamauchi M, Sricholpech M : Lysine post-translational modifications of collagen. Essays Biochem 52:113-133, 2012.
PubMed
5) Pornprasertsuk S, et al : Lysyl hydroxylase-2b directs collagen crosslinking pathways in MC3T3-E1 cells. J Bone Miner Res 19:1349-1355, 2004.
 
6) Schegg B, et al : Core glycosylation of collagen is initiated by two β(1-Ο) galactosyltransferases. Mol Cell Biol 29:943-952, 2009.
 
7) Sricholpech M, et al : Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast culture. J Biol Chem 286:8846-8856, 2011.
 
8) Sricholpech M, et al : Lysyl hydroxylase 3-mediated glucosylation in type I collagen. Molecular loci and biological significance. J Biol Chem 287:22998-23009, 2012.
 
9) Yamauchi M, Katz EP : The post-translational chemistry and molecular packing of mineralizing tendon collagens. Connect Tissue Res 29:81-98, 1993.
PubMed
10) Eyre DR, et al : Cross-linking in collagen and elastin. Ann Rev Biochem 53:717-748, 1984.
PubMed
11) Yamauchi M, Mechanic GL : Cross-linking of collagen. In : Collagen : Biochemistry, Biotechnology and Molecular Biology (ed by Nimni M, Olsen B), p157-172, CRC Press, Florida, 1988.
 
12) Robins SP, Duncan A : Cross-linking of collagen. Location of pyridinoline in bovine articular cartilage at two sites of the molecule. Biochem J 215:175-182, 1983.
PubMed
13) Cronlund AL, et al : Binding of lysyl oxidase to fibrils of type I collagen. Connect Tissue Res 14:109-119, 1985.
PubMed
14) Silver FH, Landis WJ : Deposition of apatite in mineralizing vertebrate extracellular matrices : A model of possible nucleation sites on type I collagen. Connect Tissue Res 52:242-254, 2011.
 
15) Sweeney SM, et al : Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J Biol Chem 283:21187-21197, 2008.
PubMed
P.102 掲載の参考文献
1) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy : Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785-795, 2001.
PubMed
2) Reifsnider KL, et al : Lon-term fatigue characteristics of composite materials. In : Long-Term Behavior of Composite Materials STP813, American Society for Testing and Materials, Philadelphia, 1983.
 
3) 小澤英浩 : 軟骨と骨の構造. 最新内科学大系73 骨疾患(中塚喜義ほか編), p9, 中山書店, 1995.
 
4) Burr DB, et al : Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12:6-15, 1997.
PubMed
5) Mori S, Burr DB : Increased intracortical remodeling following fatigue damage. Bone 14:103-109, 1993.
PubMed
6) Frost HM : Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull 8:25-35, 1960.
 
7) 森諭史 : 骨微細損傷とその修復-骨疲労の病態と整理-. 臨床整形外科 33:975-981, 1998.
 
8) Schaffler MB, et al : Aging and matrix microdamage accumulation in human compact bone. Bone 17:521-525, 1995.
PubMed
9) Mori S, et al : Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 12:521-526, 1997.
PubMed
10) Mashiba T, et al : Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620, 2000.
PubMed
11) Komatsubara S, et al : Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005, 2004.
 
12) Boivin G, et al : Influence of remodeling on the mineralization of bone tissue. Osteoporos Int 20:1023-1026, 2009.
PubMed
13) Odvina CV, et al : Severely suppressed bone turnover : a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301, 2005.
PubMed
14) Goh SK et al : Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg 89-B:349-353, 2007.
 
15) Whitaker M, et al : Bisphosphonates for osteoporosis - Where do we go from here? N Engl J Med 366:2048-2051, 2012.
PubMed
16) Black DM, et al : Continuing bisphosphonate treatment for osteoporosis - For whom and for how long? N Engl J Med 366:2051-2053, 2012.
 

III 骨研究フロンティア - 基礎から臨床まで -

P.110 掲載の参考文献
1) Anderson DM, et al : A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997.
PubMed
2) Lacey DL, et al : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
PubMed
3) Yasuda H, et al : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
4) Kong YY, et al : OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
5) Dougall WC, et al : RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424, 1999.
PubMed
6) Takayanagi H, et al : Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901, 2002.
PubMed
7) Miyauchi Y, et al : The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med 207:751-762, 2010.
PubMed
8) Nishikawa K, et al : Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci USA 107:3117-3122, 2010.
PubMed
9) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234, 2011.
PubMed
10) Cummings SR, et al : Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765, 2009.
PubMed
11) Arai F, et al : Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754, 1999.
PubMed
12) Yagi M, et al : DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351, 2005.
PubMed
13) Yagi M, et al : Induction of DC-STAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 22:992-1001, 2007.
PubMed
14) Iwasaki R, et al : Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. Biochem Biophys Res Commun Dec 377:899-904, 2008.
 
15) Miyamoto H, et al : Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 27:1289-1297, 2012.
PubMed
P.114 掲載の参考文献
1) Kotake S, et al : Activated human T cells directly induce osteoclastogenesis from human monocytes : possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003-1012, 2001.
 
2) Kong YY, et al : Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999.
PubMed
3) Horwood NJ, et al : Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265:144-150, 1999.
PubMed
4) Yago T, et al : IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody : A novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108:947-955, 2009.
PubMed
5) Fuller K, et al : TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 143:1108-1118, 2002.
PubMed
6) Shinoda K, et al : Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 33:711-720, 2003.
PubMed
7) Takayanagi H, et al : T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605, 2000.
PubMed
8) Kotake S, et al : IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol 35:3353-3363, 2005.
 
9) Miranda-Carus ME, et al : Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 54:1151-1164, 2006.
 
10) Kotake S, et al : IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345-1352, 1999.
PubMed
11) Mosmann TR, et al : Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357, 1986.
PubMed
12) Liu H, Rohowsky-Kochan C : Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 180:7948-7957, 2008.
PubMed
13) Yago T, et al : Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation. Cytokine 59:252-257, 2012.
PubMed
14) Wyzga N, et al : Effects of activated T cells on osteoclastogenesis depend on how they are activated. Bone 35:614-620, 2004.
PubMed
15) Kanamaru F, et al : Expression of membrane-bound and soluble receptor activator of NF-kappa B ligand (RANKL) in human T cells. Immunol Lett 94:239-246, 2004.
 
16) Kotake S, et al : Human osteoclastogenic T cells and human osteoclastology. Arthritis Rheum 60:3158-3163, 2009.
PubMed
P.119 掲載の参考文献
1) Komori T, et al : Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997.
 
2) Otto F, et al : Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771, 1997.
PubMed
3) Mundlos S, et al : Mutations involving the transcription factor CBEA1 cause cleidocranial dysplasia. Cell 89:773-779, 1997.
PubMed
4) Ducy P, et al : Osf2/Cbfa1 : a transcriptional activator of osteoblast differentiation. Cell 89:747-754, 1997.
PubMed
5) Liu T, et al : BMP-2 promotes differentiation of osteoblasts and chondroblasts in Runx2-deficient cell lines. J Cell Physiol 211:728-735, 2007.
PubMed
6) Yoshida CA, et al : Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 32:633-638, 2002.
PubMed
7) Hong JH, et al : TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074-1078, 2005.
 
8) Nishikawa K, et al : Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest 120:3455-3465, 2010.
PubMed
9) Yang X, et al : ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology ; implication for Coffin-Lowry Syndrome. Cell 117:387-398, 2004.
 
10) Nakashima K, et al : The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29, 2002.
PubMed
11) Sabatakos G, et al : Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985-990, 2000.
PubMed
12) Eferl R, et al : The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J 23:2789-2799, 2004.
PubMed
13) Kenner L, et al : Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 164:613-623, 2004.
PubMed
14) Murakami T, et al : Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat Cell Biol 11:1205-1211, 2009.
PubMed
15) Saito A, et al : Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 286:4809-4818, 2011.
PubMed
P.125 掲載の参考文献
1) Nakashima T, et al : New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 23:582-590, 2012.
PubMed
2) Manolagas SC : Birth and death of bone cells : basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21(2):115-137, 2000.
PubMed
3) Bonewald LF : The amazing osteocyte. J Bone Miner Res 26(2):229-238, 2011.
PubMed
4) Young RW : Cell proliferation and specialization during endochondral osteogenesis in young rats. J Cell Biol 14:357-370, 1962.
PubMed
5) Palumbo C, et al : Morphological study of intercellular junctions during osteocyte differentiation. Bone 11(6):401-406, 1990.
PubMed
6) Franz-Odendaal TA, et al : Buried alive : how osteoblasts become osteocytes. Dev Dyn 235(1):176-190, 2006.
PubMed
7) Aarden EM, et al : Function of osteocytes in bone. J Cell Biochem 55(3):287-299, 1994.
 
8) Teti A, Zallone A : Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 44(1):11-16, 2009.
PubMed
9) Mosekilde L, et al : A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 204(1-2):97-102, 1978.
 
10) Tazawa K, et al : Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered. J Bone Miner Metab 22(6):524-529, 2004.
PubMed
11) Qing H, et al : Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 27(5):1018-1029, 2012.
PubMed
12) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17(10):1231-1234, 2011.
PubMed
13) Burger EH, et al : Osteoclast formation from mononuclear phagocytes : role of bone-forming cells. J Cell Biol 99(6):1901-1906, 1984.
 
14) Takahashi N, et al : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123(5):2600-2602, 1988.
PubMed
15) Takayanagi H : Osteoimmunology : shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7(4):292-304, 2007.
PubMed
16) Xiong J, et al : Matrix-embedded cells control osteoclast formation. Nat Med 17(10):1235-1241, 2011.
PubMed
P.129 掲載の参考文献
1) The ADHR Consortium : Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348, 2000.
PubMed
2) Shimada T, et al : Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505, 2001.
PubMed
3) Urakawa I, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774, 2006.
PubMed
4) Ben-Dov IZ, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008, 2007.
PubMed
5) Yuan B, et al : Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118:722-734, 2008.
PubMed
6) Feng JQ, et al : Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315, 2006.
PubMed
7) Endo I, et al : Clinical usefulness of measurement of fibroblast growth factor 23(FGF23) in hypophosphatemic patients : proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235-1239, 2008.
PubMed
8) Martin A, et al : Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGF) signaling. FASEB J 25:2551-2562, 2011.
PubMed
9) Tagliabracci VS, et al : Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 336:1150-1153, 2012.
PubMed
10) Wang X, et al : Inactivation of a novel FGF23 regulator, FAM20C, leads to hypohosphatemic rickets in mice. PLoS Genet 8:e1002708, 2012.
PubMed
11) Liu S, et al : Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305-1315, 2006.
PubMed
12) Rhee Y, et al : Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49:636-643, 2011.
PubMed
13) Perwad F, et al : Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice 146:5358-5364, 2005.
PubMed
14) Lorenz-Depiereux B, et al : Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267-272, 2010.
PubMed
15) White KE, et al : Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367, 2005.
PubMed
P.135 掲載の参考文献
1) Hobert O : Gene regulation by transcription factors and microRNAs. Science 319:1785-1786, 2008.
PubMed
2) Komori T : Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99:1233-1239, 2006.
PubMed
3) Inose H, et al : A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci USA 106:20794-20799, 2009.
PubMed
4) Li Z, et al : A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA 105:13906-13911, 2008.
 
5) Itoh T, et al : MicroRNA-208 modulates BMP-2-stimulated mouse preosteoblast differentiation by directly targeting V-ets erythroblastosis virus E26 oncogene homolog 1. J Biol Chem 285:27745-27752, 2010.
PubMed
6) Itoh T, et al : MicroRNA-141 and-200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. J Biol Chem 284:19272-19279, 2009.
PubMed
7) Gaur T, et al : Dicer inactivation in osteoprogenitor cells compromises fetal survival and bone formation, while excision in differentiated osteoblasts increases bone mass in the adult mouse. Dev Biol 340:10-21, 2010.
PubMed
8) Li H, et al : A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119:3666-3677, 2009.
 
9) Mizoguchi F, et al : Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J Cell Biochem 109:866-875, 2010.
PubMed
10) Sugatani T, Hruska KA : Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem 284:4667-4678, 2009.
PubMed
11) Kobayashi T, et al : Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci USA 105, 1949-1954, 2008.
PubMed
12) Harfe BD, et al : The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci USA 102:10898-10903, 2005.
PubMed
13) Miyaki S, et al : MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum 60:2723-2730, 2009.
PubMed
14) Miyaki S, et al : MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 24:1173-1185, 2010.
PubMed
P.139 掲載の参考文献
1) Kishimoto T : IL-6 : from its discovery to clinical applications. Int Immunol 22:347-352, 2010.
PubMed
2) Hirano T, et al : Complementary DNA for a novel human interleukin(BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.
PubMed
3) Yamasaki K, et al : Cloning and expression of the human interleukin-6(BSF-2/IFN beta 2) receptor. Science 241:825-828, 1988.
PubMed
4) Taga T, et al : Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581, 1989.
PubMed
5) Hibi M, et al : Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-1157, 1990.
 
6) Lowik CW, et al : Parathyroid hormone(PTH) and PTH-like protein(PLP) stimulate interleukin-6 production by osteogenic cells : a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162:1546-1552, 1989.
 
7) Ishimi Y, et al : IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297-3303, 1990.
PubMed
8) O'Brien CA, et al : STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274:19301-19308, 1999.
 
9) Kim S, et al : Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Mol Endocrinol 21:197-214, 2007.
PubMed
10) Duplomb L, et al : Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage : key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149:3688-3697, 2008.
PubMed
11) Yoshitake F, et al : Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 283:11535-11540, 2008.
PubMed
12) O'Brien CA, et al : IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289:E784-793, 2005.
 
13) Bellido T, et al : Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273:21137-21144, 1998.
 
14) Takeuchi Y, et al : Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem 277:49011-49018, 2002.
PubMed
15) Chipoy C, et al : Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 19:1850-1861, 2004.
 
16) Blanchard F, et al : The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 20:19-28, 2009.
 
17) Li Y, et al : IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. Cytokine 43:165-173, 2008.
PubMed
18) Poli V, et al : Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196, 1994.
PubMed
19) Kawasaki K, et al : Osteoclasts are present in gp130-deficlent mice. Endocrinology 138:4959-4965, 1997.
PubMed
20) Sims NA, et al : Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113:379-389, 2004.
PubMed
21) Jilka RL, et al : Increased osteoclast development after estrogen loss : mediation by interleukin-6. Science 257:88-91, 1992.
PubMed
22) Lin SC, et al : Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest 100:1980-1990, 1997.
PubMed
23) Girasole G, et al : Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin Endocrinol 51:801-807, 1999.
PubMed
24) Straub RH, et al : Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women : apopulation-based study. J Clin Endocrinol Metab 85:1340-1344, 2000.
 
25) Scheidt-Nave C, et al : Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 86:2032-2042, 2001.
 
26) Kanematsu M, et al : Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells : implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15:1321-1329, 2000.
PubMed
27) Kong YY, et al : Osteoprotegerin ligand : a regulator of immune responses and bone physiology. Immunol Today 21:495-502, 2000.
PubMed
P.144 掲載の参考文献
1) Yasuda H, et al : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
2) Lacey DL, et al : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
PubMed
3) Kobayashi K, et al : TNF-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-285, 2000.
 
4) Lam J, et al : TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488, 2000.
 
5) Li P, et al : RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19:207-213, 2004.
 
6) Kim N, et al : Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589-595, 2005.
 
7) Nakashima T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234, 2011.
PubMed
8) Kitaura H, et al : M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115:3418-3427, 2005.
PubMed
9) Ruocco MG, et al : 1κB kinase(IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677-1687, 2005.
 
10) Quinn JM, Saleh H : Modulation of osteoclast function in bone by the immune system. Mol Cell Endocrinol 310:40-51, 2009.
PubMed
11) Kitaura H, et al : Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells : apoptosis mediated by Fas/Fas ligand interaction. J Immunol 169:4732-4738, 2002.
PubMed
12) Kitaura H, et al : IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett 107:22-31, 2006.
PubMed
13) Kohara H, et al : IFN-γ directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interaction. Immunol Lett 137:53-61, 2011.
 
14) Fujii T, et al : IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo. Bone 51:771-780, 2012.
 
P.149 掲載の参考文献
1) Miller JR : The Wnts. Genome Biol 3:1-15, 2002.
PubMed
2) Gong Y, et al : LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19, 2002.
 
3) Rawadi G : Wnt signaling and potential applications in bone diseases. Curr Drug Targets 9:581-590, 2008.
PubMed
4) Takada I, et al : A histone lysine methyltransferase activated by non-canonical Wnt signaling suppresses PPAR-gamma transactivation. Nat Cell Biol 9:1273-1285, 2007.
 
5) Maeda K, et al : Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18:405-412, 2012.
PubMed
6) Sen M, et al : Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 97:2791-2796, 2000.
PubMed
P.153 掲載の参考文献
1) Yasuda H, et al : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
2) Simonet WS, et al : Osteoprotegerin : a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997.
PubMed
3) Lacey DL, et al : Bench to bedside : elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401-419, 2012.
PubMed
4) Lam J, et al : Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108:971-979, 2001.
PubMed
5) Luan X, et al : Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol 189:245-252, 2012.
PubMed
6) Kong YY, et al : OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 397:315-323, 1999.
PubMed
7) Sobacchi C, et al : Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960-962, 2007.
PubMed
8) Guerrini MM, et al : Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A(RANK) mutations. Am J Hum Genet 83:64-76, 2008.
PubMed
9) Hughes AE, et al : Mutations in TNFRSF11A, affecting the signal peptide of RANK cause familial expansile osteolysis. Nat Genet 24:45-48, 2000.
PubMed
10) Whyte MP, et al : Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184, 2002.
PubMed
11) Hikita A, et al : Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J Biol Chem 281:36846-36855, 2006.
 
12) Nakamichi Y, et al : Osteoprotegerin reduces the serum level of receptor activator of NF-κB ligand derived from osteoblasts. J Immunol 178:192-200, 2007.
 
13) Nakamichi Y, et al : Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci USA 109:10006-10011, 2012.
PubMed
14) Tachi K, et al : Bone morphogenetic protein 2 enhances mouse osteoclast differentiation Via increased levels of receptor activator of NF-κB ligand expression in osteoblasts. Cell Tissue Res 342:213-220, 2010.
 
15) 独立行政法人医薬品医療機器総合機構 : 審査報告書, 2012.
 
P.159 掲載の参考文献
1) Thomas DM, et al : Insulin and bone, clinical and scientific view. Endocrinol Metab 4:5-17, 1997.
 
2) Rosen CJ, Donahue LR : Insulin-like growth factors and bone, the osteoporosis connection revisited. Proc Soc Exp Biol Med 219:1-7, 1998.
PubMed
3) Piepkorn B, et al : Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 29:584-591, 1997.
PubMed
4) Krakauer JC, et al : Bone mineral density in diabetes. Diabetes Care 20:1339-1340, 1997.
PubMed
5) van Daele PL, et al : Bone density in non-insulin-dependent diabetes mellitus. Ann Intern Med 122:409-414, 1995.
PubMed
6) Rosen CJ, et al : Circulating and skeletal insulin-like growth factor-I(IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217-223, 1997.
PubMed
7) Reed BY, et al : Serum IGF-I is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 10:1218-1224, 1995.
 
8) Laron Z : Patients with Laron syndrome have osteopenia/osteoporosis. J Bone Miner Res 14:156-161, 1999.
 
9) Akune T, et al : Insulin secretory response is positively associated with the extent of ossification of the posterior longitudinal ligament of the spine. J Bone Joint Surg(Am) 83-A:1537-1544, 2001.
PubMed
10) Kawaguchi H, et al : Contribution of metabolic conditions to ossification of the posterior longitudinal ligament of the spine. In : OPLL-Ossification of the Posterior Longitudinal Ligament, 2nd ed(ed by Yonenobu K, et al), p37-40, Springer-Verlag, Tokyo, 2006.
 
11) Ogata N, et al : Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105:935-943, 2000.
PubMed
12) Akune T, et al : Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159:147-156, 2002.
PubMed
13) Shimoaka T, et al : Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem 279:15314-15322, 2004.
PubMed
14) Yamaguchi M, et al : Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146:2620-2628, 2005.
PubMed
15) Kawamura N, et al : Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE 2:e1058, 2007.
PubMed
P.164 掲載の参考文献
1) Potts JT, Gardella TJ : Progress, paradox, and potential : parathyroid hormone research over five decades. Ann N Y Acad Sci 1117:196-208, 2007.
PubMed
2) Potts JT : Parathyroid hormone : past and present. J Endocrinol 187(3):311-325, 2005.
PubMed
3) Baron R, Hesse E : Update on bone anabolics in osteoporosis treatment : rationale, current status, and perspectives. J Clin Endocrinol Metab 97(2):311-325, 2012.
 
4) Lombardi G, et al : The roles of parathyroid hormone in bone remodeling : prospects for novel therapeutics, J Endocrinol Invest 34(7 Suppl):18-22, 2011.
 
5) Bilezikian JP : Primary hyperparathyroidism. Endocr Pract 18(5):781-790, 2012.
PubMed
6) Mitchell DM, et al : Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507-4514, 2012.
PubMed
7) Hock JM, et al : Osteoblast apoptosis and bone turnover. J Bone Miner Res 16(6):975-984, 2001.
PubMed
8) Segre GV, et al : Characterization of cloned PTH/PTHrP receptors. J Endocrinol Invest 15(9 Suppl 6):11-17, 1992.
 
9) Cusano NE, Bilezikian JP : Combination anabolic and antiresorptive therapy for osteoporosis. Endocrinol Metab Clin North Am 41(3):643-654, 2012.
PubMed
10) Larsson S, Fazzalari NL : Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg, 2012.
PubMed
11) Compston J : The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1):11-18, 2012.
PubMed
12) Whitfield JF, et al : Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 1(3):175-190, 2002.
PubMed
13) Datta NS, et al : Parathyroid hormone induces bone formation in phosphorylation-deficient PTHR1 knockin mice. Am J Physiol Endocrinol Metab 302(10):E1183-1188, 2012.
PubMed
14) Lupp A, et al : Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol 162(5):979-986, 2010.
PubMed
15) Patterson EK, et al : Functional analysis of a type 1 parathyroid hormone receptor intracellular tail mutant [KRK(484-6)AAA] : effects on second messenger generation and cellular targeting. Bone 46(4):1180-1187, 2010.
PubMed
16) Tenne M, et al : Genetic variation in the PTH pathway and bone phenotypes in elderly women : evaluation of PTH, PTHLH, PTHR1 and PTHR2 genes. Bone 42(4):719-727, 2008.
PubMed
17) Guo J, et al : Phospholipase C signaling via the parathyroid hormone(PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology 151(8):3502-3513, 2010.
PubMed
18) Yamashita J, et al : Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J Bone Miner Res 23(5):621-632, 2008.
 
19) Datta NS, et al: Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22(7):951-964, 2007.
 
20) Kramer I, et al : Parathyroid hormone(PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25(2):178-189, 2010.
PubMed
21) Kramer I, et al : Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21(4):237-244, 2010.
PubMed
22) Sims NA : Building bone with a SOST-PTH partnership. J Bone Miner Res 25(2):175-177, 2010.
PubMed
23) Bikle DD, Wang Y : Insulin like growth factor-I : a critical mediator of the skeletal response to parathyroid hormone. Curr Mol Pharmacol 5(2):135-142, 2012.
PubMed
24) McCauley LK, et al : Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo. Endocrinology 142(5):1975-1981, 2001.
PubMed
25) Tawfeek H, et al : Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 5(8):e12290, 2010.
 
26) Pirih FQ, et al : Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6. PLoS One 5(10):e13657, 2010.
PubMed
27) Raggatt LJ, et al : Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem 283(11):6790-6798, 2008.
PubMed
28) Hanyu R, et al : Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor. Proc Natl Acad Sci USA 109(19):7433-7438, 2012.
 
29) Vilardaga JP, et al : Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci 33(8):423-43, 2012.
PubMed
30) Kim SW, et al : Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 27(10):2075-2084, 2012.
PubMed
31) Bonnet N, et al : Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA 109(37):15048-15053, 2012.
PubMed
32) Leupin O, et al : Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22(12):1957-1967, 2007.
PubMed
36) Rankin W, et al : Parathyroid hormone-related protein and hypercalcemia. Cancer 80(8 Suppl):1564-1571, 1997.
 
37) Jans DA, et al : Parathyroid hormone-related protein(PTHrP):a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles. Vitam Horm 66:345-384, 2003.
PubMed
38) Fiaschi-Taesch N, et al : Parathyroid-hormone-related protein as a regulator of pRb and the cell cycle in arterial smooth muscle. Circulation 110(2):177-185, 2004.
PubMed
39) Sicari BM, et al : c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein, Endocrinology 153(2):861-872, 2012.
PubMed
40) Kronenberg HM : PTHrP and skeletal development. Ann N Y Acad Sci 1068:1-13, 2006.
PubMed
41) Marino R : Growth plate biology : new insights. Curr Opin Endocrinol Diabetes Obes 18(1):9-13, 2011.
PubMed
42) Correa D, et al : Zfp521 is a target gene and key effector of parathyroid hormone-related peptide signaling in growth plate chondrocytes. Dev Cell 19(4):533-546, 2010.
 
43) Kozhemyakina E, et al : Parathyroid hormone-related peptide represses chondrocyte hypertrophy through a protein phosphatase 2A/histone deacetylase 4/MEF2 pathway. Mol Cell Biol 29(21):5751-5762, 2009.
PubMed
44) Seriwatanachai D, et al : Deletion of Zfr521 rescues the growth plate phenotype in a mouse model of Jansen metaphyseal chondrodysplasia. FASEB J 25(9):3057-3067, 2011.
 
45) Klopocki E, et al : Deletion and point mutations of PTHLH cause brachydactyly type E. Am J Hum Genet 86(3):434-439, 2010.
PubMed
46) Maass PG, et al : A cis-regulatory site downregulates PTHLH in translocation t(8;12)(q13;p11.2) and leads to Brachydactyly Type E. Hum Mol Genet 19(5):848-860, 2010.
 
47) Williams SR, et al : Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 87(2):219-228, 2010.
PubMed
48) Hirai T, et al : Parathyroid hormone/parathyroid hormone-related protein receptor signaling is required for maintenance of the growth plate in postnatal life. Proc Natl Acad Sci USA 108(1):191-196, 2011.
PubMed
49) Wang Y, et al : IGF-1R signaling in chondrocytes modulates growth plate development by interacting with the PTHrP/Ihh pathway. J Bone Miner Res 26(7):1437-1446, 2011.
PubMed
50) Amizuka N, et al : Haploinsufficiency of parathyroid hormone-related peptide(PTHrP) results in abnormal postnatal bone development. Dev Biol 175(1):166-176, 1996.
PubMed
51) Kronenberg HM : PTH regulates the hematopoietic stem cell niche in bone. Adv Exp Med Biol 602:57-60, 2007.
PubMed
P.172 掲載の参考文献
1) Khosla S, et al : Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443-1450, 2002.
PubMed
2) Vanderschueren D, et al : Androgen and bone. Endocr Rev 25(3):389-425, 2004.
PubMed
3) Tanaka S, et al : 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137:1860-1869, 1996.
PubMed
4) Gill RK, et al : Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor beta in rat bone, and reduction is prevented by testosterone. Endocrinology 139:546-550, 1998.
PubMed
5) Janssens K, et al : Transforming growth factor-beta 1 to the bone. Endocr Rev 26:743-774, 2005.
 
6) Michael H, et al : Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20:2224-2232, 2005.
PubMed
7) Bellido T, et al : Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95:2886-2895, 1995.
PubMed
8) Hofbauer LC, et al : Regulation of osteoprotegerin production by androgens and anti-androgen in human osteoblastic lineage cells. Eur J Endocrinol 147:269-273, 2002.
PubMed
9) Kousteni S, et al : Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors : dissociation from transcriptional activity. Cell 104:719-730, 2001.
 
10) Kawano H, et a : Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416-9421, 2003.
PubMed
11) Herrmann BL, et al : Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 87(12):5476-5484, 2002.
 
12) Falahati-Nini A, et al : Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560, 2000.
 
13) Clarke BL, Khosla S : Androgens and bone. Steroids 74:296-305, 2009.
PubMed
14) Oury G, et al : Endocrine regulation of male fertility by the skeleton. Cell 144:796-809, 2011.
PubMed
15) Krum SA : Direct transcriptional targets of sex steroid hormones in bone. J Cell Biochem 112(2):401-408, 2011.
 
P.176 掲載の参考文献
1) Itoh N, Ornitz DM : Evolution of the Fgf and Fgf gene families. Trends Genet 20:563-569, 2004.
PubMed
2) Muthusami S, et al : Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta 360(1-2):81-86, 2005.
 
2) Moore DD : Physiology. Sister act. Science 316:1436-1438, 2007.
PubMed
3) Shimada T, et al : FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435, 2004.
 
3) Lean JM, et al : A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112(6):915-923, 2003.
PubMed
4) Ma DF et al : Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women : meta-analysis of randomized controlled trials. Eur J Clin Nutr 62(2):155-161, 2008.
PubMed
4) Feng JQ, et al : Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315, 2006.
PubMed
5) Urakawa I, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774, 2006.
PubMed
5) Kondo H, et al : Oxidative stress and gamma radiation-induced cancellous bone loss with musculoskeletal disuse. J Appl Physiol 108(1):152-161, 2010.
PubMed
6) Sahni S, et al : High vitamin C intake is associated with lower 4-year bone loss in elderly men. J Nutr 138(10):1931-1938, 2008.
 
6) Kuro-o M, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51, 1997.
PubMed
7) Rao LG, et al : Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women. Osteoporos Int 18(1):109-115, 2007.
PubMed
7) Shimada T, et al : Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF-23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568, 2004.
 
8) Fujita K, et al : Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med 18(9):1445, 2012.
 
8) Ben-Dov IZ, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008, 2007.
PubMed
9) Fukumoto S, Martin TJ : Bone as an endocrine organ. Trends Endocrinol Metab 20:230-236, 2009.
PubMed
9) Nojiri H, et al : Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking. J Bone Miner Res 26(11):2682-2694, 2011.
PubMed
10) Frishberg Y, et al : Hyperostosis-hyperphosphatemia syndrome : a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235-242, 2007.
 
10) Ishii KA, et al : Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15(3):259-266, 2009.
PubMed
11) Kato K, et al : Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370-18377, 2006.
PubMed
11) Steinbeck MJ, et al : NADPH-oxidase expression and in situ production of superoxide by osteoclasts actively resorbing bone. J Cell Biol 126(3):765-772, 1994.
 
12) Isakova T, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370-1378, 2011.
PubMed
12) Sabanai K, et al : Genetic disruption of all NO synthase isoforms enhances BMD and bone turnover in mice in vivo : involvement of the renin-angiotensin system. J Bone Miner Res 23(5):633-643, 2008.
PubMed
13) Togari A, et al : Coexpression of GTP cyclohydrolase I and inducible nitric oxide synthase mRNAs in mouse osteoblastic cells activated by proinflammatory cytokines. FEBS Lett 428(3):212-216, 1998.
PubMed
13) Hasegawa H, et al : Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78:975-980, 2010.
PubMed
14) Komaba H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232-238, 2010.
PubMed
14) Watanuki M, et al : Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J Bone Miner Res 17(6):1015-1025, 2002.
PubMed
15) Rangaswami H, et al : Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Sci Signal 3(153):ra91, 2010.
PubMed
15) Fukumoto S, Shimizu Y : Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 29:507-514, 2011.
PubMed
16) Faul C, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393-4408, 2011.
PubMed
17) Shalhoub V, et al : FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122:2543-2553, 2012.
PubMed
P.179 掲載の参考文献
1) Altindag O, et al : Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int 28(4):317-321, 2008.
PubMed
P.184 掲載の参考文献
1) Karsenty G, et al : Genetic control of bone formation. Annu Rev Cell Dev Biol 25:629-648, 2009.
PubMed
2) Teitelbaum SL, Ross FP : Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649, 2003.
PubMed
3) Cockayne S, et al : Vitamin K and the prevention of fractures : systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-1261, 2006.
PubMed
4) Radimer K, et al : Dietary supplement use by US adults : data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160:339-349, 2004.
PubMed
5) Fujita K, et al : Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med 18:589-594, 2012.
PubMed
6) Jishage K, et al : Alpha-tocopherol transfer protein is important for the normal development of placental labyrinthine trophoblasts in mice. J Biol Chem 276:1669-1672, 2001.
PubMed
7) Yokota T, et al : Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein : model for neuronal degeneration caused by chronic oxidative stress. Proc Natl Acad Sci USA 98:15185-15190, 2001.
PubMed
8) Yagi M, et al : DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351, 2005.
PubMed
9) Greenblatt MB, et al : The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 120:2457-2473, 2010.
PubMed
10) Steingrimsson E, et al : Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc Natl Acad Sci USA 99:4477-4482, 2002.
PubMed
11) Hamidi MS, et al : Effects of Vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res 27:1368-1380, 2012.
 
P.191 掲載の参考文献
1) Gong Y, et al : LDL receptor-related protein 5(LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001.
PubMed
2) Kato M, et al : Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314, 2002.
PubMed
3) Boyden LM, et al : High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521, 2002.
PubMed
4) Little RD, et al : A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19, 2002.
PubMed
5) Urano T, et al : Association of a single nucleotide polymorphism in low-density lipoprotein receptor-related protein 5 gene with bone mineral density. J Bone Miner Metab 22:341-345, 2004.
PubMed
6) Ezura Y, et al : Association of a single-nucleotide variation(A1330V) in the low-density lipoprotein receptor-related protein 5 gene(LRP5) with bone mineral density in adult Japanese women. Bone 40:997-1005, 2007.
PubMed
7) Urano T, et al : A1330V variant of the low-density lipoprotein receptor-related protein 5(LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. Endocr J 56:625-631, 2009.
PubMed
8) Moester MJ, et al : Sclerostin : current knowledge and future perspectives. Calcif Tissue Int 87:99-107, 2010.
PubMed
9) Papapoulos SE : Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 70(Suppl 1):i119-122, 2011.
 
10) Urano T, et al : Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 97:E1473-E1477, 2012.
PubMed
11) Urano T, et al : Q89R polymorphism in the LDL receptor-related protein 5 gene is associated with spinal osteoarthritis in postmenopausal Japanese women. Spine 32:25-29, 2007.
PubMed
12) Kiel DP, et al : Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet 8(Suppl 1):S14, 2007.
 
13) Richards JB, et al : Bone mineral density, osteoporosis, and osteoporotic fractures : a genome-wide association study. Lancet 371:1505-1512, 2008.
PubMed
14) Xiong DH, et al : Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet 84:388-398, 2009.
PubMed
15) Cho YS, et al : A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 41:527-534, 2009.
PubMed
16) Fujita M, et al : Association of a single nucleotide polymorphism in the secreted frizzled-related protein 4(sFRP4) gene with bone mineral density. Ger Geront Int 4:175-180, 2004.
 
17) Nakanishi R, et al : Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res 21:1713-1721, 2006.
PubMed
18) Styrkarsdottir U, et al : New sequence variants associated with bone mineral density. Nat Genet 41:15-17, 2009.
PubMed
19) Urano T, et al : GPR98/Gpr98 gene is involved in the regulation of human and mouse bone mineral density. J Clin Endocrinol Metab 97:E565-E574, 2012.
PubMed
P.196 掲載の参考文献
1) Vestergaard P, et al : Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299, 2005.
PubMed
2) Schwartz AV, et al : Older women with diabetes have an increased risk of fracture : a prospective study. J Clin Endocrinol Metab 86:32-38, 2001.
PubMed
3) Strotmeyer ES, et al : Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults : the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005.
PubMed
4) Saito M, et al : Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rat. Osteoporos Int 17:1514-1523, 2006.
PubMed
5) Yamamoto M, et al : Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019, 2008.
PubMed
6) Viguet-Carrin S, et al : An in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties. Bone 42:139-149, 2008.
 
7) Kemink SA, et al : Osteopenia in insulin-dependent diabetes mellitus ; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295-303, 2000.
PubMed
8) van Daele PL, et al : Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122:409-414, 1995.
PubMed
9) Yamamoto M, et al : Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int 80:353-358, 2007.
 
10) Schwartz AV, et al : Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354, 2006.
PubMed
11) Bollag RJ, et al : Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 25:35-41, 2001.
 
12) Bagger YZ, et al ; PERF study group : Links between cardiovascular disease and osteoporosis in postmenopausal women : serum lipids or atherosclerosis per se? Osteoporos Int 18:505-512, 2007.
PubMed
13) Lim LS, et al ; Osteoporotic Fractures in Men(MrOS) Study Group : Loop diuretic use and increased rates of hip bone loss in older men : the Osteoporotic Fractures in Men Study. Arch Intern Med 168:735-740, 2008.
 
14) Wiens M, et al : Effects of antihypertensive drug treatments on fracture outcomes : a meta-analysis of observational studies. J Intern Med 260:350-362, 2006.
PubMed
P.201 掲載の参考文献
1) Takahashi K, Yamanaka S : Induction of pluripotent stem cell from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676, 2006.
PubMed
2) Zhou Q, et al : In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455:627-632, 2008.
 
3) Ieda M, et al : Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142:375-386, 2010.
PubMed
4) Szabo E, et al : Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468:521-526, 2010.
PubMed
5) Vierbuchen T, et al : Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035-1041, 2010.
PubMed
6) Sekiya S, Suzuki A : Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475:390-393, 2011.
PubMed
7) Hiramatsu K, et al : Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors. J Clin Invest 121:640-657, 2011.
PubMed
8) Akiyama H, et al : The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16:2813-2828, 2002.
PubMed
9) Ikegami D, et al : Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development 138:1507-1519, 2011.
PubMed
10) Ikeda T, et al : The combination of SOX5, SOX6, and SOX9(the SOX trio) provides signals sufficient for induction of permanent cartilage. Arthritis Rheum 50:3561-3573, 2004.
PubMed
11) Sudo K, et al : Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. Stem Cells 25:1610-1617, 2007.
PubMed
12) Tsumaki N, et al : Separable cis-regulatory elements that contribute to tissue- and site-specific alpha2(XI) collagen gene expression in the embryonic mouse cartilage. J Cell Biol 134:1573-1582, 1996.
 
13) Outani H, et al : Induction of chondrogenic cells from dermal fibroblast culture by defined factors does not involve a pluripotent state. Biochem Biophys Res Commun 411:607-612, 2011.
 
14) Okita K, et al : A more efficient method to generate integration-free human iPS cells. Nat Methods 8:409-412, 2011.
PubMed

IV 骨粗鬆症の診断

P.210 掲載の参考文献
1) Stone KL, et al : BMD at multiple sites and risk of fracture of multiple types : long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947-1954, 2003.
 
2) Gehlbach S, et al : Previous fractures at multiple sites increase the risk for subsequent fractures : the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 27:645-653, 2012.
PubMed
3) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗髪症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
4) http://www.shef.ac.uk/FRAX/
 
5) 射場浩介, 山下敏彦 : 骨粗鬆症による疼痛 疼痛対策と管理. Orthopaedics 25:117-122, 2012.
Medical*Online
6) Black DM, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996.
 
7) 種市洋 : 骨粗鬆症性椎体骨折の予後と椎体圧潰・偽関節発生のリスクファクター. 関節外科 29:537-542, 2010.
Medical*Online
8) Nevitt MC, et al : The association of radiographically detected vertebral fractures with back pain and function : a prospective study. Ann Intern Med 128:793-800, 1998.
PubMed
9) O'Neill TW, et al : Back pain, disability, and radiographic vertebral fracture in European women : a prospective study. Osteoporos Int 15:760-765, 2004.
PubMed
10) Sakamoto K, et al : Report on the Japanese Orthopaedic Association's 3-year project observing hip fractures at fiXed-point hospitals. J Orthop Sci 11:127-134, 2006.
PubMed
11) Fukui N, et al : Predictors for ambulatory ability and the change in ADL after hip fracture in patients with different levels of mobility before injury : a 1-year prospective cohort study. J Orthop Trauma 26:163-171, 2012.
PubMed
12) Dhillon V, et al : Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int 16:483-489, 2005.
PubMed
13) Oleksik A, et al : Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384-1392, 2000.
PubMed
14) Hagino H, et al : Sequential change in quality of life for patients with incident clinical fractures : a prospective study. Osteoporos Int 20:695-702, 2009.
PubMed
15) Nguyen ND, et al : Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women. J Bone Miner Res 22:1147-1154, 2007.
PubMed
16) Suzuki T, Yoshida H : Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporos Int 21:71-79, 2010.
PubMed
17) Cauley JA, et al : Risk of mortality following clinical fractures. Osteoporos Int 11(7):556-561, 2000.
PubMed
18) Lee YK, et al : Mortality after vertebral fracture in Korea : analysis of the National Claim Registry. Osteoporos Int 23:1859-1865, 2012.
PubMed
19) Lyles KW, et al : Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 357:nihpa40967, 2007.
 
P.216 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, p16-17, ライフサイエンス出版, 2011.
 
2) Kanis JA : A family history of fracture and fracture risk : a meta-analysis. Bone 35:1029-1037, 2004.
 
P.219 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と診療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
2) 松本千鶴夫ほか : Microdensitometry法による第2中手骨骨密度(改良型MD法). 整形外科 43:1140-1146, 1992.
 
3) 山崎薫ほか : Photodensitometry法. 日本臨牀 56:1464-1468, 1998.
Medical*Online
4) Inoue T, et al : Quantitative assessment of bone density. J Jan Orthop Assoc 57:1923-1936, 1991.
 
5) 高田政彦 : MD法. INNERVISION 13:22-24, 1998.
Medical*Online
6) 大濱紘三ほか : MD, DIP. 日本臨牀 83:2317-2322, 1994.
 
7) 山本逸雄ほか : CXD. 日本臨牀 83:2323-2328, 1994.
 
8) 福永仁夫ほか : 骨量測定. 診断と治療 99:1641-1647, 2011.
Medical*Online
9) 井上哲郎 : X線像による骨萎縮度判定の試み. 骨代謝 13:187-195, 1980.
 
10) 揖場数子 : 骨粗鬆症におけるMD法(CXD法, DIP法)による検診. 骨粗鬆症治療 7:289-293, 2008.
 
P.225 掲載の参考文献
1) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy:Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001.
PubMed
2) Cameron JR, et al : Measurement of bone mineral in vivo. An improved method. Science 142:230-232, 1963.
PubMed
3) Stein JA, et al : Dual energy X-ray bone densitometer incorporating an internal reference system. Radiology 165:313, 1987.
 
4) Johnson LC : Bone Biodynamics, p534, Little-Brown, Boston, 1964.
 
5) Marshall D, et al : Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996.
PubMed
6) 折茂肇ほか : 原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18:76-82, 2001.
Medical*Online
P.231 掲載の参考文献
1) Marshall D, et al : Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996.
PubMed
2) Schuit SC, et al : Fracture incidence and association with bone mineral density in elderly men and women : Rotterdam study. Bone 34:195-202, 2004.
PubMed
3) Cummings SR, et al : Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289, 2002.
PubMed
4) Consensus development conference : prophylaxis and treatment of osteoporosis. Am J Med 90(1):107-110, 1991.
PubMed
5) NIH Consensus Statement, March 27-29, 17(1), p1-45, 2000.
 
6) Hernandez CJ, Keaveny TM : A biomechanical perspective on bone quality. Bone 39:1173-1181, 2006.
 
7) Pinilla TP, et al : Impact direction from a fall influences the failure load of the proximal femur as much as age-related bone loss. Calcif Tissue Int 58:231-235, 1996.
PubMed
8) Turner MJ, et al : Stiffness and deflection analysis of complex structures. J Aero Sci 23:805-823, 1956.
 
9) Brekelmans WA, et al : A new method to analyze the mechanical behavior of skeletal parts. Acta Orthop Scand 43:301-317, 1972.
 
10) Faulkner KG, et al : Effect of bone distribution on vertebral strength : assessment with patient-specific nonlinear finite element analysis. Radiology 179:669-674, 1991.
PubMed
11) Keyak JH, et al : Prediction of femoral fracture load using automated finite element modeling. J Biomech 31:125-133, 1998.
PubMed
12) Crawford RP, et al : Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 33:744-750, 2003.
PubMed
13) Bessho M, et al : Prediction of the strength and fracture location of the femoral neck by CT-based finite-element method : a preliminary study on patients with hip fracture. J Orthop Sci 9(6):545-550, 2004.
 
14) Imai K, et al : Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine 31:1789-1794, 2006.
PubMed
15) Bessho M, et al : Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech 40:1745-1753, 2007.
 
16) Keller TS : Predicting the compressive mechanical behavior of bone. J Biomech 27(9):1159-1168, 1994.
 
17) Keyak JH, et al : Correlations between orthogonal mechanical properties and density of trabecular bone : use of different densitometric measures. J Biomed Mater Res 28:1329-1336, 1994.
 
18) Imai K, et al : Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801-810, 2009.
PubMed
19) Keaveny TM, et al : Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22(1):149-157, 2007.
 
20) Chevalier Y, et al : Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate : results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 46:41-48, 2010.
PubMed
21) Verhulp E, et al : Comparison of micro-level and continuum-level voxel models of the proximal femur. J Biomech 39:2951-2957, 2006.
PubMed
P.238 掲載の参考文献
1) 福永仁夫 : 骨粗鬆症検診に広く用いられている定量的超音波測定法(QUS)について. 骨粗鬆症財団ニュース 12:1, 2007.
 
2) 骨粗鬆症財団監修 : 老人保健法による骨粗鬆症予防マニュアル, p66-85, 医事新報社, 2000.
 
3) 骨粗鬆症の予防と治療ガイドライン作成委員会(代表 : 折茂肇) : 骨粗鬆症の予防と治療ガイドライン2006年版, p19-21, ライフサイエンス出版, 2006.
 
4) 曽根照喜 : QUSの原理. Osteoporosis Jpn 13:21-23, 2005.
Medical*Online
5) 山崎薫 : QUS装置. Osteoporosis Jpn 13:24-26, 2005.
Medical*Online
6) 友光達志 : QUSの測定法. Osteoporosis Jpn 13:27-30, 2005.
Medical*Online
7) 吉村典子 : スクリーニング. Osteoporosis Jpn 13:39-42, 2005.
Medical*Online
8) 藤原佐枝子 : 骨折のリスク評価. Osteoporosis Jpn 13:43-44, 2005.
Medical*Online
9) 楊鴻生 : 小児におけるQUS. Osteoporosis Jpn 13:45-47, 2005.
Medical*Online
10) 楊鴻生 : 標準化の基となった各QUS機器の測定結果. Osteoporosis Jpn 17:165-169, 2009.
Medical*Online
11) 大谷隆彦 : QUSの標準化における基本的な考え方. Osteoporosis Jpn 17:149-153, 2009.
Medical*Online
12) 楊鴻生 : 標準化SOSとBUAの基準値と有用性. Osteoporosis Jpn 19:626, 2011.
 
13) 山崎薫 : S-SOSによるYAM値設定の試み. Osteoporosis Jpn 19:621-625, 2011.
Medical*Online
14) 藤原佐枝子 : 標準化SOS/BUAを用いた骨折のカットオフ値の検討. Osteoporosis Jpn 19:627-630, 2011.
Medical*Online
15) 岸本英彰 : 標準化QUSの臨床応用と解決すべき問題. Osteoporosis Jpn 19:631-634, 2011.
Medical*Online
16) 骨粗鬆症の予防と治療ガイドライン作成委員会(委員長 : 折茂肇) : 骨粗鬆症の予防と治療ガイドライン2011年版, p22-23, ライフサイエンス出版, 2011.
 
P.242 掲載の参考文献
1) Orimo H, et al : Diagnostic criteria for primary osteoporosis : year 2000 revision. J Bone Miner Metab 19:331-337, 2001.
 
2) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 薬物治療開始基準. 骨粗鬆症の予防と治療ガイドライン2011年版(骨粗鬆症の予防と治療ガイドライン作成委員会委員長 : 折茂肇), p54-55, ライフサイエンス出版, 2011.
 
3) Black DM, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996.
PubMed
4) Kanis JA, et al : The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26, 2004.
PubMed
5) Lindsay R, et al : Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323, 2001.
PubMed
6) Fukunaga M, et al : Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22:104-110, 2004.
PubMed
7) Prevrhal S, et al : Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25:921-928, 2009.
PubMed
8) Genant HK, et al : Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148, 1993.
PubMed
9) Delmas PD, et al : Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures : results from the MORE trial. Bone 33:522-532, 2003.
PubMed
P.247 掲載の参考文献
1) Halleen JM, et al : Tartrate resistant acid phosphatase 5b(TRACP 5b) as a marker of bone resorption. Clin Lab 52:499-509, 2006.
PubMed
2) Ohashi T, et al : Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205-212, 2007.
PubMed
3) Nishizawa Y, et al : Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26:265-270, 2008.
PubMed
4) 望月善子ほか : 新規に開発された血中酒石酸抵抗性酸フォスファターゼ骨型アイソザイム(TRACP-5b)測定キット オステオリンクス「TRAP-5b」による日内および日間変動と最小有意変化の検討. Jpn J Med Pharm Sci 54:895-902, 2005.
 
5) 日本骨粗鬆症学会 骨代謝マーカー検討委員会(編) : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン 2012年版, ライフサイエンス出版, 2012.
 
6) 望月善子ほか : サンプル採取・管理に関する注意点, 骨代謝マーカー改訂版, p89-92, 医薬ジャーナル社, 2010.
 
7) Shidara K, et al : Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2:278-287, 2008.
PubMed
8) 石井光一ほか : 血清TRACP-5bはアレンドロネートの骨密度増加効果を早期に予測できる. Osteoporosis Jpn 16:193-196, 2008.
Medical*Online
9) 三木隆己ほか : 新規血中酒石酸抵抗性酸フォスファターゼ骨型アイソザイム(TRACP-5b)測定キット オステオリンクス「TRAP-5b」の臨床的検討. Jpn J Med Pharm Sci 55:443-458, 2006.
 
10) 吉田顕ほか : 原発性骨粗鬆症患者に対する新規ビスホスホネート製剤ミノドロン酸水和物による初期治療効果に関する検討. 新薬と臨床 59:2-11, 2010.
Medical*Online
11) 望月善子ほか : 塩酸ラロキシフェン治療における新規骨吸収マーカー血清TRACP-5b測定の有用性. SERM 2:62-63, 2006.
 
12) 吉田顕ほか : 椎体圧迫骨折発生直後の病態と早期改善を目指した治療法の確立. Osteoporosis Jpn 19:679-683, 2011.
Medical*Online
13) Voorzanger-Rousselot N, et al : Association of 12 serum biochemical markers of angiogenesis, tumor invasion and bone turnover with bone metastases from breast cancer ; a crossectional and longitudinal evaluation. Br J Cancer 95:506-514, 2006.
PubMed
14) Chao TY, et al : Tartrate-resistant acid phosphatase isoform 5b(TRACP 5b) as a serum marker for cancer with bone metastasis. Clin Chim Acta 411:1553-1564, 2010.
PubMed
P.251 掲載の参考文献
1) 日本骨粗鬆症学会骨代謝マーカー検討委員会 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン 2012版, ライフサイエンス出版, 2012.
 
2) 和田誠基ほか : 臨床で使われている骨代謝マーカー. Clinical Calcium 19:11-18, 2009.
 
3) 西澤良記ほか(編) : 骨代謝マーカー改訂版-これだけは知っておきたい骨代謝マーカーの基礎と適正使用法-, p39-54, 医薬ジャーナル社, 2010.
 
4) Eastell R, et al : Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056, 2003.
 
5) Takada J, et al : Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 25:142-146, 2007.
PubMed
6) Iba K, et al : Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-treatment with bisphosphonate. J Orthop Sci 16:71-76, 2011.
 
7) Matsumoto T, et al : Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis : a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429-1437, 2009.
PubMed
8) Bone HG, et al : Ten year's experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199, 2004.
 
9) Fledelius C, et al : Characterization of urinary degradation products derived from type I collagen. J Biol Chem 272:9755-9763, 1997.
PubMed
10) Herrmann M, Seibel M : The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I : a comparative review. Clin Chim Acta 393:57-75, 2008.
 
11) Bjanason NH, et al : Mechanism of circadian variation in bone resorption. Bone 30:307-313, 2002.
 
12) Iki M, et al : Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women - the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 17:1086-1095, 2006.
PubMed
13) Garnero P, et al : Markers of bone resorption predict hip fracture in elderly women : The EPIDOS prospective study. J Bone Miner Res 11:1531-1538, 1996.
PubMed
14) Robbins JA, et al : Risk factors for hip fracture in women with high BMD : EPIDOS study. Osteoporos Int 16:149-154, 2005.
PubMed
15) Hochberg MC, et al : Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592, 2002.
PubMed
P.256 掲載の参考文献
1) Nishizawa Y, et al : Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1-15, 2013.
PubMed
2) Ivaska KK, et al : Bone turnover markers and prediction of fracture : A prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 25:393-403, 2010.
PubMed
3) Tsujimoto M, et al : PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798-803, 2011.
PubMed
4) Jacques RM, et al : Relationship of changes in total hip bone mineral density to vertebral and non-vertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5mg : the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:1627-1634, 2012.
 
5) Reginster JY, et al : Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351, 2004.
PubMed
6) Miriam A, et al : Determinants of bone mineral density in obese premenopausal women. Bone 48:748-754, 2011.
 
7) Grey A, et al : Five years of anti-resorptive activity after a single dose of zoledronate - results from a randomized double-blind placebo-controlled trial. Bone 50:1389-1393, 2012.
PubMed
8) Garnero P, et al : Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188-196, 2008.
PubMed
9) Eastell R, et al : Reference intervals of bone turnover markers in healthy premenopausal women : Results from a cross-sectional European study. Bone 50:1141-1147, 2012.
PubMed
10) Brandt J, et al : Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 45:47-53, 1999.
 
11) Lemeo A : Stability of several biochemical markers of bone metabolism. Clin Chem 46:1200-1202, 2000.
PubMed
12) Jonathan PR, et al : Effect of fasting versus feeding on the bone metabolic response to running. Bone 51:990-999, 2012.
 
13) Clowes JA, et al : The effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886-890, 2002.
 
14) Clowes JA, et al : Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 8:4867-4873, 2003.
PubMed
15) Blumsohn A, et al : Absence of marked seasonal change in bone turnover : a longitudinal and multi-center cross-sectional study, J Bone Miner Res 18:1274-1281, 2003.
 
16) Ivaska KK, et al : Effect of fracture on bone turnover markers : a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22:1155-1164, 2007.
 
17) Eastell R, et al : Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 22:1927-1934, 2011.
 
18) Miyauchi A, et al : Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study : 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493-502, 2010.
 
19) Nakamura T, et al : Randomized Teriparatide [human parathyroid hormone(PTH)1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097-3106, 2012.
 
20) Padhi D, et al : Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011.
 
P.260 掲載の参考文献
1) Bauer DC, et al : Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women : the fracture intervention trial. J Bone Miner Res 19(8):1250-1258, 2004.
 
2) Orito S, et al : Age-related distribution of bone and skeletal parameters in 1,322 Japanese young women. J Bone Miner Metab 27(6):698-704, 2009.
PubMed
3) Iki M, et al : Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 15:981-999, 2004.
PubMed
4) Magnusson P, et al : Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop. Tumour Biol 23:228-248, 2002.
PubMed
5) Ostase Product Information, Beckman Coulter Inc., Fullerton, CA.
 
6) Reginster JY, et al : Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34(2):344-351, 2004.
PubMed
P.264 掲載の参考文献
1) Stenflo J, et al : Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71(7):2730-2733, 1974.
PubMed
2) Hauschka PV, et al : Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72(10):3925-3929, 1975.
PubMed
3) Price PA, et al : Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 73(5):1447-1451, 1976.
PubMed
4) Hauschka PV, Carr SA : Calcium-dependent alpha-helical structure in osteocalcin. Biochemistry 21(10):2538-2547, 1982.
PubMed
5) Hoang QQ, et al : Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 425(6961):977-980, 2003.
PubMed
6) Price PA, Williamson MK : Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem 256(24):12754-12759, 1981.
 
7) Vergnaud P, et al : Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women : the EPIDOS Study. J Clin Endocrinol Metab 82(3):719-724, 1997.
PubMed
8) Hauschka PV, et al : Osteocalcin and matrix Gla protein : vitamin K-dependent proteins in bone. Physiol Rev 69(3):990-1047, 1989.
PubMed
9) Garnero P, et al : Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9(2):255-264, 1994.
PubMed
10) Price PA, et al : Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256(24):12760-12766, 1981.
 
11) Ducy P, et al : Increased bone formation in osteocalcin-deficient mice. Nature 382(6590):448-452, 1996.
PubMed
12) Luo G, et al : Spontaneous calcfication of arteries and cartilage in mice lacking matrix GLA protein. Nature 386(6620):78-81, 1997.
PubMed
13) Amizuka N, et al : Vitamin K2, a gamma-carboxylating factor of gla-proteins, normalizes the bone crystal nucleation impaired by Mg-insufficiency. Histol Histopathol 23(11):1353-1366, 2008.
PubMed
14) Amizuka N, et al : Warfarin administration disrupts the assembly of mineralized nodules in the osteoid. J Electron Microsc 58(2):55-65, 2009.
PubMed
15) Tanaka S, et al : Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int 22(2):587-597, 2011.
PubMed
16) Lee NK, et al : Endocrine regulation of energy metabolism by the skeleton. Cell 130(3):456-469, 2007.
PubMed
17) Ferron M, et al : Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142(2):296-308, 2010.
PubMed
18) Stein GS, et al : Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 4(13):3111-3123, 1990.
 
P.270 掲載の参考文献
1) Rosen CJ, et al : The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904-1910, 1997.
PubMed
2) Delmas PD, et al : The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis Int 11(Suppl 6):s2-17, 2000.
 
3) Hauschka PV, et al : Osteocalcin and matrix Gla protein : vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047, 1989.
PubMed
4) Price PA, et al : Origin of the vitamin K-dependent bone protein found in plasma and its clearance kidney and bone. J Biol Chem 256:12760-12766, 1981.
 
5) Price PA, Williamson MK : Effects of warfarin on bone. Studies on the K-dependent protein of rat bone. J Biol Chem 256:12754-12759, 1981.
 
6) Shiraki M, et al : Vitamine K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521, 2000.
 
7) Plantalech L, et al : Impaired carboxylation of serum osteocalcin in elderly women. J Bone Miner Res 6:1211-1216, 1991.
PubMed
8) Vergnaud P, et al : Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women. The EPIDOS study. J Clin Endocrinol Metab 82:719-724, 1997.
PubMed
9) Ozuru R, et al : Time-dependent effect of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr J 49:363-370, 2002.
 
10) 善方裕美ほか : 骨代謝マーカーucOCの臨牀における有用性について. 第14回Vitamin K and Aging研究会記録集, p73-76, 2011.
 
11) Lee NK, et al : Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469, 2007.
PubMed
12) Ferron M, et al : Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266-5270, 2008.
PubMed
P.275 掲載の参考文献
1) 西澤良記ほか : 骨代謝マーカー 改訂版-これだけは知っておきたい骨代謝マーカーの基礎と適正使用-, 医薬ジャーナル, 2010.
 
2) 日本骨粗鬆症学会骨代謝マーカー検討委員会(代表 : 西澤良記): 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン(2012年度版). Osteoporosis Jpn 20:33-53, 2012.
 
3) 三浦雅一 : 骨代謝マーカー測定の現状. Osteoporosis Jpn 20:20-24, 2012.
Medical*Online
4) Inaba M, et al : Poor muscle quality rather than reduced lean body mass is responsible for the lower serum creatinine level in hemodialysis patients with diabetes mellitus. Clin Nephrol 74:266-272, 2010.
PubMed
5) Yamada S, et al : Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease : independence from renal dysfunction. Clin Endocrinol (Oxf) 69:189-196, 2008.
PubMed
6) Miyauchi A, et al : Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study : 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493-502, 2010.
 
7) Tsujimoto M, et al : PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798-803, 2011.
PubMed
8) Nakamura T, et al : Effect of Weekly Teriparatide in Patients with Osteoporosis. J Bone Miner Res 26(Suppl 1):S1201, 2012.
 
9) Greenspan SL, et al : Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women : A randomized clinical trial. J Bone Miner Res 13:1431-1438, 1998.
 

V 骨粗鬆症の治療

P.283 掲載の参考文献
1) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group, WHO technical report series 1994, 843.
 
2) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
3) 折茂肇ほか : 原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝誌 18:76-82, 2001.
 
4) Fujiwara S, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547-1553, 2003.
PubMed
5) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 2006.
 
6) Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement, Vol 17, p1-36, 2000.
 
7) Kanis JA, on behalf of the World Health Organization Scientific Group : Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Disease, University of Sheffield, Sheffield, 2007.
 
8) Fujiwara S, et al : Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19:429-435, 2008.
 
9) Fujiwara S, et al : Risk factors for hip fracture in a Japanese cohort. J Bone Miner Res 7:998-1004, 1997.
 
10) Kadowaki E, et al : Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women : the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 21:1513-1522, 2010.
PubMed
11) Klotzbuecher CM, et al : Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739, 2000.
PubMed
12) Colon-Emeric C, et al : The contribution of hip fracture to risk of subsequent fractures : data from two longitudinal studies. Osteoporos Int 14:879-883, 2003.
PubMed
13) Kanis JA, et al : A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382, 2004.
PubMed
14) Ojo F, et al : History of fractures as predictor of subsequent hip and nonhip fractures among older Mexican Americans. J Natl Med Assoc 99:412-418, 2007.
PubMed
P.287 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン2011年版, p84-91, ライフサイエンス出版, 2011.
 
2) Russell RG : Bisphosphonates : the first 40 years. Bone 49:2-19, 2011.
PubMed
3) Khosla S, et al : Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272-2282, 2012.
 
4) Hopkins RB, et al : The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in postmenopausal women. BMC Musculoskelet Disord 12:209, 2011.
PubMed
5) Wells GA, et al : Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev(1):CD003376, 2008.
PubMed
6) Cranney A, et al : A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 12:140-151, 2001.
PubMed
7) Mhaskar R, et al : Bisphosphonates in multiple myeloma : a network meta-analysis. Cochrane Data-base Syst Rev 5:CD003188, 2012.
 
8) MacLean C, et al : Systematic review : comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213, 2009.
PubMed
9) Bolland MJ, et al : Effect of osteoporosis treatment on mortality : A meta-analysis. J Clin Endocrinol Metab 95:1174-1181, 2010.
PubMed
10) Center JR, et al : Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006-1014, 2011.
 
11) Cree MW, et al : Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 14:722-727, 2003.
PubMed
12) Abrahamsen B, et al : Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 27:679-686, 2012.
PubMed
13) Chlebowski RT, et al : Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590, 2010.
PubMed
14) Christensen S, et al : Oral bisphosphonates and risk of ischemic stroke : a case-control study. Osteoporos Int 22:1773-1779, 2011.
PubMed
15) Lomashvili KA, et al : Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617-625, 2009.
PubMed
16) Vasileiadis GI, et al : Prevention of heterotopic ossification in cases of hypertrophic osteoarthritis submitted to total hip arthroplasty. Etidronate or Indomethacin? J Musculoskelet Neuronal Interact 10:159-165, 2010.
PubMed
17) Murad MH, et al : Comparative effectiveness of drug treatments to prevent fragility fractures : A systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871-1880, 2012.
PubMed
P.293 掲載の参考文献
1) Ebetino FH, et al : The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20-33, 2011.
PubMed
2) Fogelman I, et al : Risedronate reverses bone loss in postmenopausal women with low bone mass : results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895-1900, 2000.
 
3) Shiraki M, et al : A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14:225-234, 2003.
 
4) Kishimoto H, et al : Efficacy and tolerability of once-weekly administration of 17.5mg risedronate in Japanese patients with involutional osteoporosis : a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405-413, 2006.
PubMed
5) Harris ST, et al : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352, 1999.
 
6) Reginster J, et al : Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91, 2000.
 
7) Watts NB, et al : Comparison of risedronate to alendronate and calcitonin for early reduction of non-vertebral fracture risk : results from a managed care administrative claims database. J Manag Care Pharm 10:142-151, 2004.
 
8) Watts NB, et al : Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 14:437-441, 2003.
PubMed
9) Abelson A, et al : Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int 21:1021-1029, 2010.
PubMed
10) Cohen S, et al : Risedronate therapy prevents corticosteroid-induced bone loss : a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318, 1999.
 
11) Reid DM, et al : Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women : a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006-1013, 2000.
PubMed
12) Kushida K, et al : A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate : a randomized, double-masked trial. J Bone Miner Metab 22:469-478, 2004.
 
13) Boonen S, et al : Effect of osteoporosis treatments on risk of non-vertebral fractures : review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291-1298, 2005.
PubMed
14) Siris ES, et al : Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681-686, 2008.
 
15) McClung MR, et al : Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340, 2001.
 
16) Osaki M, et al : Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695-703, 2012.
PubMed
17) Silverman SL, et al : Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy : the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25-34, 2007.
PubMed
18) Ferrari S, et al : Longitudinal change in hip fracture incidence after starting risedronate or raloxifene : an observational study. J Bone Miner Metab 29:561-570, 2011.
PubMed
19) Sato Y, et al : The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease : a randomized controlled trial. Arch Intern Med 165:1737-1742, 2005.
PubMed
20) Sato Y, et al : Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743-1748, 2005.
 
21) Sato Y, et al : Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64:811-816, 2005.
PubMed
22) Brown JP, et al : The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111, 2002.
PubMed
23) Delmas PD, et al : Monthly dosing of 75mg risedronate on 2 consecutive days a month : efficacy and safety results. Osteoporos Int 19:1039-1045, 2008.
 
24) Delmas PD, et al : Efficacy and safety of risedronate 150mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36-42, 2008.
 
25) McClung MR, et al : Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis : 2-year data. Osteoporos Int 24:293-299, 2013.
PubMed
26) McClung MR, et al : Efficacy and safety of a novel delayed-release risedronate 35mg once-a-week tablet. Osteoporos Int 23:267-276, 2012.
 
P.298 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会 : アレンドロネート. 骨粗鬆症の予防と治療ガイドライン 2011年版, p86-87, ライフサイエンス出版, 2011.
 
2) Rodan GA, Fleisch HA : Bisphosphonates : mechanisms of action. J Clin Invest 97:2692-2696, 1996.
PubMed
3) Fleish H : Bisphosphonates in Bone Disease - From the Laboratory to the Patient -, 4th ed, Academic Press, San Diego, 2000.
 
4) Shiraki M, et al : A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191-201, 1998.
 
5) Black DM, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996.
PubMed
6) Cummings SR, et al : Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Trial. JAMA 280:2077-2082, 1998.
PubMed
7) Orimo H, et al : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture : the Japanese Osteoporosis Intervention Trial (JOINT) -02. Curr Med Res Opin 27:1273-1284, 2011.
PubMed
8) Uchida S, et al : Therapeutic effects of alendronate 35mg once weekly and 5mg once daily in Japanese patients with osteoporosis : a double-blind, randomized study. J Bone Miner Metab 23:382-388, 2005.
PubMed
9) Gertz BJ, et al : Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298, 1995.
PubMed
10) 赤木裕貴ほか：ラットにおけるアレンドロネート経口投与時のミネラルウォーターによる吸収率への影響. 薬誌 131:801-807, 2011.
 
11) 白木正孝, 中村利孝 : ビスホスホネート服用法に関するもう一つの可能性 : 静脈注射製剤. Osteoporosis Jpn 19:735-744, 2011.
 
12) 日本骨粗鬆症学会 骨代謝マーカー検討委員会：骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン2012年版, p45-48, ライフサイエンス出版2012．
 
13) Weinstein RS : True strength. J Bone Miner Res 15:621-625, 2000.
PubMed
14) 森諭史 : ビスフォスフォネート製剤による骨代謝の過剰抑制と骨折. 整形・災害外科 52:1415-1423, 2009.
 
15) 野坂光司ほか : ビスホスホネート製剤による骨形成マーカー, 骨吸収マーカーの過剰抑制はどのくらいの割合で起こっているのか. 別冊整形外科 60:208-211, 2011.
 
P.303 掲載の参考文献
1) Dunford JE, et al : Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235-242, 2001.
PubMed
2) Hagino H, et al : A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44(6):1078-1084, 2009.
PubMed
3) Matsumoto T, et al : Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis : a randomized placebo-controlled double-blind study. Osteoporos Int 20(8):1429-1437, 2009.
PubMed
4) Hagino H, et al : Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30(4):439-446, 2012.
PubMed
5) Okazaki R, et al : Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23(6):1737-1745, 2012.
PubMed
P.307 掲載の参考文献
1) Muhlbauer RC, et al : BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011, 1991.
PubMed
2) Chesnut III CH, et al : Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 198(8):1241-1249, 2004.
 
3) Felsenberg D, et al : Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37:651-654, 2005.
PubMed
4) Miller PD, et al : Monthly oral ibandronate therapy in postmenopausal osteoporosis : 1-year results from the MOBILE study. J Bone Miner Res 20(8):1315-1322, 2005.
PubMed
5) Reginster JY, et al : Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis : 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661, 2006.
PubMed
6) Felsenberg D, et al : Suppression of bone turnover markers with monthly oral ibandronate is sustained over 5 years : the MOBILE LTE study. ECCO 2010. Osteoporos Int 21(Suppl 1):S194, 2010.
 
7) Munno OD, et al : Efficacy of ibandronate : a long term confirmation. Clin Cases Miner Bone Metab 7(1):23-26, 2010.
 
8) Nakamura T, et al : Monthly oral ibandronate is well tolerated and efficacious in Japanese osteoporotic subjects [abstract no.T405]. J Bone Miner Res 22(Suppl 1):333, 2007.
 
9) 中村利孝ほか : 日本人骨粗鬆症例におけるイバンドロネート経口投与の骨代謝調節と骨量増加効果 第9回日本骨粗鬆症学会. Osteoporosis Japan 15(Suppl 1):175, 2007.
 
10) Eisman JA, et al : Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis : 2-year results from the DIVA study. J Rheumatol 35:488-497, 2008.
PubMed
11) Bianchi G, et al : Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis : 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769-1778, 2010.
 
13) 中村利孝ほか : 日本人骨粗鬆症例におけるイバンドロネート1カ月および2カ月に1回間欠注射の骨代謝調節と骨量増加効果 第8回日本骨粗鬆症学会. Osteoporosis Japan 14(Suppl 1):119, 2006.
 
P.324 掲載の参考文献
1) Neer RM, et al : Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001.
PubMed
2) Nakamura T, et al : Randomized teriparatide [human parathyroid hormone(PTH) 1-34] once-weekly effcacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097-3106, 2012.
 
3) Miyauchi A, et al : Effect of teriparatide on bone mineral density and biochemical markers in Japa-nese women with postmenopausal osteoporosis : a 6-month dose-response study. J Bone Miner Metab 26:624-634, 2008.
 
4) Miyauchi A, et al : Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study : 12-Months, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493-502, 2010.
 
5) McClung MR, et al : Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768, 2005.
PubMed
6) Keaveny TM, et al : Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149-157, 2007.
 
7) Eastell R, et al : Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66, 2006.
PubMed
8) Tsujimoto M, et al : PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798-803, 2011.
PubMed
9) 宮内章光 : PTH治療における骨代謝マーカーの有用性. CLINICAL CALCIUM 22(3):387-398, 2011.
 
10) Prevrhal S, et al : Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25:921-928, 2009.
PubMed
11) Hodsman AB, et al : Parathyroid hormone and teriparatide for the treatment of osteoporosis : a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703, 2005.
PubMed
12) Lindsay R, et al : Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024-2030, 2004.
PubMed
13) Prince R, et al : Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507-1513, 2005.
PubMed
14) Nakamura T, et al : Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide : a meta-analysis. J Bone Miner Metab 30:321-325, 2011.
PubMed
15) Murad MH, et al : Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures : A systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871-1880, 2012.
PubMed
16) 宮内章光 : PTH(1-34)テリパラチド連日皮下自己注射(4)骨折防止効果と適応症. ファーマナビゲーターPTH, メディカルレビュー社, 2012. (印刷中)
 
17) 日本イーライリリー株式会社 : 社内資料 : 国内第II相, 第III相臨床試験における統合データ.
 
18) 日本イーライリリー株式会社 : フォルテオ(R)皮下注キット600μg市販直後調査 結果概要のお知らせ, 2011年6月.
 
19) フォルテオ(R)皮下注キット600μgテリパラチド(遺伝子組換え) 第3回および第4回安全性定期報告のまとめ.
 
20) 宮内章光 : PTH(1-34)テリパラチド連日皮下自己注射(5)安全性と投与期間. ファーマナビゲーターPTH, メディカルレビュー社, 2012. (印刷中)
 
21) 井上大輔 : PTHと他剤の併用療法. 骨粗鬆症治療 10(2):138-144, 2011.
Medical*Online
22) Dawson-Hughes B, et al : Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 92(12):4630-4636, 2007.
PubMed
23) Cosman F, et al : Changes in vitamin D metabolites during teriparatide treatment. Bone 50(6):1368-1371, 2012.
PubMed
24) 中野真子ほか : 活性型ビタミンDの併用がテリパラチド1日1回皮下投与の安全性に及ぼす影響. 第30回日本骨代謝学会学術集会, 2012.
 
25) Miller PD : Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6:12-16, 2008.
PubMed
26) Orwoll ES, et al : The effect of teriparatide [human parathyroid hormone(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9-17, 2003.
 
27) 独立行政法人医薬品医療機器総合機構 : フォルテオ皮下注キット600μg審査報告書.
 
28) Saag KG, et al : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039, 2007.
 
29) Saag KG, et al : Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis : thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346-3355, 2009.
PubMed
30) Boonen S, et al : Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860, 2008.
 
31) Fujita T, et al : Effect of an intermittent weekly dose of human parathyroid hormone(1-34) on osteoporosis : a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296-306, 1999.
PubMed
32) Ito M, et al : Once weekly teriparatide on hip structure and biomechanical properties. J Bone Miner Res 26(Suppl 1):SA0416, 2011.
 
33) Saito M, et al : Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone(1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteopros Int 22:2373-2383, 2011.
PubMed
34) 中村利孝ほか : テリパラチド酢酸塩[PTH(1-34)]の週1回間欠皮下投与における新規椎体骨折抑制効果. Osteoporosis Jpn 17:S189, 2009.
 
35) Miki T, et al : Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J Bone Miner Metab 22:569-576, 2004.
PubMed
36) 杉本利嗣ほか : テリパラチド週1回投与の効果の持続に関して-Follow-up study of teriparatide once-weekly efficacy research (TOWER) trial-. Osteoporosis Jpn 20:S250, 2012.
 
37) 独立行政法人医薬品医療機器総合機構 : テリボン皮下注用56.5μg審査報告書.
 
38) Shiraki M, et al : Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int 24:219-226, 2013.
 
39) Sugimoto T, et al : Changes in bone turnover markers after weekly teriparatide administration in postmenopausal women with osteoporosis. J Bone Miner Res 26(Suppl 1):SA0412, 2011.
 
40) 日本骨粗鬆症学会骨代謝マーカー検討委員会 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン2012年版. Osteoporosis Jpn 20(1):33-35, 2012.
 
41) Nishizawa Y, et al : Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1-15, 2013.
PubMed
42) 旭化成ファーマ株式会社 : 医薬品インタビューフォーム テリボン(R)皮下注用56.5μg, 2011年9月.
 
43) 旭化成ファーマ株式会社 : テリボン(R)皮下注用56.5μg 市販直後調査期間中の副作用発現状況のご報告, 2012年7月.
 
44) 萩野浩 : 新しい骨粗鬆症治療薬 週1回投与テリパラチド製剤(テリボン(R)皮下注用56.5μg)の高齢者への用い方. Progress in Medicine 32:373-378, 2012.
Medical*Online
45) 宮内章光 : 骨形成促進薬としての副甲状腺ホルモン製剤の意義と使い方. Geriatic Medicine 49:1007-1016, 2011.
 
46) 橋本容子ほか : 副甲状腺ホルモン テリパラチド-PTH(1-34)連日皮下投与製剤-. CLINICAL CALCIUM 17:48-55, 2007.
 
47) 中村泰朗 : ヒトPTH(1-34)週1回皮下注射製剤による骨粗鬆症治療のエビデンス. CLINICAL CALCIUM 22:109-115, 2012.
 
48) Riggs BL. Parfitt AM : Drugs used to treat osteoporosis : the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184, 2005.
 
P.331 掲載の参考文献
1) Wysowski DK, Governale LA : Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 14(3):171-176, 2005.
PubMed
2) 水沼英樹 : 更年期障害-症状とその診断・検査の進め方. 新女性医学大系21, p19-36, 中山書店, 2001.
 
3) 麻生武志 : ホルモン補充療法 : HRTその中高年女性のヘルスケアにおける役割. 日医師会誌 128(9):1195-1198, 2002.
 
4) Rossouw JE, et al ; Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002.
 
5) 佐久間一郎 : ホルモン補充療法の臨床的応用-血液凝固・線溶系. 高齢女性の健康増進のためのホルモン補充療法ガイドライン(大内尉義編), p134-141, 医学書院, 2002.
 
6) Wakatsuki A, et al : Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106:1771-1776, 2002.
PubMed
7) Godsland IF, et al : Effect of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations : analysis of studies published from 1974-2000. Fertil Steril 75:898-915, 2001.
PubMed
8) 安井敏之：ホルモン補充療法の新たなストラテジー : 産婦人科領域におけるホルモン補充療法の今後. 骨粗鬆症治療 4(1):42-49, 2005.
 
9) Lindsay R, et al : Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenapausal women. JAMA 287:2668-2676, 2002.
 
10) 野崎雅裕ほか : 閉経後の骨量減少に対するエストリオール投与の有用性に関する検討. 日産婦会誌 48:83-88, 1996.
 
11) Cauley JA, et al : Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134, 2001.
PubMed
12) Ettinger B, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE) Investigators. JAMA 282:637-645, 1999.
PubMed
13) Silverman SL, et al : Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis : results from a 3-year randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23(12):1923-1934, 2008.
PubMed
14) Martino S, et al : Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761, 2004.
 
15) Vogel VG, et al : Effects of tamoxifene vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifene and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006.
 
16) Anderson GL, et al ; Women's Health Initiative Steering Committee : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004.
 
17) 水沼英樹 : エストロゲンとその代謝酵素の関連疾患 : HRTの現状と将来. 産婦人科の実際 56(8):1167-1172, 2007.
 
P.336 掲載の参考文献
1) 山内広世, 高橋直之 : カルシトニンのトランスレーショナルリサーチ. 日本臨牀 63(増刊号 10):233-237, 2005.
 
2) Orimo H, et al : Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73-78, 1996.
 
3) Fujita T, et al : A three-year comparative trial in osteoporosis treatment : Effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15:223-226, 1997.
 
4) Chesnut CH, et al : A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recurrence of osteoporotic fractures study ; PROOF Study Group. Am J Med 109:267-276, 2000.
 
5) Ishida Y, Kawai S : Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis : The Yamaguchi Osteoporosis Prevention Study. Am J Med 117(8):549-555, 2004.
PubMed
6) 伊丹康人ほか : 老人性骨粗鬆症に伴う腰背痛に対するエルカトニンの効果 ; 多施設二重盲検法による4:1用量比の群間比較. 医学のあゆみ 120(12):1180-1195, 1982.
 
7) Knopp JA, et al : Calcitonin for treating acute pain of osteoporotic vertebral compression fractures : a systematic review of randomized, controlled trials. Osteoporos Int 16(10):1281-1290, 2005.
PubMed
8) 中野哲雄 : 骨粗鬆症性椎体圧迫骨折による急性疼痛に対するカルシトニン製剤(エルカトニン)の効果-セミブラインド化無作為化比較試験による検討-. Osteoporosis Japan 19:151-156, 2011.
 
9) Tanaka S, et al : Effects of calcitonin treatment in patients with osteoporosis who developed acute low back pain due to a new vertebral fracture. Osteoporos Int 17(Suppl 1):S326, 2011.
 
10) Peichl P, et al : Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. J Bone Miner Metab 23:243-252, 2005.
PubMed
11) 中野哲雄ほか : 大腿骨頸部・転子部骨折症例に対するエルカトニン投与が術後リハビリテーションに及ぼす影響の検討-ランダム化比較試験. Osteoporosis Japan 17:692-696, 2009.
Medical*Online
12) Karachalios T, et al : The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial. J Bone Joint Surg Br 86:350-358, 2004.
 
13) 吉田顕, 伊東学 : 椎体圧迫骨折発生直後の病態と早期改善を目指した治療法の確立. Osteoporosis Japan 19:679-683, 2011.
Medical*Online
14) Li J, et al : Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042-2051, 2000.
PubMed
15) Cao Y, et al : Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237-2246, 2002.
PubMed
16) Solomon DH, et al : The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int 20:895-901, 2009.
PubMed
17) Manabe T, et al : Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere With fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab 27:295-302, 2009.
 
P.341 掲載の参考文献
1) Shea B, et al : Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23:552-559, 2002.
PubMed
2) Tang BM, et al : Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older : a meta-analysis. Lancet 370:657-666, 2007.
 
3) Bischoff-Ferrari HA, et al : Calcium intake and hip fracture risk in men and women : a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 86:1780-1790, 2007.
PubMed
4) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
5) Bolland MJ, et al : Effect of calcium supplements on risk of myocardial infarction and cardiovascular events : meta-analysis. BMJ 341:c3691, 2010.
PubMed
6) Bischoff-Ferrari HA, et al : Positive association between 25-hydroxy vitamin D levels and bone mineral density : a population-based study of younger and older adults. Am J Med 116:634-639, 2004.
PubMed
7) van Schoor NM, et al : Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42:260-266, 2008.
PubMed
8) Melamed ML, et al : 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168:1629-1637, 2008.
PubMed
9) Bischoff-Ferrari HA, et al : Effect of Vitamin D on falls : a meta-analysis. JAMA 291:1999-2006, 2004.
 
10) Papadimitropoulos E, et al : Meta-analyses of therapies for postmenopausal osteoporosis. VIII : Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560-569, 2002.
PubMed
11) O'Donnell S, et al : Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531-542, 2008.
 
12) Ringe JD, et al : Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425-434, 2007.
 
13) Orimo H, et al : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture : the Japanese Osteoporosis Intervention Trial (JOINT)-02. Curr Med Res Opin 27:1273-1284, 2011.
PubMed
14) Uchiyama Y, et al : ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582-588, 2002.
 
15) Matsumoto T, et al : A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study. Bone 49:605-612, 2011.
PubMed
P.347 掲載の参考文献
1) Nakagawa K, et al : Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 468:117-121, 2010.
PubMed
2) Kaneki M, et al : Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2 : possible implications for hip-fracture risk. Nutrition 17:315-321, 2001.
PubMed
3) Cockayne S, et al : Vitamin K and the prevention of fractures : systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-1261, 2006.
PubMed
4) Inoue T, et al : Randomized controlled study on the prevention of osteoporotic fractures (OF study) : a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27:66-75, 2009.
 
5) Booth SL, et al : Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 71:1201-1208, 2000.
 
6) Shiraki M, et al : Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521, 2000.
 
7) 斎藤充 : ビタミンK2と骨質 材質特性. Clinical Calcium 19:1797-1804, 2009.
 
8) 小林千益ほか : ビタミンKと骨粗鬆症治療薬併用療法. 骨粗鬆症治療 8:227-231, 2009.
Medical*Online
9) 田中郁子, 大島久二 : ステロイド性骨粗鬆症の診断と治療に関する縦断研究. Osteoporosis Jpn 11:11-14, 2003.
 
10) Kinoshita H, et al : A functional single nucleotide polymorphism in the vitamin-K-dependent gamma-glutamyl carboxylase gene (Arg325Gln) is associated with bone mineral density in elderly Japanese women. Bone 40:451-456, 2007.
PubMed
11) Vergnaud P, et al : Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women : the EPIDOS Study. J Clin Endocrinol Metab 82:719-724, 1997.
PubMed
12) Ducy P, et al : Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996.
PubMed
13) Tabb MM, et al : Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-43927, 2003.
PubMed
14) Ichikawa T, et al : Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 281:16927-16934, 2006.
 
15) Azuma K, et al : Pregnane X receptor knockout mice display osteopenia with reduced bone formation and enhanced bone resorption. J Endocrinol 207:257-263, 2010.
PubMed
P.352 掲載の参考文献
1) Kearns AE, et al : Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodelling in health and disease. Endocr Rev 29:155-192, 2008.
PubMed
2) Kumagai Y, et al : A randomized double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 49:1101-1107, 2011.
PubMed
3) Nakamura T, et al : Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporosis Int 23:1131-1140, 2012.
 
4) Cummings SR, et al : Denosumab for prevention of fracture in postmenopausal osteoporosis. N Engl J Med 361:756-765, 2009.
PubMed
5) McClung MR, et al : Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211-218, 2012.
PubMed
6) Papapoulos S, et al : Five years of denosumab exposure in women with postmenopausal osteoporosis : results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694-701, 2012.
PubMed
7) McClung MR, et al : Effect of denosumab on bone mineral density and biochemical markers of bone turnover : 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227-235, 2013.
 
8) Bone HG, et al : Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972-980, 2011.
 
9) Reid IR, et al : Effects of denosumab on bone histomorphometry : The FREEDOM and STAND Studies. J Bone Miner Res 25:2256-2265, 2010.
 
10) Brown JP, et al : Bone remodeling in postmenopausal women who discontinued denosumab treatment : off-treatment biopsy study. J Bone Miner Res 26:2737-2744, 2011.
PubMed
11) Block GA, et al : A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471-1479, 2012.
PubMed
12) Anastasilakis AD, et al : Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis. Horm Metab Res 41:721-729, 2009.
 
13) Brown JP, et al : Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass : a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161, 2009.
 
14) Kendler DL, et al : Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72-81, 2010.
 
15) Freemantle N, et al : Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study : a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317-326, 2012.
PubMed
P.355 掲載の参考文献
1) Tezuka K, et al : Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 269:1106-1109, 1994.
PubMed
2) Bromme D, Lecaille F : Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 18:585-600, 2009.
PubMed
3) Gelb BD, et al : Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238, 1996.
PubMed
4) Johnson MR, et al : A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res 6:1050-1055, 1996.
 
5) Gowen M, et al : Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663, 1999.
 
6) Saftig P, et al : Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458, 1998.
PubMed
7) Peroni A, et al : Drug-induced morphea : report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 59:125-129, 2008.
PubMed
8) Bone HG, et al : Odanacatib, a cathepsin-K inhibitor for osteoporosis : a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937-947, 2010.
PubMed
9) Eastell R, et al : Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis : The OCEAN study. J Bone Miner Res 26:1303-1312, 2011.
PubMed
10) Langdahl B, et al : Odanacatib in the treatment of postmenopausal women with low bone mineral density : 5 years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251-2258, 2012.
 
11) Eisman JA, et al : Odanacatib in the treatment of postmenopausal women with low bone mineral density : three-year continued therapy and resolution of effect. J Bone Miner Res 26:242-251, 2011.
PubMed
12) Cusick T, et al : Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27(3):524-537, 2012.
PubMed
13) Li CY, et al : Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21:865-875, 2006.
PubMed
P.360 掲載の参考文献
1) Brown EM, et al : Cloning and characterization of an extracellular Ca2+ -sensing receptor from bovine parathyroid. Nature 366:575-580, 1993.
PubMed
2) Freichel M, et al : Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 137:3842-3848, 1996.
 
3) Riccardi D, Brown EM : Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 298:F485-F499, 2010.
PubMed
4) Riccardi D, Kemp PJ : The calcium-sensing receptor beyond extracellular calcium homeostasis : conception, development, adult physiology, and disease. Annu Rev Physiol 74:271-297, 2012.
PubMed
5) Pollak MR, et al : Autosomal dominant hypocalcemia caused by a Ca2+ -sensing receptor gene mutation. Nat Genet 8:303-307, 1994.
PubMed
6) Pollak MR, et al : Mutations in the human Ca2+ -sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-1303, 1993.
PubMed
7) Wang W, et al : Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol 273:F421-F429, 1997.
PubMed
8) Block GA, et al : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004.
PubMed
9) Balan G, et al : The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 19:3328-3332, 2009.
 
10) Kimura S, et al : JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol 668:331-336, 2011.
PubMed
11) Black DM, et al : The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215, 2003.
 
12) Fitzpatrick LA, et al : The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96:2441-2449, 2011.
 
13) Fitzpatrick LA, et al : Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 27:255-262, 2012.
 
14) Fukumoto S, et al : Randomized, single-blinded placebo-controlled study of a novel calcilytic, JTT-305, in patients with postmenopausal osteoporosis. American Society of Bone and Mineral Research 31st Annual Meeting, Presentation Number 1131, 2009.
 
P.366 掲載の参考文献
1) Zhang W, Drake MT : Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr Osteoporos Rep 10:93-100, 2012.
PubMed
2) Ke HZ, et al : Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747-783, 2012.
PubMed
3) McRung MR, et al : Inhibition of Sclerostin With AMG 785 in Postmenopausal Women With Low Bone Mineral Density : Phase 2 Trial Results. ASBMR2012, Abstract 1025.
 
4) Leupin O, et al : Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489-19500, 2011.
PubMed
5) Estrada K, et al : Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44:491-501, 2012.
PubMed
6) Wang C, et al : Susceptibility genes for osteoporotic fracture in postmenopausal chinese women. J Bone Miner Res 27:2582-2591, 2012.
PubMed
7) Gatti D, et al : Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739-742, 2012.
PubMed
8) Ominsky MS, et al : Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948-959, 2010.
PubMed
9) Padhi D, et al : Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011.
 
10) Wijenayaka AR, et al : Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900, 2011.
PubMed
P.370 掲載の参考文献
1) Landfeldt E, et al : Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish Adherence Register Analysis(SARA). Osteoporos Int 23(2):433-443, 2012.
PubMed
2) 田中郁子ほか : わが国におけるビスフォスフォネートのコンプライアンス クリニックにおける骨粗鬆症診療実態調査. Osteoporosis Japan 17(2):252-255, 2009.
Medical*Online
3) 田中郁子ほか : ビスフォスフォネート継続率からみた骨粗鬆症治療の実際. Osteoporosis Japan 13(2):332-336, 2005.
Medical*Online
4) Cotte FE, et al : Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21(1):145-155, 2010.
PubMed
5) Siris ES, et al : Adherence to bisphosphonate therapy and fracture rates in osteoporotic women : relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013-1022, 2006.
PubMed
6) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン 2011年版, ライフサイエンス出版, 2011.
 
P.377 掲載の参考文献
1) Marx RE : Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws : a growing epidemic. J Oral Maxillofac Surg 61:1115-1117, 2003.
PubMed
2) Ruggiero SL, et al : American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 67(5 Suppl):2-12, 2009.
 
3) Yoneda T, et al : Bisphosphonate-related osteonecrosis of the jaw : position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society of Oral and Maxillofacial Radiology, Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010.
PubMed
4) 杉崎正志 : ビスホスホネート関連顎骨壊死の臨床対応. 慈恵医大誌 126:59-70, 2011.
Medical*Online
5) Kyrgidis A, et al : Bisphosphonate-related osteonecrosis of the jaws : a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634-4638, 2008.
PubMed
6) American Dental Association Council on Scientific Affairs : Dental management of patients receiving oral bisphosphonate therapy : expert panel recommendations. J Am Dent Assoc 137:1144-1150, 2006.
 
7) Mavrokokki T, et al : Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423, 2007.
PubMed
8) 浦出雅裕 : 骨粗鬆症と歯科治療-ビスホスホネート製剤服用中患者における顎骨壊死について-. 日歯医会誌 63:21-33, 2010.
 
9) 島原政司 : ビスホスホネート投与と関連性があると考えられた顎骨骨髄炎ならびに顎骨壊死に関する調査. 日口外誌 53:594-602, 2007.
 
10) 厚生労働省 : 医薬品・医療機器等安全性情報 No.272 ビスホスホネート系製剤による顎骨壊死・顎骨骨髄炎に係る安全対策に至る検討状況と対策について, 2010.
 
P.381 掲載の参考文献
1) Odvina CV, et al : Severely suppressed bone turnover : a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301, 2005.
PubMed
2) Goh SK, et al : Subtrochanteric insufficiency fractures in patients on alendronate therapy : a caution. J Bone Joint Surg Br 89:349-353, 2007.
PubMed
3) Shane E, et al : The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis : Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 26:2267-2294, 2010.
 
4) Meier RP, et al : Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172:930-936, 2012.
PubMed
5) Dell RM, et al : Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544-2550, 2012.
PubMed
6) 日本整形外科学会骨粗鬆症委員会 : 非定型大腿骨骨折例調査. 日整会誌 85:879-884, 2011.
 
7) 関寿大ほか : 大腿骨骨幹部に生じたLooser Zoneより転位のある骨折に至った2例. 中部整災誌 48:921-922, 2005.
 
8) 池田聡ほか : 高齢で血清ucOC高値および類骨増多を伴い頻回に骨折を生じた1例. Osteoporos Jpn 17:248-251, 2009.
 
9) 田畑聖吾ほか : 骨軟化症による大腿骨骨幹部脆弱性骨折の2例. 骨折 33:181-184, 2011.
 
10) Jamal SA et al : Atypical femoral fractures and bone turnover. N Engl J Med 365:1261-1262, 2011.
PubMed
P.388 掲載の参考文献
1) Watts NB, Diab DL : Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95(4):1555-1565, 2010.
 
2) Chlebowski RT, et al : Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28(22):3582-3590, 2010.
PubMed
3) Rennert G, et al : Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29(9):1146-1150, 2011.
PubMed
4) Lyles KW, et al : Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809, 2007.
PubMed
5) Center JR, et al : Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96(4):1006-1014, 2011.
 
6) Lindsay R : Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). Osteoporos Int 22:447-451, 2011.
PubMed
7) Cummings SR, et al : Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765, 2009.
PubMed
8) Schramek D, et al : Osteoclast differentiation factor RANKL controls development of progestin - driven mammary cancer. Nature 468:98-102, 2010.
PubMed
9) Langdahl B, et al : Odanacatib in the treatment of postmenopausal women with low bone mineral density : Five years of continued therapy in a phase 2 study. J Bone Miner Res 27(11):2251-2258, 2012.
 
10) Asagiri M, et al : Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319:624-627, 2008.
PubMed
11) Plotkin H, et al : Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans : potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786-2791, 1998.
 
12) Horwitz MJ, et al : Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575, 2003.
PubMed
13) Padhi D, et al : Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011.
 
14) Binkley N, et al : A phase 3 trial of the efficacy and safety of oral recombinant calcitonin : the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 27(8):1821-1829, 2012.
 

VI 骨粗鬆症の発症予防

P.395 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会(委員長 : 折茂肇)(編) : 骨粗鬆症の予防と治療ガイドライン, 2011年版, ライフサイエンス出版, 2011.
 
2) 厚生労働省 : 平成22年度地域保健・健康増進事業報告の概況 [http://www.mhlw.go.jp/toukei/list/dl/kekka2.pdf].
 
3) 厚生労働省 : 厚生統計要覧(平成23年度) 第4編老人保健福祉 第1章老人保健・医療 [http://www.mhlw.go.jp/toukei/youran/indexyk_4_1.html].
 
4) 山内広世ほか : わが国における骨粗鬆症検診の実態と問題点. Osteoporosis Jpn 18:161-164, 2010.
Medical*Online
5) 山内広世, 西川憲 : 住民を対象とした骨粗鬆症検診の現状-わが国における実態. 骨粗鬆症治療 7:279-282, 2008.
Medical*Online
6) 細井孝之ほか : 老人保険事業に基づく骨粗鬆症検診事業に関するアンケート調査, 骨粗鬆症による要介護状態発生の予防にむけて-今後の骨粗鬆症検診のあり方についての調査・研究-. 平成19年度老人保健健康増進等事業報告書, 2008.
 
7) 臨床内科医100名および骨粗鬆症のハイリスク対象者400名を対象とした骨粗鬆症に関する調査結果. 萬有製薬株式会社プレスリリース, 2009. [http://prtimes.jp/data/corp/1731/923f0c6aa7a34d3cf460dc74f1bbfa93.pdf]
 
8) 山内広世ほか : 骨粗鬆症検診の現況について. Osteoporosis Jpn 15:649-655, 2007.
Medical*Online
9) 細井孝之ほか : 骨量測定に関する調査・研究-骨量装置設置先における骨量測定の現状アンケート. 新しい介護予防戦略としての骨粗鬆症対策. 平成21年度老人保健健康増進等事業報告書, 2010.
 
10) Siris ES, et al : Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1113, 2004.
PubMed
11) 全国健康保険協会 : 平成23年度事業報告 [http://www.kyoukaikenpo.or.jp/resources/content/23530/20120809-140546.pdf].
 
12) 中藤真一ほか : 骨折リスク評価ツール(FRAX(R))の骨粗鬆症一次スクリーニングへの応用-特定健診での活用時の有用性と問題点-. Osteoporosis Jpn 19:71-76, 2011.
Medical*Online
13) Bogoch ER, et al : Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88(1):25-34, 2006.
 
14) Mitchell PJ : Fracture Liaison Services : the UK experience. Osteoporos Int 22(Suppl 3):487-494, 2011.
 
15) McLellan AR, et al : Fracture liaison services for the evaluation and management of patients with osteoporotic fracture : a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083-2098, 2011.
PubMed
P.402 掲載の参考文献
1) 高齢者リハビリテーションのあるべき方向, 社会保険研究所, 2004. [http://www.mhlw.go.jp/shingi/2004/03/s0331-3.html]
 
2) Kita K, et al : A simple protocol for preventing falls and fractures in elderly individuals with musculo-skeletal disease. Osteoporos Int 18:611-619, 2007.
 
3) Province MA, et al : The effects of exercise on falls in elderly patients. JAMA 273:1341-1347, 1995.
PubMed
4) Sakamoto K, et al : Effects of unipedal standing balance exercise on the prevention of falls and hip fracture among clinically defined high-risk elderly individuals : a randomized controlled trial. J Orthop Sci 11:467-472, 2006.
PubMed
5) Doi T, et al : Effect of home exercise of quadriceps on knee osteoarthritis compared with nonsteroidal antiinflammatory drugs : a randomized controlled trial. Am J Phys Med Rehabil 87(4): 258-269, 2008.
PubMed
6) Hirschberg GG : The use of stand-up and step-up exercises in rehabilitation. Clin Orthop 12:30-38, 1958.
PubMed
7) Gardner MJ, et al : Intervention to improve osteoporosis treatment following hip fracture. J Bone Joint Surg Am 87A:3-7, 2005.
 
8) Tinetti ME : Performance-oriented assessment of mobility problems in the elderly. J Am Geriatr Soc 36:613-616, 1986.
 
9) Yasumura S, et al : Rate of falls and the correlates among elderly people living in an urban community in Japan. Age Aging 23:323-327, 1994.
 
10) Gillespie LD, et al : Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 4:CD000340, 2003.
 
11) Means KM, et al : Balance, mobility, and falls among community-dwelling elderly persons. Am J Phys Med Rehabil 84:238-249, 2005.
PubMed
12) Sherrington C, et al : Effective exercise for the prevention of falls : a systematic review and meta-analysis. J Am Geriatr Soc 56:2234-2243, 2008.
 
13) 金成由美子ほか : 転倒対策による骨折予防のエビデンス. 日衛誌 58:347-356, 2003.
 
14) Latham NK, et al : A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people : the Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc 51:291-299, 2003.
 
15) Wagner H, et al : Simply ask them about their balance-future fracture risk in a nationwide cohort study of twins. Am J Epidemiol 169:143-149, 2009.
 
P.407 掲載の参考文献
1) Sinaki M, et al : Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil 75:370-374, 1996.
PubMed
2) Miyakoshi N, et al : Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int 14:1007-1012, 2003.
PubMed
3) Ishikawa Y, et al : Spinal curvature and postural balance in patients with osteoporosis. Osteoporos Int 20:2049-2053, 2009.
PubMed
4) Kasukawa Y, et al : Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab 28:82-87, 2010.
 
5) Blechacz B, Gajic O : Images in clinical medicine. Severe kyphosis. N Engl J Med 358:e28, 2008.
PubMed
6) Miyakoshi N, et al : Impact of spinal kyphosis on gastroesophageal reflux disease symptoms in patients with osteoporosis. Osteoporos Int 20:1193-1198, 2009.
PubMed
7) Mika A, et al : Association between moderate physical activity, spinal motion and back muscle strength in postmenopausal women with and without osteoporosis. Disabil Rehabil 31:734-740, 2009.
PubMed
8) Sinaki M, et al : Stronger back muscles reduce the incidence of vertebral fractures : a prospective 10 year follow-up of postmenopausal women. Bone 30:836-841, 2002.
PubMed
9) Huntoon EA, et al : Significantly fewer refractures after vertebroplasty in patients who engage in back-extensor-strengthening exercises. Mayo Clin Proc 83:54-57, 2008.
 
10) Hongo M, et al : Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis : a randomized controlled trial. Osteoporos Int 18:1389-1395, 2007.
PubMed
11) Sinaki M, et al : Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc 80:849-855, 2005.
PubMed
12) Suri P, et al : Increased trunk extension endurance is associated with meaningful improvement in balance among older adults with mobility problems. Arch Phys Med Rehabil 92:1038-1043, 2011.
PubMed
13) Miyakoshi N, et al : Effects of a simple, low-intensity back extension exercise on quality of life and back extensor strength in patients with osteoporosis and vertebral fractures : a 6-month randomized controlled trial. J Bone Miner Res 25(Suppl 1):S342, 2010.
 
14) 石川慶紀ほか : 下肢外旋起立肢位における脊柱アライメントと背筋力変化-骨粗鬆症患者のための背筋運動療法に関する基礎的研究-. 東日本整災会誌 22:17-21, 2010.
 
15) Pfeifer M, et al : Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis : a randomized trial. Am J Phys Med Rehabil 83:177-186, 2004.
PubMed
P.413 掲載の参考文献
1) Preventing osteoporosis, International Osteoporosis Foundation, London, 2012.
PubMed
2) Clinician's guide to prevention and treatment of osteoporosis, The National Osteoporosis Foundation, Washington, DC, 2010.
PubMed
3) 厚生労働省策定 : 日本人の食事摂取基準2010年版, 第一出版, 2009.
 
4) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011, ライフサイエンス出版, 2011.
 
5) Hirota T, et al : Effect of diet and lifestyle on bone mass in Asian young women. Am J Clin Nutr 55:1168-1173, 1992.
 
6) Hirota T, et al : Improvement of nutrition stimulates bone mineral gain in Japanese school children and adolescents. Osteoporos Int 16:1057-1064, 2005.
PubMed
7) 国民健康・栄養の現状. 平成20年厚生労働省国民健康・栄養調査報告, 第一出版, 2011.
 
8) Heaney RP : Calcium, dairy products, and osteoporosis. J Am Coll Nutr 2:83S-99S, 2000.
 
9) Bischoff-Ferrari HA, et al : Prevention of nonvertebral fractures with oral vitamin D and dose dependency : a meta-analysis of randomized controlled trials. Arch Intem Med 169:551-561, 2009.
 
10) 広田孝子 : 骨粗鬆症患者のカルシウムとビタミンDの栄養状態と骨代謝. Osteoporosis Jpn 16:165-169, 2008.
Medical*Online
11) Bolland MJ, et al : Calcium supplements with or without vitamin D and risk of cardiovascular events : reanalysis of the Women's Health initiative limited access dataset and meta-analysis. BMJ 342:d2040, 2011.
 
12) Li K, et al : Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European prospective investigation into cancer and nutrition study (EPIC-Heidelberg). Heart 98:920-925, 2012.
 
13) Cashman KD : Diet, nutrition, and bone health. J Nutr 137:2507S-2512S, 2007.
 

VII 骨粗鬆症の疼痛管理

P.420 掲載の参考文献
1) 高田潤一ほか : 腰背部痛を有する骨粗鬆症患者のquality of lifeの経時的変化. 整形外科 55:1265-1270, 2004.
 
2) Ohtori S, et al : Risedoronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patient without vertebral fractures. J Clin Neurosci 17:209-213, 2010.
 
3) Fujita T, et al : Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. J Bone Miner Metab 28:477-484, 2010.
PubMed
4) Mach DB, et al : Origins of skeletal pain : sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166, 2002.
PubMed
5) 熱田裕司ほか : 姿勢異常と腰痛-筋原性疼痛要素について-. 骨・関節・靱帯 16:791-797, 2003.
 
6) 山下敏彦 : 骨・関節の疼痛メカニズム. クリニカ 34:7-12, 2007.
 
7) Yoneda T, et al : Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48:100-105, 2011.
PubMed
8) Iba K, et al : Five-year follow-up of Japanese patients with Paget's disease of bone after treatment with a dose of oral alendronate : a case series. J Med Case Rep 4:166-171, 2010.
 
9) Caterina MJ, et al : The capsaicin receptor : a heat-activated ion channel in the pain pathway. Nature 389:816-824, 1997.
PubMed
10) Nagae M, et al : Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone 39:1107-1115, 2006.
 
11) Bland-Ward PA, Humphrey PP : P2X receptors mediate ATP-induced primary nociceptive neurone activation. J Auton Nerv Syst 81:146-151, 2000.
PubMed
12) Kakimoto S, et al : Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic p2X2/3 receptor function and exerts an analgesic effect in pain model. Eur J Pharmacol 589:98-101, 2008.
PubMed
13) Lyritis G, et al : Back pain during different sequential treatment regimens of teriparatide ; results from EUROFORS. Curr Med Res Opin 26:1799-1807, 2010.
PubMed
14) Dobnig H, et al : Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated alendronate. J Bone Miner Res 24:1998-2006, 2009.
PubMed
15) Ito A, et al : Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin ; participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 20:6302-6308, 2000.
 
P.424 掲載の参考文献
1) Ito A, et al : Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin : participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 20:6302-6308, 2000.
 
2) 井上哲郎ほか : 老人性骨粗鬆症に伴う腰背痛に対するエルカトニン長期投与の臨床効果. 医学のあゆみ 120:1180-1195, 1982.
 
3) Knopp JA, et al : Calcitonin for treating acute of osteoporotic vertebral compression fractures : a systematic review of randomized, controlled trials. Osteoporos Int 16:1281-1290, 2005.
PubMed
4) 中野哲雄 : 骨粗鬆症の診断と治療 骨粗鬆症性椎体骨折による急性疼痛に対するカルシトニン製剤(エルカトニン)の効果-セミブラインド化無作為化比較試験による検討. Osteoporosis Jpn 19:151-156, 2011.
 
5) 中村正生, 清水克時 : 骨粗鬆症の診断と治療 腰下肢痛を伴う骨粗鬆症症例に対する日本語版Roland-Morris Disability Questionnaireを用いたQOL評価-エルカトニン製剤投与下での疼痛に関連するQOL改善についての検討. Osteoporosis Jpn 16:333-341, 2008.
 
6) McQuay HJ, Moore A : NSAIDs and Coxibs : clinical use. In : Texbook of Pain, 5th ed(ed by McMahon SB, Koltzenburg M), p471-481, Elsevier, Philadelphia, 2006.
 
7) Hooper L, et al : The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs : systematic review. BMJ 329:948, 2004.
PubMed
8) Warner TD, et al : Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity : a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568, 1999.
PubMed
9) 菊池臣一ほか : 腰痛症患者におけるセレコキシブ(YM177)のロキソプロフェンナトリウムとプラセボを対照とする第III相二重盲検並行群間比較試験. Prog Med 29(Suppl 2):2873-2892, 2009.
 
10) 菊池臣一ほか : 腰痛症患者におけるセレコキシブ(YM177)のロキソプロフェンナトリウムとプラセボを対照とする第III相二重盲検並行群間比較試験. Prog Med 29(Suppl 2):2853-2872, 2009.
 
11) Silverstein FE, et al : Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000.
PubMed
12) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン作成ワーキンググループ(編) : 神経障害性疼痛薬物療法ガイドライン, 真興交易医書出版部, 2011.
 
13) O'Connor AB, Dworkin RH : Treatment of neuropathic pain : an overview of recent guidelines, Am J Med 122:S22-S32, 2009.
PubMed
14) Chou R, et al ; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel : Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113-130, 2009.
 
P.429 掲載の参考文献
1) 宮腰尚久 : 運動器の慢性疼痛-治療新戦略 運動器慢性疼痛の診断と治療 腰背部痛 骨粗鬆症. 整形外科 63:819-823, 2012.
 
2) Howe TE, et al : Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 7:CD000333, 2011.
PubMed
3) de Kam D, et al : Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density : a systematic review of randomized controlled trials. Osteoporos Int 20:2111-2125, 2009.
PubMed
4) Bennell KL, et al : Effects of an exercise and manual therapy program on physical impairments, function and quality-of-life in people with osteoporotic vertebral fracture : a randomised, single-blind controlled pilot trial. BMC Musculoskelet Disord 11:36, 2010.
PubMed
5) Chien MY, et al : Home-based trunk-strengthening exercise for osteoporotic and osteopenic postmenopausal women without fracture - a pilot study. Clin Rehabil 19:28-36, 2005.
 
6) Hongo M, et al : Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis : a randomized controlled trial. Osteoporos Int 18:1389-1395, 2007.
PubMed
7) Liu-Ambrose TY, et al : Both resistance and agility training reduce back pain and improve health-related quality of life in older women with low bone mass. Osteoporos Int 16:1321-1329, 2005.
PubMed
8) Malmros B, et al : Positive effects of physiotherapy on chronic pain and performance in osteoporosis. Osteoporos Int 8:215-221, 1998.
PubMed
9) Papaioannou A, et al : Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 14:677-682, 2003.
PubMed
10) Miyakoshi N, et al : Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 18:1397-1403, 2007.
PubMed
11) Sinaki M, et al : Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc 80:849-855, 2005.
PubMed
12) Sinaki M, Mikkelsen BA : Postmenopausal spinal osteoporosis : flexion versus extension exercises. Arch Phys Med Rehabil 65:593-596, 1984.
PubMed
13) Gold DT, et al : Group treatment improves trunk strength and psychological status in older women with vertebral fractures : results of a randomized, clinical trial. J Am Geriatr Soc 52:1471-1478, 2004.
PubMed
14) Chou R, Huffman LH : Nonpharmacologic therapies for acute and chronic low back pain : a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 147:492-504, 2007.
PubMed
15) Koke AJ, et al : Pain reducing effect of three types of transcutaneous electrical nerve stimulation in patients with chronic pain : a randomized crossover trial. Pain 108:36-42, 2004.
PubMed
16) Rossini M, et al : Capacitively coupled electric field for pain relief in patients with vertebral fractures and chronic pain. Clin Orthop Relat Res 468:735-740, 2010.
PubMed
17) Zambito A, et al : Interferential and horizontal therapies in chronic low back pain due to multiple vertebral fractures : a randomized, double blind, clinical study. Osteoporos Int 18:1541-1545, 2007.
PubMed
18) Slatkovska L, et al : Effect of whole-body vibration on BMD : a systematic review and meta-analysis. Osteoporos Int 21:1969-1980, 2010.
PubMed
19) Perraton L, et al : Whole-body vibration to treat low back pain : fact or fad? Physiother Can 63:88-93, 2011.
PubMed
20) Iwamoto J, et al : Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging Clin Exp Res 17:157-163, 2005.
PubMed

VIII 骨粗鬆症による骨折の予防・治療

P.436 掲載の参考文献
1) Masunari N, et al : Historical height loss, vertebral deformity, and health-related quality of life in Hiroshima cohort study. Osteoporos Int 18:1493-1499, 2007.
PubMed
2) Brenneman S, et al : Impact of recent fracture on health-related quality of life on postmenopausal women. J Bone Miner Res 21:809-816, 2006.
PubMed
3) Von Friesendorff M, et al : Long-term survival and fracture risk after hip fracture : a 22-year follow-up in women. J Bone Miner Res 23:1832-1841, 2008.
PubMed
4) Von Friesendorff M, et al : Hip fracture in men-survival and subsequent fractures : a cohort study with 22-year follow-up. J Am Geriatr Soc 59:806-813, 2011.
PubMed
5) Abrahamsen B, et al : Excess mortality following hip fracture : a systematic epidemiological review. Osteoporos Int 20:1633-1650, 2009.
PubMed
6) Kondo A, et al : Comparison of length of hospital stay after surgery and mortality in elderly hip fracture patients between Japan and the United States - the relationship between the lengths of hospital stay after surgery and mortality. Disabil Rehabil 32:826-835, 2010.
PubMed
7) Bliuc D, et al : Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521, 2009.
PubMed
8) Lee YK, et al : Mortality after vertebral fracture in Korea : analysis of the National Claim Registry. Osteoporos Int 23:1850-1865, 2012.
 
9) Masunari N, et al : Height loss starting in middle age predicts increased mortality in elderly. J Bone Miner Res 27:138-145, 2012.
PubMed
10) FitzGerald G, et al : Differing risk profiles for individual fracture sites : evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res 27:1907-1915, 2012.
 
11) Fujiwara S, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547-1553, 2003.
PubMed
12) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
13) Kanis JA, et al : Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395-2411, 2011.
PubMed
14) Leslie WD, et al : Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243-1251, 2012.
PubMed
15) Fujiwara S, et al : Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone 49:520-525, 2011.
PubMed
P.443 掲載の参考文献
1) Kanis JA, et al : Assessment of fracture risk. Osteoporos Int 16:581-589, 2005.
PubMed
2) Kanis JA, et al : The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046, 2007.
PubMed
3) Kanis JA, et al : European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428, 2008.
 
4) Dawson-Hughes B, et al : The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41-52, 2010.
PubMed
5) 五來逸雄ほか : 本邦におけるFRAX(TM)の試用に関する研究(第2報). Osteoporosis Jpn 16(Suppl):160, 2008.
 
6) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス社, 2006.
 
7) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス社, 2011.
 
8) Kanis JA, et al : FRAX(R) and its applications to clinical practice. Bone 44:734-743, 2009.
 
9) McCloskey EV, et al : Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis : results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135-141, 2007.
PubMed
10) Kanis JA, et al : Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX(R). Bone 44:49-54, 2009.
 
11) Kanis JA, et al : A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX(R). Bone 47:729-735, 2010.
 
12) Donaldson MG, et al : Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density : the Fracture Intervention Trial. J Bone Miner Res 27:1804-1810, 2012.
 
P.450 掲載の参考文献
1) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy : Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785-795, 2001.
PubMed
2) Ruff CB, Hyes WC : Subperiosteal expansion and cortical remodeling of the human femur and tibia with aging. Science 217(4563):945-948, 1982.
 
3) Heaney RP, et al : Bone dimensional change with age : interactions of genetic, hormonal, and body size variables. Osteoporos Int 7(5):426-431, 1997.
PubMed
4) Ahlborg HG, et al : Bone loss and bone size after menopause. N Engl J Med 349(4):327-334, 2003.
PubMed
5) Seeman E : Periosteal bone formation - a neglected determinant of bone strength. N Engl J Med 349(4):320-323, 2003.
PubMed
6) Matsui Y, et al : Divergent significance of bone mineral density changes in aging depending on sites and sex revealed through separate analyses of bone mineral content and area. J Osteoporos, 2012:642486. doi:10.1155/2012/642486, 2012.
 
7) Beck TJ, et al : Structural trends in the aging femoral neck and proximal shaft : analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15(12):2297-2304, 2000.
 
8) Takada J, et al : Structural trends in the aging proximal femur in Japanese postmenopausal women. Bone 41(1):97-102, 2007.
PubMed
9) Iki M, et al : Age-specific reference values of hip geometric indices from a representative sample of the Japanese female population : Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 22(6):1987-1996, 2011.
PubMed
10) LaCroix AZ, et al : Hip structural geometry and incidence of hip fracture in postmenopausal women : what does it add to conventional bone mineral density. Osteoporos Int 21(6):919-929, 2010.
PubMed
11) Mayhew PM, et al : Relation between age, femoral neck cortical stability, and hip fracture risk. Lancet 366(9480):129-135, 2005.
PubMed
12) Ito M, et al : Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. Bone 46(2):453-457, 2010.
PubMed
13) Yoshimura N, et al : Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women : the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27:620-628, 2009.
PubMed
14) Sornay-Rendu E, et al : Disc space narrowing is associated with an increased vertebral fracture risk in postmenopausal women : the OFELY Study. J Bone Miner Res 19(12):1994-1999, 2004.
 
15) Thomsen JS, et al : Age-related differences between thinning of horizontal and vertical trabeculae in human lumbar bone as assessed by a new computerized method. Bone 31(1):136-142, 2002.
PubMed
16) Ito M, et al : Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res 20(10):1828-1836, 2005.
 
P.455 掲載の参考文献
1) Vestergaard P : Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 18:427-444, 2007.
PubMed
2) Yamamoto M, et al : Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 24:702-709, 2009.
 
3) Schwartz AV, et al : Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184-2192, 2011.
PubMed
4) Saito M, et al : Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17:1514-1523, 2006.
PubMed
5) Ogawa N, et al : The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39:871-875, 2007.
PubMed
6) Yamamoto M, et al : Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019, 2008.
PubMed
7) Yamamoto M, et al : Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 97:1277-1284, 2012.
PubMed
8) Patsch JM, et al : Increased cortical porosity in type-2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 28:313-324, 2013.
PubMed
9) Kaji H, et al : Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab 95:4635-4642, 2010.
PubMed
10) Fried LF, et al : Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18:282-286, 2007.
PubMed
11) Yamaguchi T, et al : Plasma lipids and osteoporosis in postmenopausal women. Endocr J 49:211-217, 2002.
PubMed
12) Vestergaard P, et al : Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103-111, 2009.
PubMed
13) Shimizu H, et al : Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465-2475, 2008.
PubMed
14) Lehouck A, et al : COPD, bone metabolism, and osteoporosis. Chest 139:648-657, 2011.
PubMed
15) 日本骨粗鬆症学会生活習慣病における骨折リスク評価委員会 : 生活習慣病骨折リスクに関する診療ガイド, ライフサイエンス出版, 2011.
 
P.460 掲載の参考文献
1) 岡崎亮 : ビタミンDの欠乏・不足と充足. Clinical Calcium 21:1593-1600, 2011.
 
2) 厚生労働省 : 日本人の食事摂取基準(2010年版), 第一出版, 2010.
 
3) Institute of Medicine Committee to Review : Dietary Reference Intakes for Calcium and Vitamin D, National Academies Press, Washington, DC, 2011.
 
4) Holick MF, et al : Evaluation, treatment, and prevention of vitamin D deficiency : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911-1930, 2011.
PubMed
5) Bischoff-Ferrari de et al : Fracture prevention with vitamin D supplementation : a meta-analysis of randomized controlled trials. JAMA 293(18):2257-2264, 2005.
 
6) Bischoff-Ferrari HA, et al : Prevention of nonvertebral fractures with oral vitamin D and dose dependency : a meta-analysis of randomized controlled trials. Arch Intern Med 169(6):551-561, 2009.
PubMed
7) Bischoff-Ferrari HA, et al : A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 367(1):40-49, 2012.
PubMed
8) Sunyecz JA, Weisman SM : The role of calcium in osteoporosis drug therapy. J Womens Health 14:180-192, 2005.
 
9) Bischoff-Ferrari HA, et al : Effect of vitamin D on falls : a meta-analysis. JAMA 291(16):1999-2006, 2004.
 
10) Shearer MJ, et al : Vitamin K nutrition, metabolism, and requirements : current concepts and future research. Adv Nutr 3(2):182-195, 2012.
PubMed
11) Kaneki M, et al : Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2 : possible implications for hip-fracture risk. Nutrition 17(4):315-321, 2001.
PubMed
12) 虎石真弥, 上西一弘 : 大学生男子陸上長距離選手の骨状態と骨におけるビタミンK栄養状態の関連. 栄養学雑誌 69(3):115-125, 2011.
Medical*Online
13) Cockayne S, et al : Vitamin K and the prevention of fractures : systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166(12):1256-1261, 2006.
PubMed
14) 白木正孝ほか : 電気化学発光免疫法による血清中低カルボキシル化オステオカルシン(ucOC)測定キットの臨床的有用性の検討-カットオフ値の設定と骨粗鬆症患者におけるビタミンK2剤選択時の有用性の検討-. 医学と薬学 57(4):537-546, 2007.
Medical*Online
15) 上西一弘ほか : 簡易ビタミンK摂取調査表の作成とその有効性の検討. オステオポローシス・ジャパン 19(3):513-518, 2011.
Medical*Online
P.465 掲載の参考文献
1) Saito M, Marumo K : Collagen cross-links as a determinant of bone quality : a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195-214, 2010.
PubMed
2) McLean RR, Hannan MT : B vitamins, homocysteine, and bone disease : epidemiology and pathophysiology. Curr Osteoporos Rep 5:112-119, 2007.
PubMed
3) McLean RR, et al : Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab 93:2206-2212, 2008.
PubMed
4) Yazdanpanah N, et al : Effect of dietary B vitamins on BMD and risk of fracture in elderly men and women : The Rotterdam Study. Bone 41:987-994, 2007.
PubMed
5) Reynolds TM, et al : Hip fracture patients may be vitamin B6 deficient. Controlled study of serum pyridoxal-5'-phosphate. Acta Orthop Scand 63:635-638, 1992.
PubMed
6) Saito M, et al : Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79:160-168, 2006.
PubMed
7) Espallargues M, et al : Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements : a systematic review of the literature. Osteoporos Int 12:811-822, 2001.
PubMed
8) Goerss JB, et al : Risk of fractures in patients with pernicious anemia. J Bone Miner Res 7:573-579, 1992.
PubMed
9) Tucker KL, et al :Low plasma vitamin B12 is associated with lower BMD : the Framingham Osteoporosis Study. J Bone Miner Res 20:152-158, 2005.
PubMed
10) Stone KL, et al : Low serum vitamin B-12 levels are associated with increased hip bone loss in older women : a prospective study. J Clin Endocrinol Metab 89:1217-1221, 2004.
PubMed
11) Cagnacci A, et al : Relation of folates, vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation. Bone 42:314-320, 2008.
PubMed
12) Shiraki M, et al : The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fracture. J Bone Miner Metab 26:595-602, 2008.
PubMed
13) McLean RR, et al : Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042-2049, 2004.
 
14) van Meurs JB, et al : Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033-2041, 2004.
PubMed
15) Yang J, et al : Homocysteine level and risk of fracture : A meta-analysis and systematic review. Bone 51:376-382, 2012.
PubMed
P.470 掲載の参考文献
1) McClung MR, et al ; Hip Intervention Program Study Group : Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340, 2001.
 
2) Peeters GM, et al : Multifactorial evaluation and treatment of persons with a high risk of recurrent falling was not cost-effective. Osteoporos Int 22:2187-2196, 2011.
 
3) Parkkari J, et al : Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur : a prospective controlled hip fracture study with 206 consecutive patients. Calcif Tissue Int 65:183-187, 1999.
PubMed
4) Robinovitch SN, et al : Energy-shunting hip padding system attenuates femoral impact force in a simulated fall. J Biomech Eng 117:409-413, 1995.
 
5) O'Halloran PD, et al : The effect of type of hip protector and resident characteristics on adherence to use of hip protectors in nursing and residential homes - an exploratory study. Int J Nurs Stud 42:387-397, 2005.
PubMed
6) Gillespie WJ, et al : Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 10:CD001255, 2010.
PubMed
7) Koike T, et al : External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporos Int 20:1613-1620, 2009.
PubMed
8) Cameron ID, et al : Hip protectors improve falls self-efficacy. Age Ageing 29:57-62, 2000.
PubMed
9) van Schoor NM, et al : Prevention of hip fractures by external hip protectors : a randomized controlled trial. JAMA 289:1957-1962, 2003.
PubMed
P.474 掲載の参考文献
1) 萩野浩ほか : 大腿骨近位部骨折の発生および治療状況に関する全国調査-日整会骨粗鬆症委員会調査結果報告-. 日整会誌 81:S540, 2007.
 
2) Harrington JT : A decade of system- and population-based osteoporosis care improvement. Osteoporos Int 22(Suppl 3):483-486, 2011.
 
3) Roerholt C, et al : Initiation of anti-osteoporotic therapy in patients with recent fractures : a nation-wide analysis of prescription rates and persistence. Osteoporos Int 20(2):1299-307, 2009.
 
4) Solomon DH, et al : Compliance with osteoporosis medications. Arch Intern Med 165(20):2414-2419, 2005.
PubMed
5) Adachi J, et al : The association between compliance and persistence with bisphosphonate therapy and fracture risk : a review. BMC Musculoskelet Disord 8:97-102, 2007.
 
6) 宮腰尚久 : 大腿骨頸部(近位部)骨折地域連携クリティカルパスの実態に関する全国調査. 日整会誌 86:913-920, 2012.
 
7) 福島達樹ほか : 両側大腿骨頸部骨折の検討. 整形外科 53(4):380-383, 2002.
 
8) Yamanashi A, et al : Assessment of risk factors for second hip fractures in Japanese elderly. Osteoporos Int 16(10):1239-1246, 2005.
PubMed
9) Hagino H, et al : The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90(1):14-21, 2012.
PubMed
10) McLellan A, et al : The fracture liaison service : success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028-1034, 2003.
PubMed
11) Eisman JA, et al ; for the ASBMR Task Force on Secondary Fracture Prevention : Making the first fracture the last fracture : ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039-2046, 2012.
PubMed
12) 骨粗鬆症の予防と治療ガイドライン作成委員会(編) : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
13) Lyles KW, et al ; HORIZON Recurrent Fracture Trial : Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809, 2007.
PubMed
14) Osaki M , et al : Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23(2):695-703, 2012.
PubMed
15) Chapuy MC, et al : Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642, 1992.
PubMed
16) Fleisch H : Bisphosphonates in Bone Disease : From the Laboratory to the Patient, 4th ed, Academic Press, Sandiego, 2000.
 
17) Rizzoli R, et al : Subtrochanteric fractures after long-term treatment with bisphosphonates : a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373-390, 2011.
 
18) Goldhahn J, et al : Implications for fracture healing of current and new osteoporosis treatments : an ESCEO consensus paper. Calcif Tissue Int 90(5):343-353, 2012.
PubMed
19) Fu L, et al : Effect of 1,25-dihydroxy vitamin D3 on fracture healing and bone remodeling in ovariectomized rat femora. Bone 44(5):893-898, 2009.
PubMed
20) Aspenberg P, et al : Teriparatide for acceleration of fracture repair in humans : a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404-414, 2010.
PubMed
P.479 掲載の参考文献
1) Black DM, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996.
 
2) Ross PD, et al : Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24:1171-1177, 1995.
PubMed
3) Delmas PD, et al : Efficacy or raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617, 2002.
 
4) Harrison RA, et al : Osteoporosis-related kyphosis and impairments in pulmonary function : a systematic review. J Bone Miner Res 22:447-457, 2007.
PubMed
5) Miyakoshi N, et al : Impact of spinal kyphosis on gastroesophageal reflux disease symptoms in patients with osteoporosis. Osteoporos Int 20:1193-1198, 2009.
PubMed
6) 本郷道夫ほか : 逆流性食道炎に対する新たなQOL質問票の検討. Progress in Medicine 28:2219-2224, 2008.
Medical*Online
7) 山本智章ほか : 地域における骨粗鬆症患者QOL評価簡略質問票(Mini-JOQOL)の使用経験. Osteoporosis Jpn 14:107-109, 2006.
 
8) 村井肇 : 骨粗鬆症患者の脊柱変形とQOL評価. 日本臨牀 62:621-624, 2004.
Medical*Online
9) 徳永邦彦ほか : 円背が骨粗鬆症患者のQuality of lifeに及ぼす影響. Osteoporosis Jpn 9:480-484, 2001.
 
10) Ettinger B, et al : Contribution of vertebral deformities to chronic back pain and disability. J Bone Miner Res 7:449-456, 1992.
PubMed
11) Leidig-Bruckner G, et al : Clinical grading of spinal osteoporosis : quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J Bone Miner Res 12:663-675, 1997.
 
P.483 掲載の参考文献
1) Black DM, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996.
 
2) Schousboe JT, et al : Vertebral Fracture Assessment : the 2007 ISCD Official Positions. J Clin Densitom 11:92-108, 2008.
PubMed
3) Ferrar L, et al : Identincation of vertebral fracture and non-osteoporotic short vertebral height in men : the MrOS study. J Bone Miner Res 22:1434-1441, 2007.
PubMed
4) Dominguez S, et al : Prevalence of traumatic hip and pelvic fractures in patients with suspected hip fracture and negative initial standard radiographs - a study of emergency department patients. Acad Emerg Med 12:366-369, 2005.
PubMed
5) Frihagen F, et al : MRI diagnosis of occult hip fractures. Acta Orthop 76:524-530, 2005.
PubMed
6) Bangil M, et al : Subchondral insufficiency fracture of the femoral head. Rev Rhum Engl Ed 63:859-861, 1996.
PubMed
7) Ikemura S, et al : MRI evaluation of collapsed femoral heads in patients 60 years old or older : Differentiation of subchondral insufficiency fracture from osteonecrosis of the femoral head. AJR Am J Roentgenol 195(1):W63-68, 2010.
PubMed
8) Black DM, et al : Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771, 2010.
 
9) Shane E, et al : Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294, 2010.
 
10) Baur-Melnyk A : Malignant versus benign vertebral collapse : are new imaging techniques useful? Cancer Imaging 9:S49-51, 2009.
PubMed
11) Holder LE, et al : Radionuclide bone imaging in the early detection of fractures of the proximal femur (hip) : multifactorial analysis. Radiology 174:509-515, 1990.
PubMed
P.487 掲載の参考文献
1) Kiel D : Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518-523, 1995.
 
2) 山本吉蔵 : 椎体計測のための罫線設定とpointingの基準. 整形外科 46:5-17, 1995.
 
3) Genant HK, et al : Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148, 1993.
PubMed
4) Genant HK, et al : Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996, 1996.
 
5) Lindsay R, et al : Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323, 2001.
PubMed
6) Melton LJ 3rd, et al : Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214-221, 1999.
PubMed
7) 戸川大輔 : 原発性骨粗鬆症性圧迫骨折に対するBalloon Kyphoplasty-日本の臨床試験成績. J Spine Res 2:1485-1493, 2011.
Medical*Online
8) 折茂肇ほか : 原発性骨粗鬆症の診断基準(1996年度改訂版). 日骨代謝誌 14:219-233, 1997.
 
P.491 掲載の参考文献
1) Claes L, et al : Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol 8:133-143, 2012.
PubMed
2) Gerstenfeld L, et al : Fracture healing as a post-natal developmental process : Molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88:873-884, 2003.
PubMed
3) Histing T, et al : Small animal bone healing models : Standards, tips, and pitfalls results of a consensus meeting. Bone 49:591-599, 2011.
PubMed
4) Manigrasso, MB, O'Connor JP : Comparison of fracture healing among different inbred mouse strains. Calcif Tissue Int 82:465-474, 2008.
PubMed
5) Jepsen KJ, et al : Genetic variation in the patterns of skeletal progenitor cell differentiation and progression during endochondral bone formation affects the rate of fracture healing. J Bone Miner Res 23:1204-1216, 2008.
PubMed
6) Whyte MP, et al : Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904-913, 2012.
PubMed
7) de Palma L, et al : Fracture callus in osteopetrosis. Clin Orthop Relat Res 308:85-89, 1994.
PubMed
8) Khassawna TE, et al : Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia. Bone 51:651-660, 2012.
 
9) Ruther U, et al : Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325:412-416, 1987.
PubMed
10) McKay WF, et al : A comprehensive clinical review of recombinant human bone morphogenetic protein-2(INFUSE(R) Bone Graft). Int Orthop 31:729-734, 2007.
 
11) Tsuji K, et al : BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38:1424-1429, 2006.
PubMed
P.496 掲載の参考文献
1) Epstein S : Postmenopausal osteoporosis : fracture consequences and treatment efficacy vary by skeletal site. Aging (Milano) 12(5):330-341, 2000.
PubMed
2) Bliuc D, et al : Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513-521, 2009.
PubMed
3) Fujiwara S, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18(8):1547-1553, 2003.
PubMed
4) 千葉一裕ほか : 骨粗鬆症性椎体骨折に対する保存的療法の指針策定-多施設共同前向き無作為化比較パイロット試験の結果より-. 日整会誌 85:934-941, 2011.
 
5) Staples MP, et al : Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials : meta-analysis. BMJ 343:d3952, 2011.
PubMed
6) Kishikawa Y : Initial non-weight-bearing therapy is important for preventing vertebral body collapse in elderly patients with clinical vertebral fractures. Int J Gen Med 5:373-380, 2012.
PubMed
7) American Academy of Orthopaedic Surgeons. Clinical Practice Guidelines. Available from [http://www.aaos.org/research/guidelines/guide.asp].
 
8) 佐々木邦雄 : 骨粗鬆症性脊椎椎体骨折の保存的治療. MB Orthp 18(7):35-44, 2005.
 
9) 後藤健志ほか : 骨粗鬆症性椎体圧迫骨折に対する保存的治療の治療成績. 整形外科 62:405-411, 2011.
 
10) Delmas PD, et al : Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures : results from the MORE trial. Bone 33(4):522-532, 2003.
PubMed
11) Miyakoshi N, et al : Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int 14(12):1007-1012, 2003.
PubMed
P.501 掲載の参考文献
1) 安宅洋美ほか : 骨粗鬆症性胸腰椎椎体骨折偽関節に伴う遅発性脊髄障害に対する除圧および後弩矯正操作を行わない後方固定術の治療成績-生命予後および歩行機能予後にも注目して-. 別冊整形外科 60:113－117, 2011.
 
2) 伊東学ほか : 骨粗鬆症性椎体圧潰の手術適応と前方脊柱再建の臨床成績. 臨床整形外科 37:449-455, 2002.
 
3) 松崎浩巳 : Hydroxyapatite(HA block)を用いた椎体骨折に対する新しいTranspedicular Kyphoplasty. 骨・関節・靱帯 15(3):247-253, 2002.
Medical*Online
4) 室田栄宏ほか : パーキンソン病患者の骨粗鬆症性椎体圧潰に対する手術治療成績. J Spine Res 1:1898-1903, 2010.
Medical*Online
5) Oda I, et al : Surgical treatment for pseudarthrosis of osteoporotic vertebral fractures. Posterior decompression and vertebroplasty with instrumentation. J JSSR 19(3):646-651, 2008.
 
6) 織田格ほか : 骨粗鬆症性脊椎骨折に対する脊柱再建術-現状と課題-. 北海道整災外会誌 52(2):209-213, 2011.
Medical*Online
7) 種市洋ほか : 骨粗鬆症性椎体圧潰(偽関節)発生のリスクファクター解析. 臨床整形外科 37(4):437-442, 2002.
 
8) 戸川大輔, 松山幸弘 : Baloon kyphoplastyの手技と日本における現状. 脊椎脊髄 25(3):183-188, 2012.
 
9) van Staa TP, et al : The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int 13:777-787, 2002.
PubMed
10) 山本博司ほか : 骨粗しょう症性脊椎圧迫骨折に対するリン酸カルシウム骨セメント椎体内注入補填術. 臨床整形外科 34:435-442, 1999.
 
11) 山崎隆志ほか : 陳旧性骨粗鬆症性圧迫骨折・偽関節に対する固定術後の他部位での新規骨折発生要因. 整形外科 61:661-666, 2010.
 
P.510 掲載の参考文献
1) Garden RS : Low angle fixation in fractures of the femoral neck. J Bone Joint Surg Br 43:647-663, 1961.
 
2) Pauwels F : Ein mechanisches problem. Ferdinand Enke Verlag, Stuttgart, 1935.
 
3) Marsh JL, et al : Fracture and dislocation classification compendium-2007 : Orthopaedic Trauma Association classification, database and outcomes committee. J Orthop Trauma 21:S1-133, 2007.
 
4) Rupprecht M, et al : A comparative biomechanical analysis of fixation devices for unstable femoral neck fractures : the Intertan versus cannulated screws or a dynamic hip screw. J Trauma 71:625-634, 2011.
PubMed
5) Nowotarski PJ, et al : Biomechanical analysis of a novel femoral neck locking plate for treatment of vertical shear Pauwel's type C femoral neck fractures. Injury 43:802-806, 2012.
PubMed
6) Baker RP, et al : Total hip arthroplasty and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck. A randomized, controlled trial. J Bone Joint Surg Am 88:2583-2589, 2006.
PubMed
7) 本川哲, 鳥越雄史 : 大腿骨頸部骨折に対する部分セメント固定併用セメントレスステムの有用性. 骨折 34:456-458, 2012.
 
8) Evans EM : The treatment of trochanteric fracture of femur. J Bone Joint Surg Br 31:190-203, 1949.
 
9) Jensen JS, Michaelsen M : Trochanteric femoral fractures/treated with McLaughlin osteosynthesis. Acta Orthop Scand 46:795-803, 1975.
PubMed
10) 中野哲雄 : 高齢者大腿骨転子部骨折の理解と3D-CT分類の提案. Orthopaedics 19:39-45, 2006.
 
11) Baumgaertner MR, et al : The value of the tip-apex distance in predicting failure of fixation of peritrochanteric fractures of the hip. J Bone Joint Surg Am 77:1058-1064, 1995.
PubMed
12) 生田拓也 : 大腿骨転子部骨折における骨折型分類について. 骨折 24:158-162, 2002.
Medical*Online
13) Parvizi J, et al : Treatment protocol for proximal femoral periprosthetic fractures. J Bone Joint Surg Am 86:8-16, 2004.
PubMed
14) Parvizi J, Vegari DN : Periprosthetic proximal femur fractures : current concepts. J Orthop Trauma 25:S77-81, 2011.
PubMed
15) Odvina CV, et al : Severely suppressed bone turnover : a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301, 2005.
PubMed
P.514 掲載の参考文献
1) 萩野浩 : 骨粗鬆症と骨折-最近の進歩 日本人における橈骨遠位端骨折の疫学. 整形・災害外科 42:1021-1027, 1999.
 
2) 日本整形外科学会診療ガイドライン委員会, 橈骨遠位端骨折診療ガイドライン策定委員会 : 治療総論 関節外骨折に対して手術的治療は保存的治療より有効か. 橈骨遠位端骨折診療ガイドライン2012, p28-30, 南江堂, 2012.
 
3) 安藤謙一, 重盛香苗 : 見落としやすい整形外科疾患-診かた治しかたのコツ- 高齢者骨折. Monthly Book Orthopaedics 22:99-108, 2009.
 
4) 日本整形外科学会診療ガイドライン委員会, 橈骨遠位端骨折診療ガイドライン策定委員会 : 治療総論 関節内骨折における徒手整復後の残存変形の許容範囲は. 橈骨遠位端骨折診療ガイドライン 2012, p35-36, 南江堂, 2012.
 
5) 日本整形外科学会診療ガイドライン委員会, 橈骨遠位端骨折診療ガイドライン策定委員会 : 治療総論 関節外骨折における徒手整復後の残存変形の許容範囲は. 橈骨遠位端骨折診療ガイドライン 2012, p33-34, 南江堂, 2012.
 
6) 外間浩 : 橈骨遠位端骨折に対するプレート, ピンニング. OS NOW Instruction 2:120-135, 2007.
 
7) Gliatis JD, et al : Outcome of distal radial fractures in young adults. J Hand Surg Br 25:535-543, 2000.
PubMed
8) 日本整形外科学会診療ガイドライン委員会, 橈骨遠位端骨折診療ガイドライン策定委員会 : 手術治療 経皮的鋼線固定法は有効か. 橈骨遠位端骨折診療ガイドライン 2012, p57-60, 南江堂, 2012.
 
9) 日本整形外科学会診療ガイドライン委員会, 橈骨遠位端骨折診療ガイドライン策定委員会 : 手術治療 掌側ロッキングプレートは有効か. 橈骨遠位端骨折診療ガイドライン 2012, p75-78, 南江堂, 2012.
 
10) 門馬秀介ほか : 高齢女性の橈骨遠位端骨折に対する観血的整復固定術の治療成績 Locking plate群とnon-locking plate群の比較. 日手外科会誌 25:778-781, 2009.
 
11) 戸部正博 : 骨補填を併用した掌側ロッキングプレート法による橈骨遠位端骨折の治療. 整形外科最小侵襲手術ジャーナル 52:19-24, 2009.
Medical*Online
12) 高田直也ほか : 髄内釘を用いた橈骨遠位端骨折の低侵襲手術. 整形・災害外科 51:1701-1704, 2008.
 
13) 木村理夫, 松下隆 : 高齢者の不安定型橈骨遠位端骨折に対するbridging創外固定と骨ペーストの効果. 整形外科最小侵襲手術ジャーナル 38:41-45, 2006.
 
14) 坂野裕ほか : 高齢者の不安定型橈骨遠位端骨折に対するnon-bridging創外固定術の適応と限界. 整形外科最小侵襲手術ジャーナル 38:2-8, 2006.
 
P.521 掲載の参考文献
1) 瀧川直秀ほか : Anterolateral acrominal approachによる上腕骨近位部骨折の治療成績. 骨折 32:308-311, 2010.
Medical*Online
2) Gardner MJ, et al : The extended anterolateral acromial approach allows minimally invasive access to the proximal humerus. Clin Orthop Relat Res 434:123-129, 2005.
 
3) Gardner MJ, et al : The anterolateral acromial approach for fractures of the proximal humerus. J Orthop Trauma 22:132-137, 2008.
PubMed
4) Laflamme GY, et al : Percutaneous humeral plating of fractures of the proximal humerus : results of a prospective multicenter clinical trial. J Orthop Trauma 22:153-158, 2008.
PubMed
5) Roderer G, et al : Clinical result for minimally invasive locked plating of proximal humerus fractures. J Orthop Trauma 24:400-406, 2010.
PubMed
6) 松村福広ほか : 上腕骨近位端骨折に対するLCPを用いたMIPOの治療成績. 骨折 30:403-407, 2008.
Medical*Online
7) 小林誠ほか : 上腕骨近位端骨折に対するminimally invasive plate osteosynthesis. 骨折 30:408-410, 2008.
Medical*Online
8) Gardner MJ, et al : Vascular implication of minimally invasive plating of proximal humerus fractures. J Orthop Trauma 20:602-607, 2006.
PubMed
9) Koukakis A, et al : Fixation of proximal humerus fractures using the PHILOS plate ; early experience. Clin Orthop Relat Res 442:115-120, 2006.
PubMed
10) Brunner F, et al : Open reduction and internal fixation of proximal humerus fractures using a proximal humeral locked plate : a prospective multicenter analysis. J Orthop Trauma 23:163-172, 2009.
 
11) Hettrich CM, et al : Quantitative assessment of the vascularity of the proximal part of the humerus. J Bone Joint Surg Am 92:943-948, 2010.
PubMed
12) Linhart W, et al : Antegrade nailing of humeral head fractures with captured interlocking screws. J Orthop Trauma 21:285-294, 2007.
 
13) 松尾真嗣ほか : 上腕骨近位部骨折に対するlocking systemを用いた手術治療-プレートか髄内釘か-. 骨折 30:260-264, 2008.
 
P.525 掲載の参考文献
1) 神宮司誠也 : 低出力超音波パルス-骨折に対する積極的保存療法-. 骨・関節・靱帯 13:443-447, 2000.
 
2) 神宮司誠也ほか : ラット大腿骨骨折治癒への低出力超音波パルス照射の効果. 骨折 21(2):655-658, 1999.
Medical*Online
3) Azuma Y, et al : Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res 16:671-680, 2001.
PubMed
4) Yang K-H, et al : Exposure to low-intensity ultrasound increases aggrecan gene expression in a rat femur fracture model. J Orthop Res 14:802-809, 1996.
 
5) Wang SJ, et al : Low intensity ultrasound treatment increases strength in a rat femoral fracture model. J Orthop Res 12:40-47, 1994.
 
6) 神宮司誠也 : 低出力超音波パルスによる骨折治療の基礎と臨床. 整形外科 51:1471-1477, 2000.
 
7) Heckman JD, et al : Acceleration of tibial-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg 76-A:26-34, 1994.
PubMed
8) 渡辺充伸, 野村一俊 : 高齢者大腿骨粉砕骨折(AO A2型)術後の荷重時痛に対する低出力超音波パルス(LIPUS)の影響. 骨折 33:142-145, 2011.
 
P.529 掲載の参考文献
1) Muenke M, et al : A common mutation in the fibroblast growth factor 1 gene in Pfeiffer syndrome. Nat Genet 8:269-272, 1994.
 
2) Shiang R, et al : Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342, 1994.
PubMed
3) Deng C, et al : Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921, 1996.
PubMed
4) Kawaguchi H, et al : Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 135:774-781, 1994.
PubMed
5) Kato T, et al : Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J Orthop Res 16:654-659, 1998.
PubMed
6) Kawaguchi H, et al : Acceleration of fracture healing in non-human primates by fibroblast growth factor-2. J Clin Endocrinol Metab 86:875-880, 2001.
 
7) Nakamura K, et al : Local application of basic fibroblast growth factor into the bone increases bone mass at the applied site in rabbits. Arch Orthop Trauma 115:344-346, 1996.
PubMed
8) Nakamura K, et al : Stimulation of bone formation by intraosseous application of recombinant basic fibroblast growth factor in normal and ovariectomized rabbits. J Orthop Res 15:307-313, 1997.
PubMed
9) Nakamura K, et al : Stimulation of bone formation by intraosseous application of basic fibroblast growth factor in ovariectomised rats. Int Orthop 22:49-54, 1998.
 
10) Nakamura T, et al : Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:1276-1284, 1995.
PubMed
11) Kawaguchi H, et al : Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor. J Clin Invest 96:923-930, 1995.
PubMed
12) Rodan SB, et al : Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin and type I collagen mRNA levels in ROS 17/2.8 cells. J Biol Chem 264:19934-19941, 1989.
 
13) Noda M, Vogel R : Fibroblast growth factor enhances type b1 transforming growth factor gene expression in osteoblast-like cells. J Cell Biol 109:2529-2535, 1989.
 
14) Kawaguchi H, et al : Local application of recombinant human fibroblast growth factor-2 on bone repair : a dose-escalation prospective trial on patients with osteotomy. J Orthop Res 25:480-487, 2007.
 
15) Kawaguchi H, et al : A local application of recombinant human fibroblast growth factor-2 for tibial shaft fractures : a randomized, placebo-controlled trial. J Bone Miner Res 25:2735-2743, 2010.
 
P.533 掲載の参考文献
1) Urist MR : Bone : formation by autoinduction. Science 150:893-899, 1965.
PubMed
2) Wozney JM, et al : Novel regulators of bone formation : molecular clones and activities. Science 242:1528-1534, 1988.
PubMed
3) Rosen V : BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068:19-25, 2006.
 
4) Govender S, et al : Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures : a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123-2134, 2002.
PubMed
5) Aro HT, et al : Recombinant human bone morphogenetic protein-2 : a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am 93:801-808, 2011.
PubMed
6) Giannoudis PV, Tzioupis C : Clinical applications of BMP-7 : the UK perspective. Injury 36(Suppl 3):S47-50, 2005.
 
7) Saito N, et al : A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotechnol 19:332-335, 2001.
 
8) Namikawa T, et al : Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine 30:1717-1722, 2005.
 
9) Yoneda M, et al : Repair of an intercalated long bone defect with a synthetic biodegradable bone-inducing implant. Biomaterials 26:5145-5152, 2005.
PubMed
10) Nakagawa K, et al : Prostaglandin E2 EP4 agonist(ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 41:543-548, 2007.
PubMed
11) Pauly S, et al : Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone 45:505-511, 2009.
PubMed
12) Yoshimura Y, et al : Colocalization of noggin and bone morphogenetic protein-4 during fracture healing. J Bone Miner Res 16:876-884, 2001.
PubMed
13) Takayama K, et al : RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro. J Bone Miner Metab 27:402-411, 2009.
PubMed
14) Yano K, et al : Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processing. J Bone Miner Metab 27:355-363, 2009.
PubMed
15) Boerckel JD, et al : Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 32:5241-5251, 2011.
PubMed
P.538 掲載の参考文献
1) Szade K, et al : CD45-CD14+CD34+ murine bone marrow low-adherent mesenchymal primitive cells preserve multilineage differentiation potential in long-term in vitro culture. Mol Cells 31:497-507, 2011.
PubMed
2) Park D, et al : Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 10:259-272, 2012.
PubMed
3) Takashima Y, et al : Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129:1377-1388, 2007.
PubMed
4) Crisan M, et al : A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301-313, 2008.
PubMed
5) Uezumi A, et al : Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 12:143-152, 2010.
PubMed
6) Takemoto T, et al : Tbx6-dependent Sox2 regulation determines neural or mesodermal fate in axial stem cells. Nature 470:394-398, 2011.
 
7) Banglio SR, et al : Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 3:359, 2012.
 
8) Granero-Molto F, et al : Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27:1887-1898, 2009.
PubMed
9) Granchi D, et al : A regenerative approach for bone repair in congenital pseudarthrosis of the tibia associated or not associated with type 1 neurofibromatosis : correlation between laboratory findings and clinical outcome. A regenerative approach for bone repair in congenital pseudarthrosis of the tibia associated or not associated with type 1 neurofibromatosis : correlation between laboratory findings and clinical outcome. Cytotherapy 14:306-314, 2012.
PubMed
10) Hernigou P, Beaujean F : Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop 405:14-23, 2002.
PubMed
11) Gangji V, et al : Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 86A:1153-1160, 2004.
 
12) 戸口田淳也ほか : 大腿骨頭無腐性壊死症に対する細胞治療. 日本臨牀 69:2225-2230, 2011.
Medical*Online
13) Horwitz EM, et al : Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309-313, 1999.
PubMed
14) Horwitz EM, et al : Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97:1227-1231, 2001.
PubMed
15) Ohgushi H, et al : Tissue engineered ceramic artificial joint - ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials 26:4654-4661, 2005.
PubMed
P.543 掲載の参考文献
1) [http://www.osteofound.org/stop-one-make-your-first-break-your-last-0]
 
2) Eisman JA, et al : Making the first fracture the last fracture : ASBMR task force report on secondary fracture prevention ; ASBMR Task Force on Secondary Fracture Prevention. J Bone Miner Res 27(10):2039-2046, 2012.
PubMed
3) [http://www.ff-network.org/]
 
4) Klotzbuecher CM, et al : Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739, 2000.
PubMed
5) Hagino H, et al : The Risk of a Second Hip Fracture in Patients after Their First Hip Fracture. Calcif Tissue Int 90:14-21, 2012.
PubMed
6) Delmas PD, et al : Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures : results from the MORE trial. Bone 33:522-532, 2003.
PubMed
7) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン 2011年版, ライフサイエンス出版, 2011.
 
8) 日本整形外科学会診療ガイドライン委員会・大腿骨頚部/転子部骨折診療ガイドライン策定委員会(編) : 大腿骨頚部/転子部骨折診療ガイドライン(改訂第2版), 南江堂, 2011.
 
9) Osaki M, et al : Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695-703, 2012.
PubMed
10) Lyles KW, et al : Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967, 2007.
 
11) Gardner MJ, et al : Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am 87:3-7, 2005.
 
12) McLellan AR, et al : Fracture liaison services for the evaluation and management of patients with osteoporotic fracture : a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083-2098, 2011.
PubMed

IX 続発性骨粗鬆症

P.549 掲載の参考文献
1) Jahannsson G, et al : Two years of growth hormone(GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81:2865-2873, 1996.
 
2) Abe E, et al : TSH is a negative regulator of skeletal remodeling. Cell 115:151-162, 2003.
PubMed
3) Abe Y, et al : Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol(Oxf) 52:203-209, 2000.
PubMed
4) Okada Y, et al : Immune signals in the context of secondary osteoporosis. Histol Histopathol 19:863-866, 2004.
 
5) Rossouw JE, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002.
PubMed
6) Anderson GL, et al ; Women's Health Initiative Steering Committee : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004.
 
7) Ettinger B, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE) investigators. JAMA 282:637-645, 1999.
PubMed
P.554 掲載の参考文献
1) Alem AM, et al : Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396-399, 2000.
PubMed
2) Mittalhenkle A, et al : Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44(4):672-679, 2004.
PubMed
3) Hosoya T, et al : Changes in renal function with aging among Japanese. Intern Med 34(6):520-527, 1995.
PubMed
4) Ohya M, et al : Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol 15(6):877-883, 2011.
PubMed
5) Chan TM, et al : Total and regional bone densities in dialysis patients. Nephrol Dial Transplant 7(8):835-839, 1992.
PubMed
6) Fukumoto S : Kidney and bone update : the 5-year history and future of CKD-MBD. CKD-MBD and phosphotropic hormones. Clin Calcium 22(7):987-991, 2012.
PubMed
7) Rodriguez M, et al : Calcemic response to parathyroid hormone in renal failure : role of phosphorus and its effect on calcitriol. Kidney Int 40(6):1055-1062, 1991.
PubMed
8) Shigematsu T, et al : Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29(3):230-236, 2009.
PubMed
9) Shigematsu T, Negi S ; COLC Research Group : Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH(COLC Study). Nephrol Dial Transplant 27(3):1050-1054, 2012.
 
P.558 掲載の参考文献
1) Janghorbani M, et al : Systematic review of type 1 and type-2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495-505, 2007.
PubMed
2) Hamada Y, et al : Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice : a possible role of oxidative stress. Bone 40:1408-1418, 2007.
PubMed
3) Ogata N, et al : Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105:935-943, 2000.
PubMed
4) Ikeda K, et al : The role of insulin in the stimulation of renal 1,25-dihydroxyvitamin D synthesis by parathyroid hormone in rats. Endocrinology 12:1721-1726, 1987.
PubMed
5) Vestergaard P : Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 18:427-444, 2007.
PubMed
6) Suzuki K, et al : Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:176-180, 1998.
PubMed
7) Saito M, et al : Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneous diabetic WBN/Kob rats. Osteoporos Int 17:1514-1523, 2006.
PubMed
8) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン2011年版, ライフ・サイエンス出版, 2011.
 
P.563 掲載の参考文献
1) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines : Guidelines for the management of rheumatoid arthritis : 2002 update. Arthritis Rheum 46:328-346, 2002.
PubMed
2) Combe B, et al : EULAR recommendations for the management of early arthritis : report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics(ESCISIT). Ann Rheum Dis 66:34-45, 2007.
PubMed
3) Smolen JS, et al : New therapies for treatment of rheumatoid arthritis. Lancet 370:1861-1874, 2007.
PubMed
4) McInnes IB, Schett G : Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-442, 2007.
PubMed
5) Dirven L, et al : Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis : bone mineral density measurements in a multicenter randomized clinical trial. Arthritis Care Res 63:1691-1699, 2011.
 
6) Tanaka Y, et al : Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4:325-358, 2005.
PubMed
7) Marotte H, et al : A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61, 2007.
 
8) Wijbrandts CA, et al : Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy : arrest of bone loss. Ann Rheum Dis 68(3):373-376, 2009.
PubMed
9) Hoff M, et al : Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis : explorative analyses from the PREMIER study. Ann Rheum Dis 68(7):1171-1176, 2009.
PubMed
10) Goekoop-Ruiterman YP, et al : Clinical and radiolographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis(the BeSt study) : a randomized controlled trial. Arthritis Rheum 52:3381-3390, 2005.
 
11) Guler-Yuksel M, et al : Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67(6):823-828, 2008.
PubMed
12) Seeman E, Delmas PD : Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261, 2006.
PubMed
13) Schwarz EM, Ritchlin CT : Clinical development of anti-RANKL therapy. Arthritis Res Ther 9(Suppl 1):S7, 2007.
 
14) Dore RK, et al : Inhibiting RANKL with denosumab increases bone mineral density in patients with rheumatoid arthritis : 6-month results from a randomized, placebo-controlled trial [abstract]. Ann Rheum Dis 66(Suppl II):428, 2007.
 
15) van der Heijde D, et al : Denosumab inhibits RANKL, reducing progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis : 12-month X-ray results [abstract]. Arthritis Rheum 56:S698, 2007.
 
16) van der Heijde D, et al : The RANKL inhibitor denosumab reduces progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis : X-ray results at 12 months [abstract]. Ann Rheum Dis 66(Suppl II):89, 2007.
 
17) Deodhar A, et al : Denosumab-mediated increase of hand bone mineral density(BMD) in patients with rheumatoid arthritis is associated with decreased progression of bone erosion [abstract]. Arthritis Rheum 56:S944, 2007.
 
18) Lane L, et al : Denosumab increases bone mineral density in patients with glucocorticoid-induced bone loss and rheumatoid arthritis [abstract]. Arthritis Rheum 56:S953, 2007.
 
19) Cohen SB, et al : Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis : a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-1309, 2008.
PubMed
20) Dore RK, et al : Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872-875, 2010.
PubMed
21) Confavreux CB, Chapurlat RD : Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 22:1023-1036, 2011.
PubMed
P.569 掲載の参考文献
1) 日本移植学会 : 脳死下での臓器提供事例に係る検証会議102例の検証のまとめ. [http://www.asas.or.jp/jst/pdf/info-20120703.pdf]
 
2) 日本造血細胞移植学会 : 2010年における疾患大分類別のドナー・細胞ソース別の移植件数. [http://www.jshct.com/report-2011/2-10-3.pdf]
 
3) Cohen A, et al : Transplantation osteoporosis. In : Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 5th ed, American Society of Bone and Mineral Research, Washington DC, 2003.
 
4) Grossman JM, et al : American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515-1526, 2010.
PubMed
5) Cueto-Manzano AM, et al : Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 75:2053-2058, 2003.
PubMed
6) Goffin E, et al : Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transplant Int 15:73-80, 2002.
PubMed
7) Ball AM, et al : Risk of hip fracture among dialysis and renal transplant recipients. JAMA 299:3014-3018, 2002.
 
8) Shane E, et al : Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776, 2004.
PubMed
9) Monegal A, et al : Bone disease after liver transplantation : a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484-492, 2001.
PubMed
10) Tauchmanova L, et al : Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogenic stem cell transplantation. J Clin Endocrinol Metab 87:5058-5065, 2002.
PubMed
11) Ebeling PR : Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy. J Clin Endocrinol Metab 90:4414-4416, 2005.
PubMed
12) Crawford BA, et al : Zoledronic acid prevents bone loss after liver transplantation : a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239-248, 2006.
PubMed
13) Jeffery JR, et al : Prevalence and treatment of decreased bone density in renal transplant recipients ; a randomized prospective trial of calcitriol versus alendronate. Transplantation 76:1498-1502, 2003.
PubMed
14) Kananen K, et al : Prevention of bone loss after allogeneic stem cell transplantation by calcium vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90:3877-3885, 2005.
PubMed
15) Epstein S, Stuss M : Transplantation osteoporosis. Pol J Endocrinol 62:472-485, 2011.
 
P.574 掲載の参考文献
1) Sato Y, et al : Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in stroke patients. Neurology 61:338-342, 2003.
PubMed
2) Sato Y, et al : Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease. Parkinsonism Relat Disord 17:22-26, 2011.
PubMed
3) Sato Y, et al : Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke : a randomized controlled trial. Cerebrovasc Dis 20:187-192, 2005.
PubMed
4) Sato Y, et al : Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 23:291-296, 1998.
 
5) Sato Y, et al : Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 31:114-118, 2002.
 
6) Sato Y, et al : Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : a randomized controlled trial. Mov Disord 21:924-929, 2006.
PubMed
7) Sato Y, et al : Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743-1748, 2005.
 
8) Sato Y, et al : Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64:811-816, 2005.
PubMed
9) Sato Y, et al : Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911-915, 2007.
PubMed
10) Sato Y, et al : Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease : a randomised controlled trial. J Neurol Neurosurg Psychiatry 82:1390-1393, 2011.
PubMed
11) Sato Y, et al : Effect of folate and mecobalamin on hip fractures in patients with stroke : a randomized controlled trial. JAMA 293:1082-1088, 2005.
PubMed
12) Grisso JA, et al : Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 324:1326-1331, 1991.
 
13) Poplingher AR, Pillar T : Hip fracture in stroke patients. Epidemiology and rehabilitation. Acta Orthop Scand 56:226-227, 1985.
PubMed
14) Sato Y, et al : Homocysteine as a predictive factor for hip fracture in stroke patients. Bone 36:721-726, 2005.
 
15) Sato Y, et al : Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 118:1250-1255, 2005.
PubMed
P.581 掲載の参考文献
1) 鈴木康夫 : ステロイド性骨粗鬆症の特異性. Clinical Calcium 20:645-653, 2010.
 
2) Kirigaya D, et al : Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment : current status of adherence to clinical guidelines and elated factors. Intern Med 50:2793-2800, 2011.
 
3) 鈴木康夫 : 膠原病における骨粗鬆症の治療ガイドラインUpdate. 成人病と生活習慣病 42:937-943, 2012.
Medical*Online
4) 鈴木康夫 : ステロイド性骨粗鬆症-疫学・病態・予防治療ガイドライン-. Osteoporosis Japan 11(3):427-436, 2003.
 
5) van Staa TP, et al : The epidemiology of corticosteroid-induced osteoporosis. A meta-analysis. Osteoporos Int 13:777-787, 2002.
PubMed
6) Luengo M, et al : Vertebral fractures in steroid dependent asthma and involutional osteoporosis : a comparative study. Thorax 46:803-806, 1991.
PubMed
7) Nawata H, et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab 23:105-109, 2005.
PubMed
8) Saag KG, et al : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039, 2007.
 
9) Kanis JA ; on behalf of the World Health Organization Scientific Group : Assessment of Osteoporosis at the Primary Health Care Level, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 2007.
 
10) Grossman JM, et al : American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515-1526, 2010.
PubMed
11) Lekamwasam S, et al : A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int, DOI:10.1007/s00198-012-1958-1951, 2012.
 
P.587 掲載の参考文献
1) Peacock M, et al : Genetics of osteoporosis. Endocr Rev 23:303-326, 2002.
PubMed
2) Ward LM, et al : Osteogenesis imperfecta type VII : an autosomal recessive form of brittle bone disease. Bone 31:12-18, 2002.
PubMed
3) Morello R, et al : CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 127:291-304, 2006.
PubMed
4) Cho TJ, et al : A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 91:343-348, 2012.
PubMed
5) Rauch F, Glorieux FH : Osteogenesis imperfecta. Lancet 363:1377-1385, 2004.
PubMed
6) 田中弘之ほか : 骨形成不全症の診療ガイドライン. 日小児会誌 110:1468-1471, 2006.
 
7) Gong Y, et al : LDL receptor-related protein 5(LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001.
PubMed
8) Narumi S, et al : Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome : identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am J Med Genet A 152A:133-140, 2010.
PubMed
9) Kubota T, et al : Wnt signaling in bone metabolism. J Bone Miner Metab 27:265-271, 2009.
PubMed
10) Bonewald LF, Johnson ML : Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615, 2008.
PubMed
11) Cheung WM, et al : A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene. Bone 39:470-476, 2006.
PubMed
12) Yadav VK, et al : Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-837, 2008.
PubMed
13) Mani A, et al : LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278-1282, 2007.
 
14) Mudd SH, et al : The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37:1-31, 1985.
PubMed
15) van Meurs JB, et al : Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033-2041, 2004.
PubMed

X 骨粗鬆症の類縁疾患の診断と治療

P.595 掲載の参考文献
1) 大薗恵一 : 小児とビタミンD. The Bone 25:285-290, 2011.
Medical*Online
2) Endo I, et al : Clinical usefulness of measurement of fibroblast growth factor 23(FGF23) in hypophosphatemic patients : proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235-1239, 2008.
PubMed
3) Ruppe MD, Jan de Beur SM : Disorders of phosphate metabolism. In : Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 7th ed, p317-353, American Society for Bone and Mineral Research, Washington, DC, 2008.
 
4) A gene(PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136, 1995.
PubMed
5) Jonsson KB, et al : Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663, 2003.
 
6) Bresler D, et al : Serum MEPE-ASARM-peptides are elevated in X-linked rickets(HYP) : implications for phosphaturia and rickets. J Endocrinol 183:R1-9, 2004.
 
7) Rowe PS : Regulation of bone-renal mineral and energy metabolism : the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 22:61-86, 2012.
PubMed
8) ADHR Consortium : Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348, 2000.
PubMed
9) Imel EA, et al : Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541-3549, 2011.
PubMed
10) Feng JQ, et al : Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315, 2006.
PubMed
11) Lorenz-Depiereux B, et al : Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267-272, 2010.
PubMed
12) Riminucci M, et al : FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692, 2003.
PubMed
13) Bhattacharyya N, et al : Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:1132-1141, 2012.
PubMed
14) Wagenstaller J, et al : Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193-201, 2006.
PubMed
15) Magen D, et al : A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 362:1102-1109, 2010.
 
P.601 掲載の参考文献
1) Paget J : On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans 60:37-63, 1877.
PubMed
2) Siris ES, Roodman GD : Paget's disease of bone. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (ed by Favus MJ), p495-506, The American Society of Bone and Mineral Research, Washington, DC, 2003.
 
3) Hansen MF, et al : Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res 14(Suppl 2):39-44, 1999.
 
4) Cossetto D, et al : Malignant fibrous histiocytoma in Paget's disease of bone. A report of seven cases. Aust NZ J Surg 62(1):52-55, 1992.
 
5) Takata S, et al : Guideline on the Management of Paget's Disease of Bone in Japan. J Bone Miner Metab 24(5):359-367, 2006.
PubMed
6) Hashimoto J, et al : Prevalence and clinical features of Paget's disease of bone in Japan. J Bone Miner Metab 24(3):186-190, 2006.
PubMed
7) Selby PL, et al : Guidelines on the management of Paget's disease of bone. Bone 31(3):366-373, 2002.
PubMed
8) Cooper C, et al : The epidemiology of Paget's disease in Britain : Is the prevalence decreasing? J Bone Miner Res 14(2):192-197, 1999.
PubMed
9) Altman RD, et al : Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 15(3):461-465, 2000.
PubMed
10) Rebel A, et al : Bone tissue in Paget's disease of bone. Ultrastructure and immunocytology. Arthritis Rheum 23:1104-1114, 1980.
PubMed
11) Rima BK, et al : The pro and con of measles in virus in Paget's disease : Con. J Bone Miner Res 17:2290-2292, 2002.
 
12) Sofaer JA, et al : A family study of Paget's disease of bone. J Epidemiol Community Health 37:226-231, 1983.
PubMed
13) Fotino M, et al : Evidence for linkage between HLA and Paget's disease. Transplant Proc 9:1867-1868, 1977.
PubMed
14) Hughes AE, et al : Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet 3:359-361, 1994.
PubMed
15) Laurin N, et al : Paget disease of bone : mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 69:528-543, 2001.
PubMed
16) 高田信二郎 : 骨Paget病およびその関連疾患と骨代謝関連分子の遺伝子異常. リウマチ科 40(2):204-208, 2008.
 
17) Whyte MP, et al : Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347(3):175-184, 2002.
PubMed
18) Takata S, et al : Evolution of understanding of genetics of Paget's disease of bone and related diseases. J Bone Miner Metab 22(6):519-523, 2004.
PubMed
19) Nakatsuka K, et al : Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 18:1381-1385, 2003.
 
20) Dickson GR, et al : Familial expansile osteolysis : a morphological, histological, histomorphometric and serological study. Bone 12:331-338, 1991.
 
21) Hughes AE, et al : Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24(1):45-48, 2000.
PubMed
22) Whyte MP, Hughes AE : Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17:26-29, 2002.
PubMed
23) Laurin N, et al : Recurrent mutation of the gene encoding sequestosome 1(SQSTSM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582-1588, 2002.
PubMed
24) 高田信二郎ほか : 骨パジェット病の診断と治療ガイドライン委員会報告. Osteoporosis Japan 15(2):116-119, 2007.
 
25) 高田信二郎 : 病態と疾患からみたカルシトニン. 骨パジェット病. 日本臨牀 63(増刊号10):219-225, 2005.
 
26) 吉川秀樹ほか(日本骨粗鬆症学会 骨パジェット病の診断と治療ガイドライン委員会) : 骨パジェット病アトラス. Osteoporosis Japan 13(1)別冊, 2005.
 
27) Delmas PD, Meunier PJ : The management of Paget's disease of bone. N Engl J Med 336:558-566, 1997.
PubMed
28) Yoh K, et al : Efficacy, tolerability and safety of risedronate in Japanese patients with Paget's disease of bone. J Bone Miner Metab 28(4):468-476, 2010.
PubMed
P.608 掲載の参考文献
1) Yoneda T, Hiraga T : Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679-687, 2005.
PubMed
2) Kohno N, et al : Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer : a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005.
 
3) Gnant M, et al : Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009.
PubMed
4) Storto G, et al : Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35-41, 2006.
PubMed
5) Lipton A, et al : Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092, 2012.
PubMed
6) Reid DM, et al : Guidance for the management of breast cancer treatment-induced bone loss : a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3-18, 2008.
 
7) Sverrisdottir A, et al : Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694-3699, 2004.
 
8) Taylor LG, et al : Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388-2399, 2009.
PubMed
9) Shahinian VB, et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005.
PubMed
10) Gnant M, et al : Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer : 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008.
PubMed
11) Brufsky A, et al : Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829-836, 2006.
PubMed
12) Takahashi S, et al : Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole : 12-month results. Breast Cancer Res Treat 133:685-693, 2012.
PubMed
13) Smith MR, et al : Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012, 2003.
PubMed
14) Ellis GK, et al : Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882, 2008.
PubMed
15) Smith MR, et al : Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755, 2009.
PubMed
P.612 掲載の参考文献
1) Rosen LS, et al : Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma : a phaseIII, double-blind, comparative trial. Cancer J 7:377-387, 2001.
PubMed
2) Rosen LS, et al : Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003.
PubMed
3) Kyle RA, et al : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472, 2007.
 
4) Morgan GJ, et al : First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX) : a randomised controlled trial. Lancet 376:1989-1999, 2010.
 
5) Henry DH, et al : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125-1132, 2010.
PubMed
6) Ozaki S, et al : Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86:180-185, 2007.
PubMed
7) Mukherjee S, et al : Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504, 2008.
PubMed
8) Qiang YW, et al : Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113:4319-4330, 2009.
PubMed
P.615 掲載の参考文献
1) Frontail M, Dallapiccola B : Osteoporosis-pseudoglioma syndrome and the ocular form of osteogenesis imperfecta. Clin Genet 29:262, 1986.
 
2) Somer H, et al : Osteoporosis-pseudoglioma syndrome : clinical, morphological, and biochemical studies. J Med Genet 25:543-549, 1988.
PubMed
3) Gong Y, et al : LDL receptor-related protein 5(LRP5) affects bone accrual and eye development. Cell 107(4):513-523, 2001.
PubMed
4) Laine CM, et al : Novel mutation affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet 19:875-881, 2011.
 
5) Jeon H, et al : Implication for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol 8:499-504, 2001.
PubMed
6) Brown SD, et al : Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 248:879-888, 1998.
PubMed
7) Bienz M, Clevers H : Linking colorectal cancer to Wnt signaling. Cell 103:311-320, 2000.
PubMed
8) van Bezooijen RL, et al : Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814, 2004.
 
9) Avsian-Kretchmer O, Hsueh AJW : Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol 18:1-12, 2004.
PubMed
10) Balemans W, et al : Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543, 2001.
 
11) Padhi D, et al : Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26, 2011.
 

XI 大規模臨床試験の概要・住民コホート研究の概要

P.624 掲載の参考文献
1) Shiraki M, et al ; Adequate Treatment of Osteoporosis(A-TOP) Research Group : The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria : prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis(A-TOP) Research Group. J Bone Miner Metab 24:219-225, 2006.
 
2) Shiraki M, et al : Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures. J Bone Miner Metab 29:37-43, 2011.
PubMed
3) Orimo H, et al : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture : the Japanese Osteoporosis Intervention Trial(JOINT)-02. Curr Med Res Opin 27:1273-1285, 2011.
PubMed
P.630 掲載の参考文献
1) 太田博明 : 日常診療とpractice based medicine-JOINT-02を踏まえて-. The Bone 25(1):69-73, 2011.
Medical*Online
2) 折茂肇ほか : 原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18(3):76-82, 2001.
Medical*Online
3) 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 2006.
 
4) van Meurs JB, et al : Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350(20):2033-2041, 2004.
PubMed
5) Shiraki M, et al : Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 26(1):93-100, 2008.
PubMed
6) Kumamoto K, et al : Validation of the Japanese Osteoporosis Quality of Life Questionnaire. J Bone Miner Metab 28(1):1-7, 2010.
PubMed
7) Vergnaud P, et al : Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women : the EPIDOS Study. J Clin Endocrinol Metab 82(3):719-724, 1997.
PubMed
8) 白木正孝ほか : 電気化学発光免疫法による血清中低カルボキシル化オステオカルシン(ucOC)測定キットの臨床的有用性の検討. 医学と薬学 57(4):537-546, 2007.
Medical*Online
9) Orimo H, et al : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture : the Japanese Osteoporosis Intervention Trial(JOINT)-02. Curr Med Res Opin 27(6):1273-1284, 2011.
PubMed
10) Ozuru R, et al : Time-dependent effects of vitamin K2(menatetrenone) on bone metabolism in postmenopausal women. Endocr J 49(3):363-370, 2002.
 
11) Iwamoto J, et al : Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats : a bone histomorphometry study. J Nutr Sci Vitaminol (Tokyo) 52(5):307-315, 2006.
PubMed
12) 骨粗鬆症の予防と治療ガイドライン2011年版, ライフサイエンス出版, 2011.
 
13) [http://www.clinicalstudyresults.org/drugdetails/?drug_name_id=468&sort=c.company_name&page=1&drug_id=2217]
 
14) Iwamoto J, et al : Menatetrenone (vitamin K2) and bone quality in the treatment of postmenopausal osteoporosis. Nutr Rev 64(12):509-517, 2006.
PubMed
15) 久島泰仁ほか : 原発性骨粗鬆症に対するリセドロネートとビタミンK2の併用効果に関する多施設共同研究-1年経過症例の中間解析-. Osteoporos Jpn 15(2):234-237, 2007.
 
P.636 掲載の参考文献
1) 白木正孝 : エビデンス取得のための大規模臨床試験(JOINT研究). 日本臨牀 69:1281-1286, 2011.
Medical*Online
2) 骨粗鬆症の予防と治療ガイドライン2011年版(折茂肇編), p126, ライフサイエンス出版, 2011.
 
3) Nakamura T, et al : Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab 24:414-418, 2006.
PubMed
4) 生活習慣病骨折リスクに関する診療ガイド(杉本利嗣編), ライフサイエンス出版, 2011.
 
5) Nicodemus KK, et al ; Iowa Women's Health Study : Type I and type II diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001.
PubMed
6) 鳥羽研二ほか : 転倒リスク予測のための「転倒スコア」の開発と妥当性の検証. 日老医誌 42(3):346-352, 2005.
 
7) 運動器不安定症2008 [http://www.joa.or.jp/jp/public/locomo/mads.html].
 
P.641 掲載の参考文献
1) Muraki S, et al : Impact of degenerative spinal diseases on bone mineral density of lumbar spine. Osteoporos Int 15:724-728, 2004.
 
2) Yoshimura N, et al : Cohort profile : research on osteoarthritis/osteoporosis against disability study. Int J Epidemiol 39:988-995, 2010.
PubMed
3) Yoshimura N, et al : Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women : the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27:620-628, 2009.
PubMed
4) Muraki S, et al : Health-related quality of life with vertebral fracture, lumbar spondylosis and knee osteoarthritis in Japanese men : the ROAD study. Arch Osteoporos 5:91-99, 2010.
 
5) Muraki S, et al : Risk factors for falls in a longitudinal population-based cohort study of Japanese men and women : The ROAD Study. Bone 52:516-523, 2013.
 
P.645 掲載の参考文献
1) 吉村典子 : 厚生労働科学研究費補助金(長寿科学総合研究事業)平成23年度総括報告書.
 

XII 特論

P.651 掲載の参考文献
1) 日本骨粗鬆症学会生活習慣病における骨折リスク評価委員会(編) : 生活習慣病骨折リスクに関する診療ガイド, ライフサイエンス出版, 2011.
 
2) Vestergaard P, et al : Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int 88:209-214, 2011.
PubMed
3) Iwamoto J, et al : Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res Clin Pract 93:166-173, 2011.
 
4) Mori H, et al : Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. J Bone Miner Metab 31:89-95, 2013.
PubMed
5) Yoneda T, et al : Bisphosphonate-related osteonecrosis of the jaw : position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365-383, 2010.
PubMed
6) Akhtar NH, et al : Osteonecrosis of jaw with the use of denosumab. J Can Res Ther 7:499-500, 2011.
PubMed
7) Rizzoli R, et al : Subtrochanteric fractures after long-term treatment with bisphosphonates : a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373-390, 2011.
 
8) Ariyoshi T, et al : Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215-222, 2006.
PubMed
9) Celiloglu M, et al : The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689-693, 2009.
PubMed
10) Okamoto K, et al : Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients : a longitudinal study. Life Sci 87:686-691, 2010.
 
11) Silverman SL, et al : Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis : results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923-1934, 2008.
PubMed
12) Barrett-Connor E, et al : Raloxifene and cardiovascular events in osteoporotic postmenopausal women : four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857, 2002.
PubMed
13) Collins P, et al : Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial : results of subgroup analyses by age and other factors. Circulation 119:922-930, 2009.
PubMed
14) Vestergaard P : Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int 89:265-270, 2011.
PubMed
P.655 掲載の参考文献
1) Zethraeus N, et al : Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and reference model. Osteoporos Int 18:9-23, 2007.
PubMed
2) Kanis JA et al : European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428, 2008.
 
3) Strom O, et al : Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061, 2007.
PubMed
4) 萩野浩 : 骨粗鬆症治療の費用対効果分析. 日本臨牀 60(増刊号3):645-654, 2002.
Medical*Online
5) 林泰史 : 寝たきり患者数と原因. Clinical Calcium 9:1186-1188, 1999.
 
6) 太田壽城ほか : 日本における大腿部頸部骨折の医療経済. 日老医誌 39:483-488, 2002.
 
7) 原田敦ほか : 骨粗鬆症の医療経済 : 疫学, 費用と介入別費用・効用分析. 日老医誌 42:654-657, 2005.
 
8) Kanis JA, et al : Treatment of established osteoporosis : a systematic review and cost-utility analysis. Health Technol Assess 6(29):1-146, 2002.
PubMed
9) Stevenson M, et al : A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9(22):1-160, 2005.
 
10) Moriwaki K, et al : Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28:395-403, 2013.
PubMed
11) Zethraeus N, et al : The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidemia in Sweden. Osteoporos Int 19:819-827, 2008.
 
12) Ebrahim S, et al : What role for statins? A review and economic model. Health Technol Assess 3(19):i-iv, 1-91, 1999.
 
13) Strom O, et al : The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX(R). Osteoporos Int 21:495-505, 2010.
 
14) McLean AR, et al : Fracture liaison services for the evaluation and management of patients with osteoporotic fracture : a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083-2098, 2011.
 
15) Sanders KM, et al : Half the burden of fragility fractures in the community occur in women without osteoporosis. Bone 38:694-700, 2006.
PubMed

書評

最近チェックした商品履歴

Loading...